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Summary 
Introduction:  
In organisational theory there is an assumption that knowledge is used effectively in 
healthcare systems that perform well. Actors in healthcare systems focus on 
managing knowledge of clinical processes like, for example, clinical decision-making 
to improve patient care. We know little about connecting that knowledge to 
administrative processes like high-risk medical device procurement or technology 
assessments. Well-tailored policies for health technologies such as medical devices 
are essential and contribute to improved quality of health care. The regulation, 
assessment, and management represent important functions of the Medical Device 
Life-Cycle (MDLC). Insufficiently developed interactions between these functions 
impact the quality of health care and health system’s effectiveness. To date studies 
lack to analyse these functions in a broad way even though they are increasingly of 
interest to policy makers and health system experts in Mexico. 
Objective:  
This Ph.D. research was designed and carried out so get a better understanding on 
policies and practices of the MDLC areas for orthopaedic medical devices in Mexico. 
The research encompasses four objectives spanning from (i) defining which areas of 
procurement are crucial for clinical practice and outcomes of orthopaedic medical 
devices, (ii) assessing attitudes of stakeholders regarding outcomes of the MDLC 
areas and analysing knowledge-related factors that influence these areas, (iii) 
analysing challenges of and discussing possible ways forward in fostering the 
regulation, assessment, and management of orthopaedic medical devices in Mexico, 
and (iv) analysing interests, positions, and power of stakeholders to three alternative 
strategies to improve processes and practices with regard to the regulation, 
assessment, and management of orthopaedic medical devices in Mexico to assess 
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the political feasibility of these strategies. 
Methods:  
We used a mainly qualitative research approach through overall 166 interviews (four 
sub-studies) and 187 survey participants (one sub-study) as well as a literature 
review (one sub-study) based on an overall framework that considers the MDLC 
relevant areas and the different levels by which the delivery of health care is being 
shaped.  
First, we determined and analysed themes that were relevant to the different interest 
groups of the MDLC by using ‘procurement’ as starting point. We used in-depth 
interviews and interviewed 58 persons representing different stakeholders from four 
countries to define which areas of procurement are crucial for clinical practice and 
outcomes of orthopaedic HRMDs. 
Second, we generated initial conclusions that served to further provide more specific 
insights on the most relevant themes. To do so we conducted two sub-studies: (i) we 
conducted a study using semi-structured interviews to assess opinions from 48 
stakeholders from Mexico, and (ii) we conducted a survey to assess attitudes of 187 
orthopaedic specialists from Mexico. 
Third, we discussed ideas for possible ways forward in fostering the MDLC. To do so 
we conducted two sub-studies: (i) we interviewed 42 persons representing different 
stakeholders from Mexico to analyse challenges of and discuss possible ways 
forward in fostering the regulation, assessment, and management of orthopaedic 
medical devices in Mexico, and (ii) we used a literature review to discuss the 
contribution of survival rate benchmarks as decision-making rule.  
Fourth, we analysed interests, positions, and power of stakeholders to specific 
strategies with regard to changes of processes and practices of the MDLC relevant 
areas. We used a stakeholder analysis method and included 17 persons 
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representing multiple interest groups to analyse interests, positions, and power of 
stakeholders to three alternative strategies to improve processes and practices with 
regard to the regulation, assessment, and management of orthopaedic medical 
devices in Mexico to assess the political feasibility of these strategies. 
Results:  
The MDLC system in Mexico is not coherently outlined and set-up across the 
regulatory, the assessment, and the management domains of orthopaedic medical 
devices, and this results in a situation that the quality of services delivered to patients 
is sub-optimal. First, the management of data and information is a critical aspect of 
the performance of the MDLC. Our research provided insights into problems related 
to data and information, and how this might have an influence on outputs and 
outcomes of the MDLC. 
The focus on knowledge-related factors (second sub-study) allowed us to better 
explain the relation of MDLC function such as ‘management’ and clinical procedures 
for orthopaedic medical devices in Mexico. Second, technovigilance receives 
relatively high attention by policy makers in Mexico but that stakeholders of the 
MDLC underestimate its contribution regarding improving MDLC outcomes. Our 
research showed that the information flow between the micro level (observations 
from clinical practice) and macro level is relatively weak. 
Third, in Mexico, HTA adds little value to decision-making and HTA at the level of 
hospitals has not received a lot of attention yet even though it may provide important 
benefits to the quality of health care and to the health system’s effectiveness. Fourth, 
stakeholders of the MDLC function ‘management’ in Mexico underestimate the role 
played by procurement regarding purchasing of orthopaedic HRMDs. Our research 
showed that decisions are either based on simple decision criteria or impacted by 
	 VIII	
lowest-price offers. Quality attributes such as clinical long-term performance and 
intra-operative handling performance is rarely influencing into decision-making. 
Conclusion:  
Only some of the findings that our research has produced have been discussed in 
the literature before. This research is novel in terms of its specific focus on key 
MDLC functions and on orthopaedic medical devices. Further, it was timely because 
some of the presented themes are currently undergoing policy discussion in Mexico. 
The MDLC system in Mexico is not coherently outlined and set-up across the 
regulatory, the assessment, and the management domains of orthopaedic medical 
devices. 
The fragmentation of responsibilities of the MDLC areas, which is underpinned by the 
health system structure, has recently received more attention from different 
stakeholders and is subject to the current policy discussion. The suggested changes 
of current processes and practices of the regulation, assessment, and management 
can improve outputs and outcomes of these functions and positively influence the 
quality of health care and health system’s effectiveness. We have the following 
recommendations to the Mexican policy makers and other stakeholders related to the 
MDLC: (i) A government agency is needed to broadly oversee, monitor and report on 
quality-related issues within the health system; (ii) Decision-makers should apply an 
integrative approach of selecting medical devices to better prevent an economic and 
health burden due to disconnected processes and practices of the MDLC functions; 
(iii) Specific policies and organizational practice targeting orthopaedic medical 
devices are necessary; (iv) Technovigilance needs to be strengthened to improve the 
understanding of potential health risks associated with sub-standard HRMDs; (v) 
Data, information, and knowledge need to be managed appropriately across the sub-
systems of health care provision; (vi) Technologies should be assessed during the 
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purchasing process by applying strategies such as risk assessment, the adequate 
involvement of end-users, and basing decisions on multiple criteria including clinical 
impact in the short-term and long-term; (vii) The methodology applied to technology 
assessments for evaluating HRMDs needs to be adapted to the gold standard and 
HTAs at the level of hospitals should be introduced; (viii) Decision-making needs to 
distinguish between different risk classes of medical devices because decisions on 
complex medical devices are based on simple decision criteria; and (ix) 
‘Procurement’ needs more attention so that actors involved in procurement or 
impacted by procurement decisions are less confronted by problems. 
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1. Introduction 
1.1. Quality of health care 
“Health care outcomes become the ultimate measure of quality as they reflect the 
influence of both, structure and processes of care.” [2] 
 
There are multiple ways to define quality of health care and for the present research, 
the following definition is appropriate: “The degree to which health services for 
individuals and populations increase the likelihood of desired health outcomes and 
are consistent with current professional knowledge” [3]. The World Health 
Organization (WHO) states that one goal of a health system and their actor is to 
ensure and improve quality of health care [4]. High quality of health care improves 
the chances of successful treatments and promotes better outcomes for health in 
general. According to the literature, quality improvement is a process that can be 
addressed from different dimensions of quality [5, 6] and levels within a health 
system [7]. These dimensions were first defined almost 50 years ago [2] and were 
specified in more detail by, e.g., WHO: Health care should be efficient, effective, 
accessible, equitable, acceptable and safe [5]. 
Quality is therefore one of the cornerstones of health care [5] and is of high 
importance to health systems [8]. The multiple actors and processes within a health 
system aim at specific quality goals for health care [9]. Failures determined by actors 
or processes influence health outcomes. For this reason, ensuring and improving 
quality receives high attention by, e.g., policy makers and has an evolutionary nature 
[10]. However, knowledge and resources of a health system do not always translate 
into the desired effects for quality of health care [5]. This concerns high-income 
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countries as well as middle- and low-income countries [5, 8, 9, 11-13]. How can 
policy makers and health system experts respond to this? 
First, to provide important insights about specific aspects of the delivery of 
quality of care different perspectives can be applied [7, 14]. This allows the multiple 
actors focusing on the patient and the health care professional as well as on 
organizational aspects and health system functions [15]. For instance, applying a 
health system’s perspective can help to uncover and explain performance gaps or 
inefficiencies of processes, which a health system might have across the different 
levels of health care delivery. These approaches might contribute to the identification 
and analysis of quality issues, and help improve the delivery of quality of care, and 
consequently, strengthen the health system [16]. 
Second, the health care delivery model (HCDM) emphasises four levels by 
which the delivery of health care is being shaped [15]. This model helps to 
understand the conditions under which the multiple actors and organizational groups 
operate so that appropriate quality of care results (Figure 1.1). The interrelations are 
determined by processes, which contribute to the health care delivery function. 
Distinguishing between the different levels of the HCDM not only allows policy 
makers to focus on inputs at the macro level of policies and regulations, or clinical 
outcomes at the micro level, it also enables the researcher to provide the multiple 
actors with important insights about aspects that contribute to or inhibit the delivery of 
high quality of health care [7]. 	
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Figure 1.1. Healthcare Delivery Model (adapted from [15]) 	
1.2. Health technologies 
 “Good health services deliver effective, safe, high-quality care to those who need 
them with a minimum waste of resources.” [17] 
 
A health system consists of multiple actors aimed at promoting, restoring or 
maintaining health. To better explain the relationships and interactions within a health 
system the WHO defined six Health System Building Blocks [9] that can be 
understood as sub-systems encompassing several other systems [16]. These blocks 
are: Leadership and governance; healthcare financing; health workforce; medical 
products and technologies; information and research; and service delivery. Four main 
groups of goals/outcomes of the system building blocks are of interest: Improved 
health (level and equity); responsiveness; financial risk protection; and improved 
efficiency. 
Medical devices, together with other health technologies, laboratory items and 
medicines, are essential for patient care and producing good health outcomes. As 
such, they are considered by the WHO [18] as one of the six building blocks of health 
systems. They can essentially influence the quality of delivered healthcare based on 
the following considerations that were defined by WHO to better explain why medical 
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devices can fit within a national overarching health policy [19]: Regulations of medical 
devices minimize risk to the population; safe use and availability of medical device 
improve health service delivery; affordability of medical devices increases health 
service coverage; telemedicine enhances patient-centred care; health technology 
assessment provides basis for priority setting and informed decision-making; needs 
assessment helps in rational allocation of resources; research and innovations 
respond to the needs of a particular health system and population. 
1.2.1. Medical devices 
A health technology encompasses the application of technology-based knowledge 
and skills to solve a health problem and improve quality of life using devices, 
medicines, vaccines, procedures and systems [20]. A medical device is „an article, 
instrument, apparatus or machine that is used in the prevention, diagnosis or 
treatment of illness or disease, or for detecting, measuring, restoring, correcting or 
modifying the structure or function of the body for some health purpose.“ [19]. WHO 
explains the role played by medical devices as [19]: “Medical devices save lives, 
improve health and quality of life, and are indispensable for the prevention diagnosis, 
treatment, and management of all medical conditions, diseases, illnesses and 
disabilities…”. The regulatory authorities of countries have established classifications 
for medical devices to better distinguish between the requirements needed to 
evaluate their sanitary risk. The device classification depends on the intended use of 
the medical device and thus classification is risk based [21]. Class I includes medical 
devices with the lowest risk and requires general controls before granting market 
approval, for example enema kits and elastic bandages. Class II includes medical 
devices with moderate risk and requires general and specific controls, for example 
powered wheelchairs and some pregnancy test kits. Finally, class III includes medical 
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devices with high-risk and requires additionally premarket approval, for example 
breast implants, pacemakers or joint replacements. 
1.2.2. Impact of medical devices on quality of healthcare 
This research is concerned with class III medical devices, which are also described 
as high-risk medical devices (HRMDs) for orthopaedic speciality. HRMDs are 
implanted in the human body (such as a knee joint implant) and are therefore 
recommended subject to the highest level of pre-market and post-market [22, 21]. 
Their clinical indication is to replace the original joint by an artificial joint (implant) and 
to reconstruct the affected function of the locomotor system entirely or partially (see 
system building block goal ‘improved health’). They will remain in the patient’s body 
as long as they fulfil their mechanical function, which is to restore the joint function, 
and are not associated with any other complication such as an infection. Therefore a 
HRMD is not based on pharmacological, immunological or metabolic effects, but on a 
physical interaction (mode of action) in or on the patient’s body to achieve an 
intended effect [23]. 
Studies concerned with the epidemiology of hip and knee joint replacements 
show that the demand for primary joint replacements and revision surgery is growing 
[24, 25]. To meet the system building block goal ‘financial risk protection’ health 
systems respond by different strategies. For instance, to control the financial impact 
of joint replacements regarding its demand, some health systems define a maximum 
number of joint replacements per year (United Kingdom), a maximum budget for a 
period of time that can be used for joint replacements (part of the public sector in 
Mexico), or intervening in the entitlement of clinical decisions for joint replacements 
(in discussion in the United Kingdom). The financial impact of joint replacements 
depends as well on the implant quality. It is important to achieve good quality of 
delivered healthcare, which is represented by good survival rates of the used 
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implants (number of years that the implant remains successfully in the human body 
after surgery), for example. Arthroplasty register data shows that the clinical 
performance of hip and knee implants in the long-term demonstrate a strong variation 
[26]. Using poorly performing implants increases the revision risk. Studies for joint 
replacements in the United States show that primary joint replacements and revisions 
will increase. Knee-replacement revisions, for instance, are predicted to increase by 
332% between 2012 and 2030 [24]. Further, the rate of primary joint replacement for 
patients aged 65-74 years and 75-84 years is much higher than for patients aged 85 
years and older. Overall, the incidence has increased significantly between 2000 and 
2006 [25]. 
These findings may be relevant for middle-income countries and countries with 
moderate life expectancy. Mexico is the second largest importer of orthopaedic 
medical devices in Latin America and the demand is increasing [27], even though this 
demand is still low in comparison to high income countries [28]. The life expectancy 
of the Mexican population has increased over the past 15 years in Mexico [29], which 
impacts among else on the incidence of osteoarthritis and thus the demand for joint 
replacements. Further, the demand is influenced by first, a larger population of 
patients over 50 years of age [30], which is affected by ostheoarthritis that increases 
rapidly. Second, Mexico is marked a population with high obesity rates [31, 32] who 
is on higher risk of early joint wear. Third, by patients who might have received a joint 
replacement with an implant of sub-standard quality that impacts the implant survival. 
The clinical long-term performance of HRMDs is an important input parameter 
for the regulation, assessment, and management areas because it determines the 
future need for a joint replacement (revision surgery) of the artificial joint and 
influences the quality of delivered healthcare. “The necessity for revision surgery has 
serious consequences for the patient’s quality of life and causes high health-care 
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expenditure” [33]. A certain number of high-income countries have access to high-
quality data of joint replacements (patient registries or arthroplasty registries), which 
they use to evaluate medical outcomes [34, 26, 35]. Using poorly performing medical 
devices is one of the reasons for high revision rates. For instance, increased 
incidence of post-operative problems resulting from the use of metal-on-metal hips 
led to higher hip revision rates [36]. But only few upper middle-income countries have 
a comparable access to high-quality data of joint replacements such as Romania. 
However, in Mexico, no arthroplasty register is established and clinical long-term 
performance of HRMDs is rarely included into the quality agenda of the functions of 
the MDLC areas. Currently, only the federal techno-vigilance department and health 
technology assessments may consider this data type to improve decision-making. 
1.3. Regulation, assessment, and management of medical devices 
Policies for health technologies such as medical devices are essential to assure 
equitable access to high quality and affordable devices and their appropriate use and 
thus, contributing to improved quality of care [37]. The WHO emphasizes the 
importance of developing and implementing health technology policies within the 
context of a national health plan. WHO indicated that 34% of 145 countries have a 
health technology national policy in place that is part of the national health 
programme [38]. Such policies are concerned with the regulation, assessment, or 
with the management of health technologies. 
Health technology policies are aimed at outreaching safety, equity, quality, and 
universal coverage. They are thus closely related to important functions for medical 
devices. Understanding the challenges among the multiple actors involved 
contributes to clearly defined policy needs [39]. For instance, countries are 
increasingly considering integrating the evaluation and monitoring of HRMDs into 
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their quality agenda [35, 40]. In the United States and in many European countries 
the policy discussion about medical devices has encouraged policymakers to change 
policies and procedures that specifically govern the regulation of medical devices to 
improve the post-market safety of orthopaedic HRMDs [41, 39]. Less information is 
available from middle-income countries such as Ukraine, which started to improve 
regulation in 2016 [42]. Studies show that using poorly performing implants has a 
financial impact due to higher revision rates [43, 44]. The potential consequences in 
the absence of strategies to solve the evidence gap and prevent the selection of 
poorly performing implants are spanning from the provision of inferior healthcare 
provision to increased healthcare expenditures [45]. To clearly define health 
technology policy needs the delivery of care for using orthopaedic HRMDs must be 
understood in a holistic context such as the Medical Device Life-Cycle (MDLC) 
(Figure 1.2). 
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Figure 1.2. Medical Device Life-Cycle (adapted from [19]) 
 
The MDLC integrates important functions for medical devices and encompasses four 
areas [37]: (1) research and development; [23] medical device assessment; [23] 
medical device regulation; and [23] medical device management. Table 1.1 displays 
important inputs, outputs, and outcomes for each area. In the following subsection 
we outline important aspects of the regulation, assessment, and management of 
medical devices. 
 
  
	 10	
Table 1.1. Important outputs and outcomes of the MDLC areas 
	
Areas Description Outputs Outcomes 
    
Regulation Safety and efficacy are 
in the focus of this 
phase to aim 
population safety. Key 
elements are 
performing testing, 
safety assessment & 
post-market reporting 
using criteria of safety 
and quality standards. 
 
Mandatory 
compliance 
Assuring 
minimal 
standards of 
quality 
Assessment Key elements are 
systematic analysis 
and critical review 
using epidemiology 
and evidence data and 
assessing the cost-
effectiveness. 
 
Recommendations 
on highly complex 
technologies 
Responsiveness 
and 
maximization of 
clinical 
outcomes and 
cost-
effectiveness 
Management Health service 
providers are in the 
focus of this phase. 
Key element is the 
operational 
management of 
technology life-cycle 
using needs analysis 
and reliable device 
availability for clinical 
use. 
 
Operational rules 
and guidance for 
all medical 
devices 
Improved health 
delivery; 
sustainable 
availability of 
high-quality and 
safe devices 
Source: Adapted from WHO [19, 46] 
1.3.1. Regulation of medical devices 
The aim of the regulation is to “protect the public through the publication of 
standards, testing protocols, pre-market approval, registration, post-market 
surveillance, and adverse event reporting” [19]. Various countries have a regulation 
for medical devices [19], and/or a regulatory agency. In addition policymakers are 
frequently concerned with effectively ensuring standards of clinical safety, 
performance, and efficacy of, e.g., orthopaedic high-risk medical devices [47, 48]. 
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Medical device regulation is challenged with the mismatch of validity of 
information needed for the market approval and evidence from actual use of high-risk 
medical devices [49-51, 18]. One reason for this is that pre-market regulation is 
mainly based on conformity assessments and does not include findings from clinical 
long-term outcome studies [51, 52]. Therefore, post-market regulation plays an 
important role. For instance, post-market surveillance (e.g., supervised by techno-
vigilance officers) seeks to monitor the safety and effectiveness of HRMDs once they 
are on the market and is aimed at detecting adverse events [53]. This is an important 
step of medical device regulation concerning the identification of the quality of an 
implant. Countries use different strategies in terms of ensuring or monitoring safety 
and performance of medical devices. These strategies range from strengthening the 
post-market regulation [54, 40], monitoring clinical treatment outcomes by introducing 
arthroplasty registers [34], to assessing the risk of HRMDs by post-market due 
diligence programmes [55], classifying the quality of implants [56], and establishing 
revision rate benchmarks to prevent the use of poorly performing implants [57]. 
These strategies are frequently integrated into the regulators’ work and help bridge 
the gap of evidence and uncertainty [58, 59]. 
1.3.2. Assessment of medical devices 
Health Technology Assessments (HTAs) represent one area of the MDLC. HTAs 
include clinical and economic analysis and they take place at the level of the 
regulation of high-risk medical devices. Their findings are used to define the eligibility 
of technologies. However, assessing the value of medical device technologies 
through HTA depends on the existence of relevant evidence on safety, performance 
and effectiveness of the technology [51]. Nevertheless, this data is often not 
available. Further, HTAs assess the value of a technology at a certain time based on 
the existing evidence data. Data that is generated afterwards is not integrated. This 
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limitation inhibits HTAs to integrate the survivorship of implants in actual use and 
should be covered by post-market regulation. 
1.3.3. Management of medical devices 
This area of the MDLC encompasses a wide range of functions and starts with the 
influence of the regulation and assessment areas and ends with outputs that 
determine desired clinical services [37]. The procurement process of a health system 
is expected to support the quality of healthcare and “it is an essential element for 
service delivery” [60]. Moreover, it has the potential to contribute to improved health 
system performance [61]. However, it does not always receive the recognition it 
deserves. This fact can be observed more frequently in countries with less developed 
health systems [62]. When the procurement function fails, a health system is 
weakened with regards to the quality of delivered healthcare. 
The procurement process aims to transfer inputs into outputs to satisfy the 
customer’s needs [63]. One crucial factor of the procurement process is the 
procedure that results in a decision on the purchase and use of services. This 
procedure can fail in terms of financial indicators but also with regards to delivering 
the required quality. Two important dimensions of this process are efficiency and 
effectiveness [64, 65]: Efficiency measures the success of transferring inputs into 
outputs whereas effectiveness measures the success of the system in terms of the 
outputs received. 
Procurement processes of health systems might impact the goal of the MDLC 
significantly. This raises an important question that could be subject of future 
research: How does the impact of procurement processes translate into results for 
the micro level? Further, studies often focus on procurement performance in general 
but rarely on the meaning that procurement performance might have for other MDLC 
areas and in specific in the context of quality of healthcare. Procurement 
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performance can be evaluated, besides others, based on generic measures, among 
others, for which the procurement functionaries do have the control over. The focus 
lies on the supply link (relation between internal customer, purchasing department 
and supplier) and therefore, focuses mainly on efficiency and effectiveness of the 
procurement process [66]. The measurement areas that can be derived from it are 
illustrated in Figure 1.3. 
	
Figure 1.3. Key areas of the procurement process (adapted from [67]) 
 
Cost respectively potential savings are used by various countries as important 
indicators or measures of performance. Therefore, the function of the procurement is 
in several instances established to achieve cost minimization and efficiency 
maximization at the same time. But financial indicators or measures do not permit 
covering all relevant performance areas [68]. What possible disadvantages do health 
systems have when procurement is used as isolated and generic measure driven 
administrative function for medical devices? Non-financial measures are also very 
relevant. They help to better understand the effects of performance among core 
areas and activities of procurement. This leads to the consideration of more 
components that can be evaluated [66] such as environment and structure, and 
operating procedures within procurement (management area of MDLC) but also 
outside procurement (other areas of MDLC). Based on the prior theoretical 
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frameworks, the evaluation of the non-financial performance can also be derived 
from an amplified perspective (Figure 1.4). 
 
Figure 1.4. Performance of procurement process in the context of its 
environment 
1.4. Mexico 
Mexico is the second largest economy in Latin America with an estimated population 
of over 127 million [69]. It is a middle-income country built up along 32 states.  
1.4.1. Mexican Health System 
The Mexican health system is relatively segmented and fragmented, and it is 
characterized by a public and a private sector [70]. The latest OECD report on 
Mexico from 2016 [32] states that “Mexico’s health system persists as a cluster of 
distinct sub-systems, each offering different levels of care, to different groups, at 
different prices, and with different outcomes”. Figure 1.5 provides an overview on the 
multiple actors providing health services. 
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Figure 1.5. Overview over the multiple actors providing healthcare in Mexico 
(adapted from [70]) 
 
The public sector provides healthcare attention to the Mexican population with and 
without social security based on a centralized service provision scheme. The 
centralized service provision scheme encompasses multiple social security 
institutions and the state-level healthcare services (SESA). The social security 
institutions encompass population groups that are employed in the formal sector of 
the economy and are represented by: Mexican Institute of Social Security (IMSS, 
Instituto Mexicano de Seguro Social), Institute of Social Services for State Workers 
(ISSSTE, Instituto de Seguridad y Servicios Sociales de los Trabajadores del 
Estado), Mexican Petroleums (PEMEX, Petróleos Mexicanos), Secretariat of 
National Defense (SEDENA, Secretaría de la Defensa Nacional), Secretariat of 
National Marine (SEMAR, Secretaría de la Mariana), and Federal Commission of 
Electricity (CFE, Comisión Federal de Electricidad). SESA belongs to the MOH and 
attend the population that is not employed in the formal sector of the economy. In 
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addition to SESA the MOH installed a decentralized service provision scheme, which 
encompasses programmes that attend the population without social insurance and 
limited or no financial resources to pay health services such as IMSS Oportunidades. 
The private sector attends that part of the population that can afford to pay private 
insurance or that has access to private insurance through its employer. That way it 
plays a role in respect to some of the health systems functions such as service 
provision and financing. 
The National Health Program (PRONASA) and the Sectorial Health Program 
(PROSESA) aim to guarantee the access to basic health services and reduce 
disparities. However, the fragmentation of the health system takes place as well at 
the level of disease treatment, which are often distinguished into three attention 
levels [71]: (i) first level attention encompasses the basic treatment of diseases, (ii) 
second level attention focuses on a variety of different diseases that require a 
treatment in a hospital, and (iii) third level attention encompasses specialized 
treatments such as a joint replacement. 
The general health law specifies that the MOH is in charge of the strategic 
planning of the sector, the definition of priorities, the coordination within and across 
sectors, and the development and introduction of health policies [72]. However, the 
health service provision at the level of the public and private sector are not obliged to 
adhere to all regulations from the various MOH departments that operate at the 
national level [72, 73]. This causes a variety of problems ranging from the 
reimbursement to important aspects of information flow between the sectors and the 
MOH [71]. For instance, CENETEC provides purchasing guidance to procurement 
agents within SESA based on recommendations for expensive medical equipment 
such as a computer tomography scanner. If and how this might influence the quality 
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of provided health services regarding medical devices hasn’t been investigated yet in 
detail. 
1.4.2. Policies for health technologies in Mexico 
WHO indicated that globally 35% of 174 countries for which information is available 
have a national health technology policy in place that is part of the National Health 
Program [38]. Mexico is one of these countries and its response to the call for 
developing and implementing health technology policies within the context of a 
national health plan can be described by three aspects: 
• the introduction of the Inter-institutional Commission of the Standard List for 
Health Supplies in 1975, which is responsible for the eligibility of health 
technologies by assessing their cost-effectiveness [1]; 
• the establishment of the Federal Commission for the Protection against 
Sanitary Risks (COFEPRIS) in 2002, which is responsible for the regulation of 
health technologies; 
• the creating of the National Centre for Health Technology Excellence 
(CENETEC) in 2004, which is a specialized agency of the MOH to support 
policy decisions based on e.g. and for instance health technology 
assessments (HTA). 
Mandating government agencies and defining regulations that support policies for 
health technologies is essential to establish and develop important functions for 
medical devices that support healthcare delivery at different organizational levels 
within the health system as described by the MDLC. Besides the development and 
implementation of health technology policies, WHO emphasizes the importance of 
the commitment for, and realization of a continuous improvement plan within and 
between the areas of the MDLC (improving organizational practice) in order to 
strengthen the implementation of national health technology policies and to 
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contribute to improved health [37]. This can be achieved when necessary interactions 
between the areas are established, which are necessary because of the 
interdependence of these areas. In this context, WHO emphasises the role played by 
organizational structures at different levels within the country [37]. 
1.4.3. MDLC in Mexico 
In Mexico, several governmental offices as well as several non-governmental 
stakeholders are involved in the MDLC (Table 1.2). 
	
Table 1.2. Principle actors involved in the regulation, assessment, and management 
of medical devices in Mexico 
Principal actors Main responsibility and regulatory reference 
General Council of 
Health (CSG, Consejo 
de Salubridad General) 
• Sanitary authority directly accountable to the President 
• Council whose mission it is to strengthen the governance and 
the articulation of the National System of Health. Founded: 
1917 
Regulatory reference: Article 4 of the Political Constitution of 
Mexico 
• Publishes the standard list of Health Supplies 
• Holds the Inter-institutional Commission of the standard list 
for Health Supplies whose mission is to manage the 
approved technologies in the standard list for Health Supplies 
Regulatory reference: DOF-22-06-2011; Edition 2015 of the 
Standard list; Article 9, fraction XXI and XXII, 15, fraction II, 
and 22 of the Interior Regulation of the General Council of 
Health 
• Auditing of hospitals with regards to quality standards 
(certification process) 
Regulatory reference: Interior regulation of the commission 
for the certification of health provider facilities DOF-22-10-
2003 
Ministry of Health 
(MOH, Secretaria de 
Salud) 
• Government department and member of executive cabinet in 
charge of all health services in Mexico. Its mission is to 
establish the state policies towards the realization of the right 
to health for all. Founded: 1943 
Regulatory reference: Law of General Health, DOF-01-06-
2016; Interior regulation of the Ministry of Health, DOF-10-01-
2011 
Sub-secretariat for 
Health System 
Integration and 
Development (SIDSS, 
Subsecretaria de 
Integración y 
Desarrollo del Sector 
Salud) 
• Government agency whose mission is to propose to the MOH 
national policies that improve the quality of social health 
services; issues the Mexican Official Norms (NOM) 
Regulatory reference: Article 19 of the Organic Law of the 
Federal Public Administration, DOF-18-07-2016 
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Federal Commission 
for the Protection 
against Sanitary Risks 
(COFEPRIS, Comisión 
Federal para la 
Protección contra 
Riesgos Sanitarios) 
• Decentralized organ of the MOH whose mission is to protect 
the population against medical risks derived from the 
introduction of new medical drugs, medical devices and other 
health inputs. Founded: 2002 
Regulatory document: Regulation of the Federal Commission 
for the Protection against Sanitary Risks, DOF-13-04-2004; 
and Regulation for Health Supplies, DOF-12-03-2014 
• Sanitary Authorization Commission whose mission is the 
market approval of medical products and technologies 
Regulatory reference: Medical devices class III are subject of 
the requirements of the articles 179 and 180 of the 
Regulation of Health Services; NOM-064-SSA1-1993, NOM-
137-SSA1-2008, NOM-163-SSA1-2000 
• Technovigilance department whose mission is to implement 
and realize post-market surveillance 
Documents: NOM-240-SSA1-2012 
• Support function of “Sanitary Authorization Commission” 
whose mission is to provide technovigilance reports for the 
renovation of market approval 
• Regulatory reference: Article 190 Bis 3, fraction IV of the 
Regulation of Health Services 
National Centre for 
Health Technology 
Excellence 
(CENETEC, Centro 
Nacional de Excelencia 
Tecnológica en Salud) 
• Governmental organization and unit under the scope of the 
SIDSS whose mission is to contribute to the development 
and governance of the National Health System in Mexico 
based on: Health Technology Assessments, Supervision of 
medical equipment, Telemedicine, Clinical guidelines. 
Founded: 2004 
Regulatory reference: Interior Regulation of the MOH, article 
41, DOF-02-02-2010 
• WHO collaborating centre 
Ministry of the Public 
Function (SFP, 
Secretaria de la 
Función Publica) 
• Governmental organ whose mission is to coordinate, 
evaluate and oversee the governmental public practice at 
federal level such as for example the public spending 
Regulatory reference: Administrative Manual for General 
Application in the Acquisition, Leasing and Services of the 
Public Sector, DOF-03-02-2016; Application of the evaluation 
criteria “binario” (cost benefit), article 42 of the Regulation of 
the law for acquisition, leasing and services of the public 
sector, DOF-20-08-2001; Organic Law of Federal Public 
Administration, articles 31, 34, and 37, DOF-18-07-2016 
General directorate of 
health planning and 
development 
(DGPLADES, 
Dirección General de 
Planeación y 
Desarrollo en Salud) 
 
• Governmental organization and unit under the authority of 
the SIDSS whose mission is to steer the strengthening of 
health services among policy makers, and giving guidance to 
improve health services sustainable and cultural based on 
populations’ needs 
Regulatory reference: Interior regulation of the MOH, article 
25 
General directorate of 
quality and education 
(DGCES, Dirección 
General de Calidad y 
Educación) 
• Governmental organization and unit under the authority of 
the SIDSS whose mission is to ensure that the quality and 
safety of health services, including human resources of the 
health sector and the regulatory environment of social health 
supplies is aligned with national policies 
Regulatory reference: Interior Regulation of the MOH, article 
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18 
Public sector for 
healthcare delivery 
Via MOH 
• State-level healthcare services (SESA, Servicios Estatales 
de Salud) 
• MOH facilities such as National Institutes 
• MOH programmes for service provision such as IMSS-
Opportunities (IMSS-O, IMSS oportunidades) or financial 
programmes such as Social Population Insurance (SPS, 
Seguro Popular de Salud), initiated 1979 
Social Security Institutions 
• Mexican Institute of Social Security (IMSS, Instituto Mexicano 
de Seguro Social), founded 1943 
• Institute of Social Security and Services for State Workers 
(ISSSTE, Instituto de Seguridad y Servicios Sociales de los 
Trabajadores del Estado), founded 1960 
• Mexican Petroleums (PEMEX, Petróleos Mexicanos) 
• Secretariat of National Defense (SEDENA, Secretaría de la 
Defensa Nacional) 
• Secretariat of Marine (SEMAR, Secretaría de la Marina) 
Private sector for 
healthcare delivery 
• Private insurance companies 
• Private healthcare facilities 
 
 
General directorate of 
information in health for 
data collection (DGIS, 
Dirección General de 
Información en Salud)  
• Governmental organization and unit under the authority of 
the SIDSS whose mission is to collect and make available 
health information, including the administration of the general 
health information 
Regulatory reference: NOM-035-SSA3-2012 
• Oversees the implementation of the National System of 
Essential Information in Healthcare [74] whose mission it is to 
improve the collection and exchange of health information of 
the social security institutions and the state healthcare 
systems 
• Regulatory reference: NOM-024-SSA3-2012 
National Commission 
for Medical Arbitration 
(CONAMED, Consejo 
Nacional de Ciencia y 
Tecnología) 
• Contribute to guarantee the right of health protection and to 
improve the quality of health providers in terms of intervening 
in case of patient/health provider conflicts 
Regulatory reference: Introduction of CONAMED, DOF-03-
06-1996; Regulation of procedures for the management of 
complaints and incidents of CONAMED, DOF-21-01-2003 
General directorate of 
evaluation of 
performance (DGEP, 
Dirección General de 
Evaluación del 
Desempeño) 
• Governmental organization and unit under the authority of 
the SIDSS whose mission is to evaluate the performance of 
the national and state health systems, and of the health 
programmes and services; to provide relevant information to 
improve policies, programmes and services 
Regulatory reference: Interior Regulation of the MOH, article 
23 
National Academy of 
Medicine (ANM, 
Academia Nacional de 
Medicina,) 
• Professional association of doctors that promotes scientific 
corporation, organises congresses and continuous 
professional education; consultant organization of the 
Federal Government of Mexico that proposes and discuss 
among its affiliates solutions to the main health problems of 
the Mexican society.  
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However, the different sub-systems of the public sector have relatively high decision-
spaces (and legal autonomy) regarding post-market regulation, assessment and 
management of medical products. For instance, they have their own health service 
providers, manage medical products (purchasing and delivering services) to their 
covered populations, and define and set their own priorities. The ability of 
policymakers to comprehensively oversee the MDLC in Mexico regarding challenges 
in organizational practice is limited because their responsibilities are limited by the 
design of the health system. 
Regulation: 
COFEPRIS is the main institution for the pre- and post-market regulation of medical 
devices. It establishes and implements policies, programmes and projects at the level 
of international best practice, and in coordination with the different actors of the 
health system to prevent health risks. This encompasses the market approval of 
medical products (pre-market regulation) and the post-market surveillance of medical 
products in clinical use (post-market regulation). In the United States and in many 
European countries, the policy discussion about medical devices has encouraged 
policymakers to change policies and procedures that govern the regulation of 
medical devices [41]. Studies show that using poorly performing implants has a 
financial impact due to higher revision rates [43, 44]. To date, no studies or grey 
literature (websites, reports, etc. from government offices and national or 
international organizations) indicate the multiple actors in Mexico have similar 
discussions. 
Assessment: 
The General Council of Health [75] is the main actor for decisions about the eligibility 
of medical products at national level [1]. The CSG oversees the Inter-institutional 
Commission of the Standard List for Health Supplies that decides the listing of health 
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technologies in the national standard list. It integrates information from health 
technology assessments into their decision-making process. However, articles 83, 
179 and 180 of the current Medical Device Regulation of Mexico indicate that there 
are no specific regulations for HRMD differentiating them from lower risk medical 
devices. Medical devices of different risk classes are bundled within the same list. 
There is uncertainty how this influences e.g. procurement agents and their 
assessment of medical devices of different risk classes. 
Management including procurement of medical devices 
The sub-systems, which have their own facilities, are responsible for purchasing and 
the delivery of services to their covered populations. “The Mexican federal public 
administration has strengthened its public procurement function in recent years, 
which contributed to a more professional handling of medical product purchase” [60]. 
A better understanding of the context, in which purchasing takes place, might help to 
identify challenges of organizational practice and discussing possible ways to 
fostering the management of medical products. Procurement of healthcare providers 
belonging to the MOH is relatively decentralized while procurement of the public 
social security institutions is centralized at regional or national level. 
 
The OECD report from 2012 on the public procurement process of IMSS, which 
represents one of the largest public insurance sectors [60], and the latest OECD 
report on the Mexican health system from 2016 provide the most complete 
information on current findings for procurement in Mexico. OECD noted in its report 
regarding IMSS that they demonstrate a lack of well documented procurement 
strategy and communication through the organization of IMSS and a lack of sufficient 
procurement data, which compromises important management activities, and 
monitoring of procurement performance [60]. Further, current resource management 
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is associated with the risk of sub-standard quality. In its report about the Mexican 
health system OECD concluded that Mexico should strengthen the governance of its 
health system aiming at a more data-driven health system (raise data availability and 
use among the areas regulation, assessment, and management) and that the public 
sub-systems need a smarter purchasing of goods and services (raise efficiency and 
quality of care). 
1.5. Research gap 
Research gaps have been identified based on the previous literature research and 
reviewing grey literature (websites, reports, etc. from government and national or 
international organizations). This contributed to the definition of the present research 
topic and the identification of research objectives. Talking in a first step to public 
health experts provided some insights and supported to the definition of the present 
research question: 
• Studies or other public information provides information in terms of the 
accessibility and coverage of healthcare services of specific public institutions 
but rarely for the whole Mexican health sector [76]. 
• Few aspects are documented on other quality dimensions to improve the 
delivery of healthcare such as organizational or operational processes 
influencing the outputs and outcomes of the MDLC. 
• In Mexico, little research has been done to understand challenges of the 
regulation, assessment, and management for orthopaedic HRMDs and how 
these challenges influence the outputs and outcomes of the MDLC areas, and 
affect the goal of national health technology policies.  
• To date, some aspects regarding the structure and the performance of 
procurement are highlighted in the OECD reports from 2012 and 2016 [60, 
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32]. But evidence on the regulation and assessment of medical devices is still 
scarce. 
• Literature research for the HCDM applied for the Mexican health system only 
provided results for specific institutions and for some of the four levels the 
HCDM is representing. 
• To date, literature is lacking regarding the quality of delivered orthopaedic 
HRMD and effects on quality of care across the various sub-systems of the 
Mexican health system. There is a need to bring insight into quality 
dimensions, which are relevant to foster the quality of the delivered 
healthcare. 
• There are doubts regarding different attributes of the MDLC areas of 
orthopaedic HRMDs in Mexico and their influence on clinical practice and 
thus, on the delivered quality of care. However, these perceptions were based 
on viewpoints of the orthopaedic society of physicians and mainly address the 
content of the area ‘technology management’, which encompasses 
procurement. 
• Literature research for the relation of the procurement process and the 
delivery of quality of care did not provide specific results. Nevertheless, the 
OECD from 2012 presents some aspects of the relation of ‘technology 
management’ and the quality of care for the largest institution of the public 
sector. 
Mexico is classified as a middle-income country. Compared to high-income countries, 
typically we observe a limited amount of research in low- and middle-income 
countries (LMIC) [77]. Little published evidence does exist regarding regulation, 
assessment, or management of medical devices in Mexico [78]. This situation 
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warrants detailed research for Mexico necessary to provide a better understanding of 
the regulation, assessment, and management of orthopaedic HRMD and their role for 
the quality of delivered healthcare necessary. Despite the fact, that available 
information from the literature is insufficient to realize the research project, it is 
mandatory to involve a broad range of local actors. 
2. Study aim and objectives 
This research was designed and carried out in the context of gaining insight on 
policies and practices of the MDLC areas for orthopaedic medical devices in Mexico 
and to discuss and analyse possible ways forward in fostering them. In specific this 
thesis encompasses four research objectives. 
 
Objective 1 (Chapter 4) 
• Define which areas of procurement are crucial for clinical practice and 
outcomes of orthopaedic HRMDs. 
Objective 2 (Chapters 5 and 6) 
• Analyse knowledge-related factors that influence procurement of orthopaedic 
HRMDs in Mexico. 
• Assess the attitudes and thoughts of orthopaedic specialists regarding their 
role in purchasing decision-making of HRMDs, their experience with 
purchasing processes and impact on clinical practice as well as potential 
areas for improvement. 
Objective 3 (Chapter 7 and 8) 
• Analyse challenges of and discuss possible ways forward in fostering the 
regulation, assessment, and management of orthopaedic medical devices in 
Mexico. 
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• Discuss possible ways forward in fostering the regulation, assessment, and 
management of orthopaedic medical devices in Mexico. 
Objective 4 (Chapter 9) 
• Analyse interests, positions, and power of stakeholders to three alternative 
strategies to improve processes and practices with regard to the regulation, 
assessment, and management of orthopaedic medical devices in Mexico to 
assess the political feasibility of these strategies.  
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3. Research design and methods 
A mainly qualitative research approach is used to support the four research 
objectives (Creswell 2009). This research encompasses six sub-studies. For each 
sub-study, we will consider different approaches and include multiple stakeholder 
groups. The main focus regarding interest groups representing the meso and micro 
levels will be on the public sector while the private sector investigation will serve 
rather as comparative element. The final goal is the analysis of possible strategies in 
fostering the MDLC areas. To assure feasibility of the objectives, the qualitative 
research approaches will be focused on a region of interest that is defined by 2 out of 
31 states (Estado de Mexico and Cuernavaca) plus the federal district (Distrito 
Federal). We selected this region of interest because it represents important offices 
of the MOH, international organizations or experts of the health system, and it 
represents the highest volume for orthopaedic surgeries within the country 
encompassing representations of all public sub-systems and the private sector. 
Our research approach is based on an overall framework (Figure 3.1) that 
includes two main perspectives: the MDLC areas in the context of the HCDM levels. 
It served us to capture important findings regarding the MDLC areas and the HCDM 
levels. 
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Figure 3.1. Overall framework 
 
The framework guided our research in three ways. First, to determine and analyse 
themes that were relevant to the different interest groups of the MDLC for 
orthopaedic medical devices using ‘procurement’ as starting point and describing the 
identified themes regarding their meaning for the MDLC areas, and distinguishing 
between the macro, meso, and micro levels (sub-studies one to three). Second, to 
generate initial conclusions that serve to further provide more specific insights on the 
most relevant themes and to discuss possible ways forward in fostering the 
regulation, assessment, and management of orthopaedic medical devices in Mexico 
(sub-study four and five). Third, to overall conclude on the findings of the different 
sub-studies and to overall answer our research questions by analysing possible 
changes of processes and practices regarding the MDLC areas in a stakeholder 
context (sub-study six). For this inductive research approach we focused on mainly 
qualitative methods in our effort to collect first in-depth qualitative data (in-depth and 
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semi-structured interviews), second highlight specific aspects by quantitative data 
(structured survey), and third narrowing down the findings by terminal qualitative data 
collection (semi-structured interviews). 
 
Figure 3.2. Overview table with study and method per objective 
 
3.1. Research methods to achieve objective 1 
For sub-study one (see chapter 4), we took a healthcare delivery perspective in our 
effort to determine (i) how the set-up of HRMD regulations exerts influence on 
procurement (macro level), (ii) how procurement regulations and practices align with 
expectations of clinical practice (meso level) and, (iii) how procurement practices 
affect clinical practice and outcome (micro). We adapted the HCDM [16] and the 
supply link framework [13] so our research approach model captured the factors that 
influence procurement regulations and practices for orthopaedic HRMDs (Figure 4.1). 
We focused on three levels by which the delivery of healthcare is being shaped: 1) 
macro (regulatory, normative, managing); 2) meso (care provider facility); and, 3) 
micro (healthcare professional and patient). We emphasised procurement based on 
Mai 30, 2017 HRMD decision-making Mexico 1 
Study 1 Study 2 Study 3 Study 4 Study 5 Study 6 
Setting MX, UK, DE, CH Mexico Mexico Mexico Mexico Mexico 
Objective Define which areas 
of procurement are 
crucial for clinical 
practice and 
outcomes of 
orthopaedic 
HRMDs. 
Analyse 
knowledge-related 
factors that 
influence 
procurement of 
orthopaedic 
HRMDs in Mexico 
Assess the 
attitudes and 
thoughts of 
orthopaedic 
specialists 
regarding their role 
in purchasing 
decision-making of 
HRMDs, their 
experience with 
purchasing 
processes and 
impact on clinical 
practice as well as 
potential areas for 
improvement. 
Analyse 
challenges of and 
discuss possible 
ways forward in 
fostering the 
regulation, 
assessment, and 
management of 
orthopaedic 
medical devices in 
Mexico. 
Discuss 
possible ways 
forward in 
fostering the 
regulation, 
assessment, 
and 
management 
of orthopaedic 
medical 
devices in 
Mexico. 
 
Analyse interests, 
positions, and 
power of 
stakeholders to 
three alternative 
strategies to 
improve processes 
and practices with 
regard to the 
regulation, 
assessment, and 
management of 
orthopaedic 
medical devices in 
Mexico to assess 
the political 
feasibility of these 
strategies .  
Method Qualitative study; 
59 in-depth 
interviews  
Qualitative study; 
48 semi-
structured 
interviews  
Cross-sectional 
study; 187 
participants 
Qualitative study; 
42 semi-structured 
interviews  
Review of 
literature and 
grey literature 
Qualitative study;  
17 structured 
interviews  
Target 
group 
Stakeholders from 
macro, meso, and 
micro level 
Stakeholders from 
macro, meso, and 
micro level 
Orthopaedic 
specialists 
Stakeholders from 
macro, meso, and 
micro level 
- Stakeholders from 
macro, meso, and 
micro level 
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the supply link framework and installed it between the meso and micro levels. 
Procurement has three main actors: supplier; procurement administration 
(purchaser); and, meso level (internal customer) and micro level (user). The 
interaction between the main actors is defined by (i) procurement administration and 
internal customer or user, and (ii) procurement administration and supplier. We also 
defined themes related to procurement: (i) regulations (pre- and post-market), (ii) 
eligibility, (iii) procurement, and (iv) clinical procedure. We compared the context and 
set-up of procurement for orthopaedic HRMDs across four countries: Mexico (upper-
middle income country) and United Kingdom, Switzerland and Germany (high income 
countries) and conducted in-depth interviews with healthcare system stakeholders. 
We used semi-structured interviews among four interest groups: (i) healthcare 
system stakeholders who represented macro and meso levels, and supplier (Group 
1, 2, and 4) to understand how the health system environment affects procurement 
(regulations for HRMDs, eligibility for HRMDs, programmes targeting quality of 
HRMDs, etc.), and (ii) orthopaedic specialists who represent the micro level (Group 
3) to capture the interplay between procurement regulations and practices, the 
interests of parties involved directly or indirectly in procurement, and clinical practice 
and outcomes. 
3.2. Research methods to achieve objective 2 
Sub-study two (see chapter 5) 
For sub-study two, our research approach is based on a working framework 
presented in Figure 5.1, which is guided by two considerations (i) procurement 
supports healthcare delivery and (ii) procurement decision-making is knowledge 
sensitive. First, we defined three healthcare delivery levels based on the healthcare 
delivery model [7]: 1) macro (normative and policy mechanism); 2) meso (insurance 
system & care provider facility); and, 3) micro (orthopaedic specialist and patient). 
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Differentiating between these levels is a crucial aspect of our research because 
public procurement in Mexico and procurement decisions take place at the meso 
level and not at the micro level. The user is employed by the social security institute 
or MOH and has little autonomy during procurement decision-making in respect to 
select a medical device. This differs from other healthcare systems where users are 
self-employed and the procurement mechanism used by healthcare providers is 
independent of a central purchasing function [79]. Second, we explain procurement 
based on the supply link framework [66] and embed it along the three healthcare 
delivery levels. Procurement has three main actors: supplier; procurement 
administration (purchaser); and, internal customers (at the meso level) and users (at 
the micro level). The interaction between the main actors is shown by arrows and 
defined by (i) procurement (administrator or agent) and internal customer or user, 
and (ii) procurement and supplier. Third, we implemented the four knowledge 
management dimensions [80] as the underlying concept of this research approach 
and used them as orientation to analyse factors of managing knowledge (healthcare 
delivery levels), to assess the role of knowledge from clinical procedures and in 
relation to procurement, and to identify findings having the ability to improve 
managing knowledge. We used semi-structured interviews among different interest 
groups. The study is based on: (i) semi-structured interviews with healthcare system 
stakeholders that represented macro and meso levels (Group 1) to analyse how 
knowledge of clinical procedures is managed among the knowledge management 
dimensions; and (ii) semi-structured interviews with orthopaedic specialists who 
represent the micro level (Group 2) to assess the role of knowledge from clinical 
procedures and in relation to procurement of orthopaedic medical devices. 
Sub-study three (see chapter 6) 
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For sub-study three, our research approach is based on a working framework, which 
is guided by two considerations: (i) end-users have low purchasing decision 
autonomy, and (ii) purchasing fails to integrate a broader spectrum of decision 
criteria such as clinical long-term outcome of medical device brands. The framework 
influenced the data collection and analysis in three ways. First, the framework helped 
to describe the role of orthopaedic specialists in purchasing decision-making. 
Second, to assess their experience with purchasing processes and the relationship to 
clinical results. Third, to obtain ratings of them on areas for the improvement of 
outcomes of purchasing processes. The study is based on primary data collected 
through a survey, representing end-users of orthopaedic HRMDs, defined as 
orthopaedic specialists in Mexico. 
3.3. Research methods to achieve objective 3 
Sub-study four (see chapter 7) 
For sub-study four (see chapter 7), our research approach is based on a working 
framework (Figure 7.1), which is guided by two considerations: (i) MDLC represents 
key functions for medical devices and as a whole it is a functional system contributing 
to improved health, and (ii) important stakeholders related to the MDLC exert their 
influence at the macro level (regulation and policy mechanism), meso level (public 
healthcare institutions and care provider facilities), and micro level (healthcare 
professional and patient). The framework guided the data collection and analysis. We 
used semi-structure interviews among different interest groups: (i) stakeholders 
influencing MDLC areas; (ii) stakeholders influencing between MDLC areas; and (iii) 
stakeholders that have potential to influence MDLC areas in the future. 
Sub-study five (see chapter 8) 
For sub-study five (see chapter 8), our research approach is based on a literature 
review, which is guided by two considerations: (i) issues concerning medical devices 
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(regulation, quality standards, technology policies, epidemiology of joint 
replacements, economic and health burden of revision surgery), and (ii) the use of 
survival rate benchmarks of orthopaedic implants as „do not do recommendations“-
rule for decision-making in Mexico. 
3.4. Research methods to achieve objective 4 
For sub-study 6 (see chapter 9), our research approach is based on a stakeholder 
analysis used as foresight and based on four steps: demarcating the analysis, 
identifying stakeholders, analysing stakeholder characteristics, concluding on 
stakeholder’s position, interest, and resources in relation to the proposed changes or 
improvements. This study encompasses possible ways forward in fostering the 
regulation, assessment, and management of orthopaedic medical devices that 
address the macro (federal level), meso (institutions of public and private sector), and 
micro (orthopaedic specialist) level of healthcare delivery. For this study we use a 
national level of analysis collecting data from the multiple interest groups concerned 
with the different healthcare delivery levels. We used structured interviews [81] and 
included stakeholder groups that are directly or indirectly related to the MDLC areas 
at the macro, meso, micro, and/or supplier level. The information obtained during 
qualitative data collection is used to provide important insights from stakeholders 
regarding if and how they can affect or be affected by the issues under consideration 
among different interest groups. 
3.5. Ethical statement 
The sub-studies were conducted in compliance with good epidemiological practice. 
The work proposed herein fully complied with the ethical principles stipulated in the 
declaration of Helsinki. The researcher ensured that generated data was anonymised 
and confidentiality was maintained during all the proposed work, for survey reports 
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and scientific publications. An informed consent was obtained of participants who 
participate either in the survey or in the focus groups. They were informed about the 
survey purposes in detail, their involvement (answering questionnaire) and benefits 
from participation and that the participation in the survey was entirely voluntary. 
The ethical committee of the Autonomous University of Mexico [82] approved 
this research project (Date of approval: November 4th 2014, 
FMED/CI/SPLR/188/2014). The study was submitted to the ethical review committee 
of Northwest and Central Switzerland overseeing research activities at the University 
of Basel. Given the characteristics and the involved methods, the committee 
exempted the study by decision letter dated 24th June 2014 from an ethical review. 
Along the national guidelines of the Health Research Authority Decision Tool, no 
formal ethical approval was required for the United Kingdom. Similarly in Germany, 
guidelines of the ethic committees of the State Chambers of Physicians for 
“Nordrhein”, “Hessen”, “Baden-Württemberg”, and “Bayern” waive the present study 
from formal ethical approval (paragraph 15 of the medical professional code of 
conduct and their requirements for studies to be registered [83]). All interviewees 
gave written or verbal informed consent before the interview. 
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4.1. Abstract 
Background: We know little about how procurement of high-risk medical devices 
(HRMD) affects clinical practice and outcomes. In health systems in high-income 
countries, and specifically those that maintain a national arthroplasty registry, 
procurement decisions are frequently influenced by long-term clinical results, with the 
goal of ensuring at least standard quality of HRMDs. But in countries like Mexico, 
decision-making is often dominated by lowest acquisition price. We set out to study 
the impact of procurement for orthopaedic HRMDs on clinical procedures and 
outcomes. 
Methods: We based our qualitative study on 59 in-depth interviews with 
stakeholders from Mexico, Switzerland, Germany, and UK: orthopaedic specialists, 
government officials, other experts, and social security system managers or 
administrators. We took a healthcare delivery approach to capturing and comparing 
factors that affected the regulations of HRMDs and procurement processes, and to 
understanding connections between procurement and clinical practice. 
Results:  Our findings demonstrate for procurement processes that the three 
European countries compared to Mexico don’ t have similar concerns with regards to 
their procurement processes. Deficiencies of procurement regulations and practices 
identified from representatives in Mexico were almost absent in European countries. 
We identified three areas of deficiency: 1) HRMD regulations based on insufficiently 
robust clinical evidence (mainly noted by European countries); 2) Follow-up on 
Health Technology Assessments is inadequate (noted by Mexico) and methodology 
not always good enough (noted by European countries); and, 3) Lowest-acquisition 
price often guides procurement decisions and thus may not align with needs of 
clinical procedures (noted by Mexico and some European countries). 
Conclusions: Procurement processes for orthopaedic HRMDs may have an impact 
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on clinical procedures and outcomes. A favourable approach is one where 
orthopaedic specialists are parties to the procurement process, and post-market 
surveillance data informs decision-making. Actors in the procurement process can 
improve their impact on clinical procedures and outcomes by developing specific 
strategies that better align the needs of both, procurement and clinical procedures. 
 
Keywords 
Medical devices, Procurement, Purchasing, Health systems, Medical technology, 
Orthopaedic 
 
4.2. Background 
The procurement process supports healthcare delivery ][60] and includes activities 
related to purchasing and managing inputs, such as demand management, selection 
and contracting, relationship management, and operational delivery [67]. Ideally, 
procurement decisions should be guided by principles of transparency and money 
should be spent efficiently [84]. However, in some procurement systems, the 
pressure to contain cost is very high, and clinicians have less input into the process 
than administrators. We are here concerned with the procurement of high-risk 
medical devices (HRMDs), and that some procurement systems do not take the 
concerns of all parties into account, or work to resolve their competing interests. 
HRMDs are highly regulated medical devices (class III medical devices) implanted in 
patients, such as knee or hip prostheses used for arthroplasty surgery. 
In health systems of high-income countries, specifically those that have a 
national arthroplasty registry, procurement decisions usually take long-term clinical 
results into account. National registries can contribute to quality assurance by 
tracking and monitoring the clinical performance of orthopaedic implants [26]. Clinical 
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performance can be measured with outcome data, like the length of time certain 
implants last (implant survival) [85] and used to define implant survival requirement 
[55]. Low- and middle-income countries may lack these quality assurance initiatives, 
and not give the procurement process the attention it deserves [62]. In these 
countries, healthcare system actors are urgently concerned with resolving larger 
healthcare questions, like universal access to healthcare services, before they turn 
their attention to optimization. For example, reorganizing Mexican procurement 
processes would improve outcomes but Mexico’s’ resources are mainly dedicated to 
meeting other goals, including universal coverage [86]. 
There is a dearth of knowledge about the processes health service providers 
have devised for procurement [8, 87, 88]. Papers that discuss procurement are 
usually concerned with evaluation measures [66], including financial measures like 
cost and time [88]. Extra-financial measures can also be used to flag weaknesses in 
the procurement process [64]. These measures can capture aspects of the 
procurement process that financial measures cannot [68]. A recent paper from the 
United Kingdom reflected on the history of procurement processes of the health 
sector, and offered a conceptual framework for clinicians and managers in the 
National Health Service (NHS) to help them better understand their role in 
procurement and to improve procurement practices [84]. A study on Mexico 
described the association between procurement practices and the risk of sub-
standard medical devices or services received [8, 60], but there were no follow-up 
studies providing insight into this association. 
Purpose 
We set out to study the impact of procurement on clinical practice and outcomes for 
orthopaedic HRMD (highly regulated medical devices that remain in the patients’ 
body). We took a healthcare delivery perspective in our effort to determine (i) how the 
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set-up of HRMD regulations exerts influence on procurement (macro level), (ii) how 
procurement regulations and practices align with expectations of clinical practice 
(meso level) and, (iii) how procurement practices affect clinical practice and outcome 
(micro). We adapted the healthcare delivery model (HCDM) [7] and the supply link 
framework [66] so our research approach model captured the factors that influence 
procurement regulations and practices for orthopaedic HRMDs (Figure 4.1). 
	
Figure 4.1. Research approach model 
 
We focus on three healthcare delivery levels: 1) macro (regulatory, normative, 
managing); 2) meso (care provider facility); and, 3) micro (healthcare professional 
and patient). We emphasised procurement based on the supply link framework and 
installed it between the meso and micro levels. Procurement has three main actors: 
supplier; procurement administration (purchaser); and, meso level (internal customer) 
and micro level (user). The interaction between the main actors is defined by (i) 
procurement administration and internal customer or user, and (ii) procurement 
administration and supplier. We also defined themes related to procurement: (i) 
regulations for HRMDs, (ii) MD eligibility, (iii) procurement, and (iv) clinical 
procedures. 
4.3. Methods 
Setting 
Environment Macro (Group 1) 
Regulatory, normative, managing 
Meso (Group 2) 
Care provider facilities 
Micro (Group 3) 
Healthcare professional & patient 
Supplier (Group 4) 
Procurement of high-risk 
medical devices 
Clinical practice and outcome 
using high-risk medical devices 
Eligibility of high-risk 
medical devices 
Regulations of high-
risk medical devices 
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To better understand the impact of procurement on clinical procedures and 
outcomes, we compared the context and set-up of procurement for orthopaedic 
HRMDs across four countries: Mexico (upper-middle income country) and United 
Kingdom, Switzerland and Germany (high income countries) and conducted in-depth 
interviews with healthcare system stakeholders. We interviewed (i) healthcare 
system stakeholders who represented macro and meso levels, and supplier (Group 
1, 2, and 4) to understand how the health system environment affects procurement 
(regulations for HRMDs, eligibility for HRMDs, programmes targeting quality of 
HRMDs, etc.), and (ii) orthopaedic specialists who represent the micro level (Group 
3) to capture the interplay between procurement regulations and practices, the 
interests of parties involved directly or indirectly in procurement, and clinical practice 
and outcomes. 
Rationale and validity of selected research method 
We chose this approach because a quantitative approach would not have given us 
enough data to answer our sensitive and complex research question, and because 
there were so few prospective participants representing the macro level and low-to-
moderate number of prospective participants representing the meso level. 
To ensure validity and reliability we used the following strategies: (i) during 
interviews we probed deeply to uncover attitudes, open up new dimensions of a 
problem, and to urge the stakeholder to describe their personal stake in the process, 
(ii) we triangulated data by defining four groups of stakeholders per study country, 
and (iii) we used different interview guides (described in “data collection”) that we 
pre-tested with few stakeholders from the study countries. 
 
Study country selection  
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We wanted to compare the context and set-up of procurement in Mexico in relation to 
countries that met the following inclusion criteria: (i) No centrally organized 
procurement process mandated for the whole healthcare system; (ii) Healthcare 
system had a DRG payment mechanism to reimburse for HRMD; (iii) Country had a 
National Arthroplasty Registry for HRMDs (established or in progress); and, (iv) 
Discussion about the clinical burden of high-risk HRMDs was on-going in that 
country. We selected The United Kingdom, Switzerland and Germany from a list of 
countries that met these criteria and on purposive criteria. 
Study population and recruitment 
We interviewed 59 people. Of these, 26 (44%) were government officials or experts 
who focused on health regulations, health technology assessment, reimbursement, 
adverse events and complaints, medical device quality, investigation, or medical 
training (Group 1 represented the macro level); 6 (10%) were staff of the healthcare 
provider facility, responsible for or expert in procurement, quality and investigation 
(Group 2 represented the meso level); 15 (26%) were orthopaedic specialists (Group  
3 represented the micro level); and, 12 (20%) were employed by the medical device 
industry (Group 4 represented the supplier level). Table 4.1 shows the composition of 
participants by stakeholder country. 
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Table 4.1. Composition of participants 
 
We identified and recruited participants for interviews: (i) by searching each countrys’ 
listings from the ministry of health and industry for orthopaedic HRMDs, national 
academic expert, orthopaedic key opinion leaders, organisations, hospitals, and 
institutions; and (ii) we asked interviewees to recommend other national or 
international experts in our area of interest. We focused on generating sufficient and 
useful material to reflect a variety of opinions and experience, and achieving 
saturation for general themes. We based the sample we selected for each country on 
three criteria: (i) it should include at least one stakeholder for each group; (ii) 
stakeholders from each group should be distributed evenly across study countries; 
and, (iii) each country group provided its experience and opinions on each of the four 
theme (regulations for HRMDs, eligibility for HRMDs, procurement, clinical practice, 
and clinical outcome). We approached prospective interviewees between June and 
September 2014, contacting them by email or phone to introduce them to our study 
rationale and research. Before we invited them to an interview, the principal 
investigator talked or wrote to them. 
Stakeholder group Mexico Switzer-
land 
German
y 
UK Other Total 
Group 1 (macro 
level) 
9 (38%) 7 (50%) 5 (50%) 4 (40%) 1 (100%)* 26 (44%) 
  Regulations  2 (22%) 2 (29%) 1 (20%) - - 7 (27%) 
  Eligibility  2 (22%) 2 (29%) 2 (40%) - - 7 (27%) 
  International expert 2 (22%) -* -* -* 1 (100%)* 3 (11%) 
  Quality assurance 3 (34%) 3 (42%) 2 (40%) - - 9 (35%) 
Group 2 (meso 
level) 
3 (12%) 1 (8%) 1 (10%) 1 (10%) - 6 (10%) 
Group 3 (micro 
level) 
8 (33%) 3 (21%) 2 (20%) 2 (20%) - 15 (26%) 
Group 4 (supplier) 4 (17%) 3 (21%) 2 (20%) 2 (20%) - 12 (20%) 
Total per country 
24 (41%) 
14 
(24%) 
10 (17%) 10 (17%) 1 (1%)* 
59 
(100%) 
* As an international expert for the three European countries under review we selected one 
stakeholder that is listed in column “Other”. 
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Data collection 
Interviews averaged 24 minutes (min=17 min, max=45 min) and were conducted in 
the language of the country (English, Spanish or German). We used a file naming 
system and anonymised interviewees by generating a list of archival numbers. The 
principal investigator interviewed all participants. Of the 59 interviews we conducted, 
44 (74%) were face-to-face and 14 (24%) were phone interviews; only one (2%) 
interviewee submitted a written answer because his employer required it. We audio 
recorded 53 (90%) interviews and transcribed them with F5 software [89]. The 
transcriptions of the interviews that we did not record were based on an interview 
protocol. The principal investigator and one assistant transcribed the interviews, and 
the principal investigator reviewed them again. The interviewer used semi-structured 
interview guides (Table 4.2) to explore stakeholder experiences and solicit their 
opinions on the environment of the health system, its effect on procurement, and the 
role of programmes that target quality and support procurement (Group 1, 2, 4). They 
also asked about the influence of procurement regulations and practices on clinical 
procedures and outcomes (Group 3). 
	
Table 4.2. Extraction of interview guide questions 
Q1 What do you think induces healthcare professionals to claim that the clinical 
practice is sometimes affected adversely when the medical device (clarify that 
this question does not address the device technology but the brand) is selected 
by a purchasing or procurement department rather than by the physician itself? 
Q2 What do you think are core aspects for the provision of medical device quality? 
The term “medical device quality” refers to a medical device that demonstrates 
the successful use intra-operatively (no failures of implant, instrument or 
surgical technique) and post-operatively (average to high implant survival rate 
based on clinical data). The term “provision” covers all aspects that contribute 
to the decision process of the purchasing or procurement department. 
Q3 Evaluating the performance of a procurement process, generally generic 
measures (costs, time, etc.) are considered. The literature appeals that the 
performance of a procurement process within the health system has to be 
based on non financial measures too; this permits also to evaluate how the 
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procurement process is embedded in its environment. Non financial measures 
cover i.e. information flow, failure reporting, quality monitoring, etc. What do 
you think are important non financial measures that contribute to the successful 
“provision” of “medical device quality”? 
Q4 As a follow up of Q3: From the perspective of a HCP, what do you think are 
additional and desirable non financial measures that contribute to the 
successful provision of “medical device quality”? 
Q5 The procurement function generally implements a quality assurance system to 
guarantee good practices and outcomes of a procurement process. What do 
you think such a system should incorporate to provide medical device quality 
(consultation of clinical studies, arthroplasty registers, HTAs, internal reports on 
implant use, etc.)? 
Data analysis 
We iteratively analysed the content of all interviews in MAXQDA software [90] and 
systematically inferred interdependencies between the experiences and opinions of 
stakeholders. First, we closely read each transcript (data orientation) during initial 
coding. Second, we selected statements that addressed frequently mentioned 
themes and fact-based arguments (data reduction). Third, we revised our list of 
themes, improved codes if necessary, and clarified ambiguous statements (data 
display). Fourth, we drew on the themes we identified as deficiencies in the 
understanding of the impact of procurement and factors influencing procurement 
(conclusion drawing). The main researcher analysed all data. 
4.4. Results 
We divided our findings into three perspectives: macro; meso; micro. Table 4.3 
contains a selection of relevant quotations. 
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Table 4.3. E
xtraction of original statem
ents 
Them
es 
Illustrative quotations 
Interview
ee 
M
acro level: H
ow
 does the set-up of m
edical device regulations exert influence on procurem
ent 
R
egulation for 
m
edical devices 
„[W
]ho gives us the m
ayor quality guarantee is C
ofepris...“ 
M
exico 
(O
.1._201409251747_M
E
X
) 
“[B
]ecause w
e had to m
ake the experience that the regim
e of m
edical devices …
 in com
parison to the 
regim
e of pharm
aceuticals is frequently criticized due to its putative rather liberal m
arket access 
requirem
ents.” 
S
w
itzerland 
(O
.1._201409020858_ZR
H
) 
„[F]or all other products especially m
edical devices that are classified as high-risk products there are 
requirem
ents that these have to w
ork. H
ow
 this is m
easured is not clearly described.“ 
G
erm
any 
(O
.1._201410291400_TU
T) 
„[E
]ach car that is being validated hast four w
heels and confirm
 w
ith a specific quality norm
 and for 
m
edical devices it is the sam
e” 
G
erm
any 
(O
.1._201406260812_ZR
H
) 
“[I]ndeed w
e have a discussion that w
e could say that since ever there have been som
etim
e problem
s 
also w
ith hip im
plants and other im
plants. B
ut this is alm
ost not possible to avoid because for technical 
innovations you obtain a better understanding based on practical experiences…
” 
G
erm
any 
(O
.1._201409020858_ZR
H
) 
E
ligibility for 
m
edical devices 
“…
[t]he standard list is based on evidence that is already 6 to 10 years old, obsolete, and it w
ill be used 
for additional 6 years.” 
M
exico 
(O
.1._201410031215_M
E
X
) 
“…
[b]ut w
hat exists already w
hich has years, our w
ork w
ill be to update and to classify or segm
ent.” 
M
exico 
(O
.1._201410311530_ZR
H
) 
“[I]t doesn’t im
ply any problem
, no, because the standard list contains good products.” 
M
exico 
(O
.1._201409251747_M
E
X
) 
“[M
]edical devices have relatively im
m
ature H
TA
 m
ethodologies that frequently fail to address the low
er 
levels of evidence associated w
ith m
edical devices…
” 
U
nited K
ingdom
 
(O
.1._201409181100_ZR
H
) 
“[C
]urrently it seem
s that in the m
inistry of health there w
ill be m
ore focus on new
 responsibilities w
ith a 
focus on H
TA
.” 
S
w
itzerland 
(O
.1._201408211231_ZR
H
) 
M
eso level: H
ow
 are procurem
ent practices and regulations aligned w
ith expectations of clinical practice 
P
rocurem
ent 
regulations and 
practices 
“…
[i]t is very econom
ic driven and w
hat is cheaper is w
hat w
ill be purchased.” 
M
exico 
(O
.1._201409251542_M
E
X
) 
“[T]he provider of service packages has a free ticket to select the m
edical device that he w
ill provide to 
the hospital.” 
M
exico 
(O
.1._201409180852_M
E
X
) 
“[T]here have been problem
s like alw
ays and w
e try to prevent this w
ith a new
 tender.” 
M
exico 
(O
.1._201409251542_M
E
X
) 
“[I]f w
e are lucky in procurem
ent there are adm
inistrators that have experience and know
 w
hat they are 
procuring. B
ut norm
ally this is not the case and they base their docum
entation on the standard list that 
isn’t alw
ays updated and that is very generic and in consequence w
e are purchasing sub-standard 
quality.” 
M
exico 
(O
.1._201410311530_ZR
H
) 
“…
[i]t is not the best quality because the standard list is very obsolete and not updated and there are no 
specific guides to m
ake an evaluation.” 
M
exico 
(O
.1._201409191334_M
E
X
) 
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“…
[t]he adm
inistrator now
 use providers for service packages …
 but the quality is not guaranteed 
because these providers don’t have to provide w
hat has been included in the standard list and they can 
provide w
hat they w
ant.” 
M
exico 
(O
.1._201409191334_M
E
X
) 
“[S
]o w
hat I am
 trying to say is that it is not just the cost you need, you need have really good health 
econom
ist data to support your products really w
ell, and to also calculate the actual full treatm
ent cost 
including the health benefits and the cost of the revision or failure or lack of perform
ance …
“   
U
nited K
ingdom
 
(O
.1._201407211627_Y
R
K
) 
“…
[w
]e are under huge fiancial pressures to trying to save m
oney and w
e w
ill save on certain, any 
reasonable thing w
e can but you cannot com
prom
ise the quality on patients safety and outcom
es.” 
U
nited K
ingdom
 
(O
.1._201407221144_B
O
L) 
“[T]he expectation w
as that hip joint should have a survival ship of 90 %
 at 10 years at post m
arket.” 
U
nited K
ingdom
 
(O
.1._201408011100_LU
Z) 
“…
[a] new
 product and the clinical data isn't gonna be there and how
 do you fight against that. A
nd that 
is w
hen you need that senior engagem
ent w
here you end up ... A
nd quality is there, finance is there, 
they than gonna said to m
e "but how
 does it interact in the patient?” 
U
nited K
ingdom
 
(O
.1._201407221144_B
O
L) 
“[I] think w
hat w
e do is continuing to m
ature and it gets better each year.” 
U
nited K
ingdom
 
(O
.1._201408011100_LU
Z) 
“[S
]o H
TA
 they are useful but they are not anything like w
hat is a clinical outcom
e.” 
U
nited K
ingdom
 
(O
.1._201408241352_LU
Z) 
“[W
]ell there are hospitals w
here the price takes over priority so that the surgeon just has to accept 
w
hat he get provided.” 
G
erm
any 
(O
.1._201408061342_D
O
R
) 
P
rogram
m
es 
targeting quality 
and supporting 
procurem
ent 
“…
[i]n M
exico w
e are m
issing som
ething such as a departm
ent that m
onitors clinical practice…
”  
M
exico  
(O
.1._201410070910_M
E
X
) 
“…
[w
]e have different social security system
s and in consequence the secretary of health doesn’t have 
full regulatory control.” 
M
exico 
(O
.1. _201410061100_M
E
X
) 
“…
[t]here is no culture of quality assurance even w
e have good structures …
 but w
hen you go to a 
health centre you find disinform
ation, …
, no continuous inform
ation, no one m
onitoring clinical 
practice…
” 
M
exico 
(O
.1._201410061100_M
E
X
) 
“…
[o]r w
e do have tw
o system
s doing the sam
e and in som
e w
ay they are com
peting and this causes 
confusion.” 
M
exico 
(O
.1._201410061100_M
E
X
) 
“…
[u]nfortunately w
e cannot m
ake a patient m
onitoring of m
ore that 2 to 3 years because of the 
system
.” 
M
exico 
(O
.1._201409251747_M
E
X
) 
“…
[w
]e have indicator that doesn’t represent quality assurance but it is som
ehow
 a constant m
onitoring 
of the quality by m
eans of the indicator that w
e are using.” 
M
exico 
(O
.1._201411191930_ZR
H
) 
“[I]n m
y opinion a registry is a good basis for decision-m
aking…
” 
S
w
itzerland 
(O
.1._201408121000_B
A
A
) 
” [P
]rim
arily w
e are interested in the outcom
e quality.” 
S
w
itzerland 
(O
.1._201407291401_ZR
H
) 
“…
[t]o m
ake sure, that surgeon use evidence based, to decide on their prosthesis.” 
U
nited K
ingdom
 
(O
.1._201407231054_LO
N
) 
“…
[t]he im
plant registry for us in joint replacem
ents, is our key source of inform
ation w
ith the devices. 
U
nited K
ingdom
  
	
47	
The spontaneous reporting w
ith incidence …
 gives you incom
plete num
erators and you don't now
 the 
nom
inators. If I am
 producing registry data …
 real tim
e survival ship data, perform
ances, m
ix of devices 
and than som
e decisions in term
s of sizes, m
aterials used, etc. S
o it is a very pow
erful tool for getting 
indicators on post m
arket perform
ance.” 
(O
.1._201408011100_LU
Z) 
“…
[t]hey w
ill be able to tell how
 long the im
plant has been available and w
hat level of evidence there is 
to support its use …
” 
U
nited K
ingdom
 
(O
.1._201408072230_ZR
H
) 
“…
[c]lass II and III devices have a safety-profile, but this does not include evidence of clinical efficacy.” 
U
nited K
ingdom
 
(O
.1._201409181100_ZR
H
) 
“[S
]o the O
D
E
P
 system
 w
ould set up on the basis of guidance given by N
IC
E
 …
 The expectation w
as 
that hip joint should have a survival ship of 90 percent at 10 years at post m
arket …
 than they gave 
indications of how
 w
ell the perform
ance w
as of those devices w
ell against set N
IC
E
 criteria at a 10 year 
m
ark.” 
U
nited K
ingdom
 
(O
.1._201408011100_LU
Z) 
“[W
]ell, the surgeon can't use the B
eyond C
om
pliance im
plants unless they have been specifically 
trained and is agreed by the m
anufacturer and the cham
pions surgeons. B
eyond C
om
pliance are being 
used by a lim
ited num
ber of people.” 
U
nited K
ingdom
  
(O
.1._201408072230_ZR
H
) 
“…
[w
i]m
plant registries, w
hich com
pany devices, and that from
 all perspectives is a key item
 for gaining 
continuous inform
ation about the involving, safety profile…
” 
U
nited K
ingdom
 
(O
.1._201408011100_LU
Z) 
“[J]ust think in the patient. W
hen you are facing the problem
 of an artificial cardiac valve and you get 
inform
ed by the health professional that they don’t have inform
ation about the clinical value but that 
they can assure you that it doesn’t cause any electric shock and doesn’t oxidize…
” 
G
erm
any 
(O
.1._201408201611_K
O
L) 
M
icro level: H
ow
 m
ay procurem
ent practices influence clinical practice and outcom
e 
C
ost-related 
factors 
“[W
]e are draw
ing attention to the econom
ic aspects but not to w
hat the surgeon needs…
” 
M
exico 
(O
.1._201410031215_M
E
X
) 
“…
[t]he aspect is fundam
ental econom
ically; that w
hat is cheaper is that w
hat w
ill be purchased.” 
M
exico 
(O
.1._201409251542_M
E
X
) 
“[U
]nfortunately in our country w
hat w
e do is that w
e don’t focus on the best quality but on the best 
price. In consequence this im
pairs the delivery of quality of care, but this is only one aspect …
” 
M
exico 
(O
.1._201409171712_M
E
X
) 
“[N
]ow
, the person w
ho is just buying hips is not thinking about the added value to the hospital. That is 
w
hy the procurem
ent people got to think on value and they need to understand all the elem
ents that 
could m
ake up that value. O
therw
ise they m
ake ow
n purchasing decisions.” 
U
nited K
ingdom
 
(O
.1._201407210956_LE
E
) 
“[W
]ell, there are hospitals w
here price dom
inates everything…
” 
G
erm
any 
(O
.1._201408061342_D
O
R
) 
“…
[I] did experience in one healthcare facility that they sw
itched from
 one cicatrice m
aterial to another 
because of a low
er price …
 w
e observed m
ore w
ound problem
s than before.” 
G
erm
any 
(O
.1._201408061342_D
O
R
) 
K
now
ledge-
related factors 
“[T]he surgeons’ opinion is im
portant to determ
ine the services he is going to have and to calculate 
required quantities.” 
M
exico 
(O
.1._201410081050_M
E
X
) 
“[b]ecause the procurem
ent staff is deciding w
e don’t alw
ays receive w
hat w
e need or w
hat the patient 
requires.” 
M
exico 
(O
.1._201409191220_M
E
X
) 
“…
[w
]e as surgeon do not alw
ays agree w
ith a provided product. B
ased on our experience and 
M
exico 
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know
ledge w
e believe in other products of higher quality and superior perform
ance…
” 
(O
.1._201409251747_M
E
X
) 
“[T]he surgeon is asked to w
ork w
ith w
hat he has.” 
M
exico 
(O
.1._201409251747_M
E
X
) 
“The decision if w
e use a new
 im
plant system
 is alw
ays done by the user and the user is the surgeon” 
G
erm
any 
(O
.1._201408051326_FR
A
) 
“[I] had the im
pression that the surgeons w
eren’t very satisfied w
hen they w
ere not involved in decision-
m
aking.” 
G
erm
any 
(O
.1._201406260812_ZR
H
) 
“…
[t]he expertise of the surgeon is very crucial. H
e is responsible for w
hat the patient gets im
planted 
and therefore he needs to be convinced of w
hat he is using during surgery.” 
S
w
itzerland 
(O
.1._201408121000_B
A
A
) 
“[I]n S
w
itzerland m
uch is in the responsibility of the surgeons and the hospitals” 
S
w
itzerland 
(O
.1._201409081044_B
E
R
) 
“…
 [i]n the end it is up to 90%
 the surgeon.” 
S
w
itzerland 
(O
.1._201407101428_LU
Z) 
C
linical 
evidence 
related factors 
(please consult quotations for program
m
es targeting quality and supporting procurem
ent) 
 
P
rocurem
ent 
fram
ew
ork 
related factors 
“[I]n som
e situations w
hat w
e have seen is that they use an inadequate im
plant size …
 but there 
haven’t provided another im
plant…
“ 
M
exico 
(O
.1._201410091420_M
E
X
) 
“…
[t]hey start the surgery and w
hen they are gonna to use the im
plant system
 they realize that it is 
incom
plete …
” 
M
exico 
(O
.1._201409171712_M
E
X
) 
“[E
]ach surgeon no m
atter how
 experienced he is needs to be trained on a new
 im
plant …
 each patient 
that is suffering dam
ages due to w
rong is not acceptable.” 
S
w
itzerland 
(O
.1._201408121000_B
A
A
) 
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Macro level: How does the set-up of HRMD regulations exert influence on 
procurement? 
We asked interviewees from all countries to share their experience and opinions 
about the role played by HRMD regulations (e.g. market approval, Health Technology 
Assessments [91], eligibility of HRMD, etc.). Opinions of representatives from 
European countries and stakeholders of Group 3 and Group 4 from Mexico agreed 
that it was important to update requirements in the regulations for HRMDs. 
Regulations for HRMDs 
Health regulations focus primarily on assuring standards of clinical safety, 
performance, and efficacy of HRMDs [51]. However, this does not prevent sub-
standard clinical results in the short- or long-term. The requirements for HRMD 
include proofs of quality like risk assessments and laboratory analysis based on ISO 
norms that are important to ensure material safety. However, if HRMDs need to meet 
no other criteria for judging long-term clinical safety (e.g. adequate implant survival or 
no early implant failure), the quality of the clinical procedure and outcome may be 
compromised. 
In general, interviewees from all countries pointed out the differences between 
stringent requirements for pharmaceutical products, and less strict requirements for 
HRMDs. Most of interviewees in Groups 3 and 4 shared this view. Representatives 
from Mexico who had little or no concern about current health regulations explained 
that current regulations mostly focus on HRMDs that have already been approved by 
the United States or a European country. 
The main concern the representatives of European countries shared is that 
HRMD regulations used insufficient robust clinical evidence for HRMDs. They were 
concerned that market approval of orthopaedic HRMDs were poorly regulated 
because they were generally designed to ensure clinical safety such as material 
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conformity checks based on ISO norms. But this approach does not focus on long-
term clinical safety (e.g., post-operative survival rate of an implant). Some European 
representatives wanted to see clinical trials, or at least prospective studies, to 
become a mandatory part of the health regulation process for HRMDs. 
Regulations for the eligibility of HRMDs 
Recently, HTAs for HRMD have been criticized as not being based on available 
clinical evidence [51]. In general, the concern was that HTAs were often not followed 
up or updated [82], or not fully applied using inadequate methodology (mainly 
European countries). The role played by HTAs [92] differs between countries and the 
focus of the role of HTAs is sometimes shifted as guiding decision-making based on 
rather rigid evaluation criteria. 
In Mexico, an inter-institutional committee under the Secretariat of Health, uses 
HTA findings to decide which technologies are eligible for purchase (national 
standard list). This list guides strongly procurement decisions in the public sector in a 
way so that differences between similar medical devices are insufficiently taken into 
consideration. Different public social security systems may tailor the standard list to 
their needs. Most interviewees from Mexico thought of the standard list as a kind of 
quality seal for HRMDs. However, some Mexican representatives said that HTAs did 
not always meet the highest standards because they had methodological 
weaknesses. These respondents thought the standard list as in need of being 
updated to eliminate out-dated technologies and correct wrong or very generic 
descriptions of HRMD technologies (e.g. according to material specification). 
Representatives from European countries did not see the same problems. Both the 
UK and Germany commonly conduct HTAs and use their findings to decisions about 
reimbursement lists only. But representatives from the UK, Switzerland and Germany 
also questioned the significance of HTA findings and questioned whether HTA 
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methodology was adequate for HRMDs. In Switzerland, HTAs receive less attention 
but inform decisions about reimbursement lists. 
Meso level: How do procurement regulations and practices align with 
expectations of clinical practice 
We asked interviewees from all countries to share their experiences and opinions 
about the forces that shape the interplay between actors in procurement. Stakeholder 
groups from European countries made similar statements; representatives from 
Mexico had different opinions and experiences. 
Procurement processes regulations 
Healthcare providers have different avenues to consolidate purchase power. The 
largest concern was about to closely align procurement to clinical procedures, so that 
it met, for example, the clinical requirements of orthopaedic specialists. Regulations 
that emerged from a centrally organized procurement process system were 
associated with sub-standard delivery of healthcare due to inefficient alignment of 
procurement and clinical procedures. 
In Mexico, it is common to regroup purchase demand at regional and national 
level and per social security system so as to increase purchase power. This is why 
procurement processes in Mexico are bureaucratic and highly standardized. The 
Mexican law offers two options for evaluating offers of HRMD that are listed in the 
standard list: 1) Percentage and points or cost-benefit to choose the highest scored 
medical device, and 2) using the Binario evaluation to choose the cheapest medical 
device among those that meet device requirements. Most representatives from 
Mexico were satisfied with the tender system, but did not always agree with the way 
offers were evaluated. They were concerned about the negative effect it might exert 
on clinical practice. 
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European care providers use different ways to consolidate their purchasing 
demand. In Germany, a hospital belongs to a purchasing syndicate, or negotiates 
independently with suppliers. Some Europeans emphasized that a buying syndicate 
can exert adverse influence (provide HRMD that does not satisfy clinicians needs). In 
the UK, many trusts or hospitals use the services of, for example, organizations like 
the “NHS supply chain”, which negotiate prices for their members. In Switzerland, 
procurement is almost entirely left to hospitals and clinicians. Buying syndicates are 
rare and Swiss interviewees mostly seemed to like their independent system. In 
European countries, most orthopaedic HRMDs are reimbursed through DRG-based 
payment systems, which cover expenditures of service deliverers like hospitals. All 
European stakeholders agreed that when DRG systems were introduced, it 
pressured them to lower costs but it was not associated with a general decline in 
quality. For example, in the UK, procurers must balance cost expectations against 
quality of the HRMD. 
Programmes targeting quality and supporting procurement  
We identified a variety of programmes designed to prevent purchase of sub-standard 
orthopaedic HRMDs. Some of these fill gaps in HRMD regulations for obtaining 
commercial approval, since approval is often based on insufficiently robust clinical 
evidence [93]. These programmes were initiated and are operated by government, 
orthopaedic associations, or orthopaedic specialist groups but not all countries have 
them. Representatives from European countries were convinced of the importance of 
these programmes that, for instance, use e.g. implant survival data from a national 
arthroplasty registry to inform decision-making. But representatives from Mexico, 
which has no similar programmes, had a different opinion. 
In Mexico these types of program don’t exist. Stakeholders mentioned one 
regional project in Mexico that had been initiated by an association of orthopaedic 
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specialists in collaboration with a pharmaceutical company. The program was 
intended to make orthopaedic clinical practice in Mexico more transparent by defining 
methods for collecting and analysing clinical data. Groups 3 and 4 underlined the 
need for quality assurance programmes that support areas of decision-making like 
procurement processes and clinical procedures, but most stakeholders were not 
specifically concerned about this. Some thought the failure to define and introduce 
such programmes was due to (i) missing or recently discovered interest in integrating 
clinical evidence into decision-making and, (ii) a fragmented and segmented health 
system with different social security systems, which made it hard to ensure all 
systems equal access to all pertinent clinical evidence. 
In the European countries, stakeholders were clear about the importance of 
clinical evidence for HRMDs. In the UK, these programmes or initiatives focus on 
quality and support for procurement: the “Orthopaedic Data Evaluation Panel” [55]; 
“Beyond Compliance”; and, the national joint registry. The Orthopaedic Data 
Evaluation Panel provides a due diligence on orthopaedic HRMDs. Beyond 
Compliance offers to clinical supervise new HRMDs before they are widely used, and 
where clinical evidence is not yet robust. In Germany, EndoCert and the German 
arthroplasty registry offer support. EndoCert certifies centres of arthroplasty based on 
minimum quality standards and defines requirements (e.g. minimum of 100 
arthroplastic hip or knee surgeries per year, at least two main surgeons at the 
hospital facility, at least 1 of these surgeons is specialized in orthopaedic surgery) 
[94]. In Switzerland, we identified only the Swiss implant registry that is embedded in 
the national association for quality development. Most of the European stakeholders 
thought that registries support decision-making and improve quality in clinical 
practice. 
Micro level: How procurement practices can influence clinical practice and 
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outcome 
We identified several themes in the transcripts that described factors in the 
procurement process that influence clinical practice and outcomes. These were 
primarily identified by Mexican stakeholders and include factors related to (i) cost; (ii) 
knowledge; (iii) clinical evidence, and (iv) the setting for procurement. The themes 
found in transcripts by European stakeholders were rare and not the same as the 
themes in the transcripts of Mexican stakeholders. 
Factors related to cost: Importance of lowest acquisition price  
In Mexico, price is often more important than clinical considerations, in the selection 
and contracting phase of procurement. Many of the Mexican stakeholders thought 
this detrimental to the clinicians’ clinical practice and to quality of care. For them, this 
focus on buying at the lowest price was the root of the problem. Some Mexican 
stakeholders said that clinical evidence was often unavailable and thus could not 
factor into procurement. 
In the UK, Switzerland and Germany, interviewees did not think price was 
paramount in decision-making, though many interviewees said that when their DRG 
system was introduced, pressure to cut costs influences procurement practices. They 
did not, however, see this as a negative. For example, cost-benefit analysis is useful 
for choosing between competing HRMDs with similar characteristics, but which may 
have different clinical long-term effects. Some interviewees from Germany explained 
that price could take priority over important clinical factors for one specific buying 
syndicate. But European interviewees commonly saw clinical evidence data as 
relevant and necessary to inform procurement. 
Factors related to knowledge: Lack of orthopaedic specialist on decision-making 
committees  
Most of the interviewees from European countries, and most from group Groups 3 
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and 4 from Mexico, provided examples for the importance of the orthopaedic 
specialist to decision-making on HRMDs. But the role of the orthopaedic specialist in 
decision-making of a HRMD was different in the European countries under review 
and Mexico. 
Many representatives from Mexico said that orthopaedic specialists were not 
very involved in decision-making, and that this was typical for the public hospital they 
worked for. This was generally true for Mexican stakeholders from Groups 3 and 4, 
and was partially true of some stakeholders in Groups 1 and 2. This was mentioned 
for all public social security systems and care providers of the Secretariat of Health. 
Two exceptions for care providers of the Secretariat of Health were the National 
Institute of Rehabilitation and the National Institute of Nutrition. 
Representatives from European countries said that orthopaedic specialists are 
typically closely involved in most instances. For instance, they emphasized that 
surgical expertise is essential to determine if switching from one HRMD to another, 
cheaper HRMD would have disadvantages for clinical practice or outcome. 
Factors related to clinical evidence: Rigid evaluation criteria do not sufficiently 
differentiate between similar orthopaedic HRMDs 
Long-term clinical results of similar HRMDs are important and should be always 
considered during decision-making, but countries used this data differently for 
procurement. Representatives from European countries argued that only an expert in 
orthopaedics could evaluate long-term clinical results and decide what implications 
they had for similar HRMDs. 
Most representatives from Mexico said market approval and HTA findings often 
determined decisions on similar HRMDs, rather than basing them on long-term 
clinical effects. They said most Mexican social security systems assign procurement 
administrators and decision-making boards to make those decisions and these focus 
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on conformity to material specifications and cost-benefit aspects; however, these 
boards did not include orthopaedic experts. 
Factors related to the procurement setting: Procurement framework can influence 
quality of service received 
Short-term tenders that procure large quantities of HRMDs are very common in 
Mexico, but not in European countries. In Mexico, stakeholders from Groups 3 and 4 
but also few stakeholders from Group 1, reported that short-term tenders affect 
clinical practice. We isolated three themes: (i) the available selection of implants for 
treating different types of patients may be limited; (ii) sets of implant and instruments 
may be incomplete, and (iii) there is a learning curve for orthopaedic specialists for 
each new HRMD system. Representatives from Mexico said they sometimes need to 
treat patients with sub-optimal implants, or that they didn’t have the right HRMD sizes 
or instruments. Only few representatives thought the learning curve was an obstacle 
to their clinical practice. They liked being exposed to different HRMDs, but regretted 
that they were unable to gain long-term clinical experience on a specific HRMD. 
Stakeholders from Europe spoke hypothetically on these themes, but their situation 
was different from Mexican stakeholders. They pointed out that short-term contracts 
lead to short-term use of an orthopaedic implant, which would make it impossible to 
gain adequate experience with a given. 
4.5. Discussion 
We found that in the European countries under review, there is substantial attention 
being given to regulations, which provide the market approval and influence the 
framework for the procurement of HRMDs. In Mexico, however, there are rarely 
similar discussions or concerns because they have not identified any reason so far to 
evaluate or update the current regulations for HRMDs. Mexico does not have 
procedures in place to prevent sub-standard quality of HRMDs and apply post-
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market surveillance across all social security institutions. For instance, increased 
incidence in European countries under review of post-operative problems resulting 
from the use of metal-on-metal hips, or after breast implants, sparked wide 
discussion about HRMDs. This heightened the attention to health regulations for 
HRMDs and has recently spurred the EU to redefine the requirements for CE 
marking (founded on EU safety), health and environmental protection requirements 
before a product is placed on a market. In Mexico, however, in 2016 the inter-
institutional committee responsible for the standard list of medical devices introduced 
a specific catalogue of technologies related to orthopaedics and traumatology [1]. 
The committee has identified the need that these medical devices require specific 
attention. 
Our findings demonstrate for procurement processes that the three European 
countries compared to Mexico don’t have similar concerns with regards to their 
procurement processes. Deficiencies of procurement regulations and practices 
identified from representatives in Mexico were almost absent in European countries. 
Table 4.4 summarizes the relevance of concerns about regulations of HRMDs and 
procurement processes, and about factors influencing procurement for all groups and 
study countries. 
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Table 4.4. Relevance of concerns about regulations of HRMDs and procurement 
process, and about factors influencing procurement 
Stakeholder group Mexico Switzerland Germany UK Total 
Regulations for market approval 
Group 1 - +++ +++ +++ ++(+) 
Group 2 - ++ ++ +++ +(+) 
Group 3 ++ +++ +++ +++ ++(+) 
Group 4 ++ +++ +++ +++ ++(+) 
Total + ++(+) ++(+) +++  
Regulations for eligibility 
Group 1 + ++ +++ +++ ++(+) 
Group 2 - +++ ++ ++ +(+) 
Group 3 ++ +++ +++ +++ ++(+) 
Group 4 ++ ++ +++ +++ ++ 
Total + ++ ++(+) ++(+)  
Procurement regulations and practices 
Group 1 ++ - - - (+) 
Group 2 - - - - - 
Group 3 +++ - + - + 
Group 4 +++ - + - + 
Total ++ - (+) -  
Programmes targeting quality and supporting procurement 
Group 1 + - - - (+) 
Group 2 + - - - (+) 
Group 3 ++ - - - (+) 
Group 4 ++ - - - (+) 
Total +(+) - - -  
Factors influencing procurement 
  Cost +++ - + - + 
  Knowledge +++ - + - + 
  Clinical evidence +++ - - - + 
  Procurement 
setting 
+++ - - - + 
Total +++ - (+) -  
+++ very relevant     ++ moderate relevant    + relevant    - not relevant 
 
Taken together, our findings for the impact of procurement on clinical practice and 
outcomes demonstrate that: 
1) In Mexico and compared to the three European countries, price is often more 
important than other criteria such as the effect of different orthopaedic HRMDs on 
clinical outcomes. Basing procurement decisions on the Binario option may cause 
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this problem. Since decisions do not rely on detailed assessments of HRMDs that 
consider the effects of variants of similar orthopaedic HRMDs on clinical practice and 
outcome, knowledge of Mexican orthopaedic specialists is insufficiently integrated in 
decision-making. 
2) Mexicos’ concern is cutting cost and controlling for corruption. Short-term, high-
volume tenders cut costs and provide transparency that protects against corruption. 
The force these tenders exert on clinical practice may not leave much room for 
improvement without adequate health technology policies. European countries also 
face cost pressure, especially since the introduction of DRG systems, but the long-
term focus (clinical results) and projections of European procurement systems 
prevent some of the problems Mexico faces. 
3) Mexican orthopaedic specialists are rarely involved in procurement decision-
making, but orthopaedic specialists do not generally hold against this. It may be that 
it is difficult to voice strong critique about inconveniences caused by the very rigid 
centrally organized procurement process system, which is largely disconnected from 
clinical practice. In European countries it would be unthinkable to exclude the 
orthopaedic specialist from decision-making, perhaps since professional 
associations, are involved in setting standards and exert great deal of influence in the 
health system. 
This study proves a connectivity between procurement and clinical practice but 
does not set a standard; given that the identified aspects crucial to the procurement 
process, future studies analysing procurement processes are needed before it 
becomes apparent what aspects and factors within a health system finally determine 
procurement regulations and practices. 
The limitations and strengths of the study 
We believe this is a novel investigation of procurement processes for HRMDs as it 
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examines the influence these processes may exert on clinical practice. We identified 
specific aspects of procurement practices, using orthopaedic HRMDs as our 
example, and showed how they influence clinical practice and fail to prevent sub-
standard medical care. We included a range of stakeholders, but did not include 
patients or representatives from rehabilitation centres. Thus, representation of 
stakeholders of the micro level is incomplete and we only considered orthopaedic 
HRMDs, this limits our ability to generalize our findings. 
4.6. Conclusion 
Procurement processes for orthopaedic HRMDs may have an impact on clinical 
practice and outcomes. Health technology regulations require continuous 
improvements to prevent sub-standard clinical results in the short-term or long-tem. 
Regulations and practices for decision-making of procurement for HRMD may have a 
large influence on clinical practice. In all the health systems we reviewed, there was 
tension between cost and quality, and concern about the interaction between 
procurement and the user (orthopaedic specialist). A favourable relationship between 
procurement and clinical practice is one where orthopaedic specialists are parties to 
the procurement process, and post-market surveillance data informs decision-
making. We are not yet sure if cost is the predominant obstacle in procurement for 
HRMD in Mexico, or if other factors, like the way clinical data is managed, have as 
great an effect. We found that Mexico does not assure and monitor long-term effects 
on the health of patients implanted with HRMDs. 
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5.1. Abstract 
Background: 
In organisational theory there is an assumption that knowledge is used effectively in 
healthcare systems that perform well. Actors in healthcare systems focus on 
managing knowledge of clinical processes like, for example, clinical decision-making 
to improve patient care. We know little about connecting that knowledge to 
administrative processes like high-risk medical device procurement. We analysed 
knowledge-related factors that influence procurement and clinical procedures for 
orthopaedic medical devices in Mexico. 
Methods: 
We based our qualitative study on 48 semi-structured interviews with various 
stakeholders in Mexico: orthopaedic specialists, government officials, and social 
security system managers or administrators. We took a knowledge-management 
related perspective (i) to analyse factors of managing knowledge of clinical 
procedures, (ii) to assess the role of this knowledge and in relation to procurement of 
orthopaedic medical devices, and (iii) to determine how to improve the situation. 
Results: 
The results of this study are primarily relevant for Mexico but may also give impulsion 
to other health systems with highly standardized procurement practices. We found 
that knowledge of clinical procedures in orthopaedics is generated inconsistently and 
not always efficiently managed. Its support for procuring orthopaedic medical devices 
is insufficient. Identified deficiencies: leaders who lack guidance and direction and 
thus use knowledge poorly; failure to share knowledge; insufficiently defined formal 
structures and processes for collecting information and making it available to actors 
of health system; lack of strategies to benefit from synergies created by information 
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and knowledge exchange. Many factors are related directly or indirectly to 
technological aspects, which are insufficiently developed. 
Conclusions: 
The content of this manuscript is novel as it analyses knowledge-related factors that 
influence procurement of orthopaedic medical devices in Mexico. Based on our 
results we recommend that the procurement mechanism should integrate knowledge 
from clinical procedures adequately in their decision-making. Without strong 
guidance, organisational changes, and support by technological solutions to improve 
the generation and management of knowledge, procurement processes for 
orthopaedic high-risk medical devices will remain sub-optimal. 
 
Keywords: Medical devices, Procurement, Healthcare systems, Orthopaedic, 
Knowledge management 
5.2. Background 
Healthcare systems are knowledge intensive environments [95], where knowledge is 
a resource that must be efficiently managed [96]. “Knowledge management” and the 
“system thinking approach for systems’ knowledge” are systematic approaches to 
identifying, capturing, developing, sharing, and efficiently using knowledge [97, 16]. 
When healthcare systems take these approaches, resources like knowledge are 
used more efficiently [98-102]. Many knowledge frameworks exist and they 
encompass different strategies [103] to improve the systematic handling of 
knowledge and potential knowledge within systems [80]. In healthcare systems, 
stakeholders are concerned, for example, with knowledge from clinical procedures. 
This knowledge is created by processing different types of information, and is derived 
from health data, as well as clinical data, which includes (i) patient-related 
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information, and (ii) management information bearing on processes and outcomes, 
such as the health status of a population [104]. 
In healthcare systems actors focus on managing knowledge of clinical 
procedures like clinical decision-making to improve patient care [105-108] and 
activities to assure healthcare worker and patient safety [109] (e.g. healthcare 
working conditions that influence patient outcomes). Using this knowledge effectively 
and efficiently requires a substantial understanding of factors determining its 
management. In the general theory of knowledge management the understanding of 
these factors (success or context factors) varies [103] but can be grouped along four 
dimensions. These dimensions originated from a study comparing 160 knowledge 
management frameworks and describing these dimensions as [80]: people (culture, 
people skills, and leadership); organisation (processes and structures); management 
(strategy, goals, and measurement); and, information technology (infrastructure and 
applications). 
In healthcare systems, knowledge of clinical processes is an important resource 
across all stages of healthcare delivery (clinician, care provider facility, social security 
system, regulation, etc.) [110]. Understanding the management of knowledge in the 
context of these dimensions and across different stakeholders involved is necessary 
to solve or prevent problems related to knowledge. For instance, when organisations 
have to manage complaints and adverse events of medical devices, they must 
consider more than just organisational factors (processes, structures, etc.); they also 
need to engage relevant stakeholders working out strategies to prevent problems 
influencing clinical procedures and affecting healthcare worker and patient safety 
[109]. A complaint is a complication occurring in the course of pre- or intra-operative 
procedures like, for example, the positioning of a cap liner into the cap due to 
surgical technique, accompanying instruments or not visible damages to the liner. An 
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adverse event is an undesirable occurrence for a patient and associated with the use 
of a medical device that requires extra treatment or the removal of an implanted 
medical device. For instance, a few years ago several removals of specific breast 
implants (quality of used material) and hip resurfacing implants (metal debris 
damaging bone) were necessary [36, 111]. 
These products are high-risk medical devices (HRMD) as they are highly 
regulated because they remain in the patient. Examples for HRMDs are those used 
in reconstructive surgery (breast implants, hip or knee implants) or in the treatment of 
diseases (coronary stents). Post-market surveillance plays an important role and 
encompasses the monitoring of the safety and effectiveness of medical devices once 
they are on the market and used in clinical settings [53]. This is an important function 
within a healthcare system because HRMDs often remain in the patient body. 
Healthcare systems and healthcare providers must integrate all four dimensions into 
their processes for capturing, developing, sharing, and effectively using knowledge 
and for building administrative frameworks [112, 113]. The contribution of information 
technology in order to manage big data across different levels of an organisation and 
healthcare system is significant. 
Adequately managed knowledge can support administrative processes, such as 
procurement [112]. Procurement decision-making determines the devices and 
accompanying services used for the treatment of patients, and is knowledge-
intensive [114]. Procuring HRMDs is a process in which administrations or 
procurement agents use certain information from various parties to inform purchasing 
decisions. Based on information it is the goal of procurement to purchase goods that 
have an optimal combination of high quality and low price [115]. The ways the health 
system or social security system manages knowledge will shape the way knowledge 
is used by procurement. The administrator or agent may only use rigid information 
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about acquisition price and product specifications. Little is published about how 
knowledge of clinical procedures or information related is used in relation to 
administrative processes like procurement [88, 115]. 
Purpose 
This research is part of a larger study to improve the understanding of the connection 
between procurement processes for orthopaedic HRMDs in Mexico and clinical 
procedures. In our previous study we observed that in Mexico, mutual knowledge 
support (e.g. use of knowledge from arthroplasty registries) does not adequately 
benefit procurement and clinical procedures of orthopaedic HRMDs. In Mexico, 
orthopaedic speciality belongs to a concept of high level care attention and studies 
reported that high level care attention is still in need of being strengthened [116]. The 
role played by procurement is important because it provides clinicians with products 
and services. Previous research about public procurement in Mexico focused on one 
of the social security institutes providing an action plan for procurement officers, 
information systems and supplier performance. The aim of our study is to analyse 
knowledge-related factors that influence procurement of orthopaedic HRMDs in 
Mexico and is governed by three objectives: 
• Analyse factors of managing knowledge of clinical procedures. 
• Assess the role of this knowledge and in relation to procurement of 
orthopaedic medical devices. 
• Determine opportunities to improve the situation. 
5.3. Methods 
Study framework 
Our research approach is based on a working framework presented in Figure 5.1, 
which is guided by two considerations (i) procurement supports healthcare delivery 
and (ii) procurement decision-making is knowledge sensitive. 
	 69	
	
Figure 5.1. Research approach model 
 
First, we defined three healthcare delivery levels based on the healthcare delivery 
model [7]: 1) macro (normative and policy mechanism); 2) meso (insurance system & 
care provider facility); and, 3) micro (orthopaedic specialist and patient). 
Differentiating between these levels is a crucial aspect of our research because 
public procurement in Mexico and procurement decisions take place at the meso 
level and not at the micro level. The user is employed by the social security institute 
or ministry of health and has little autonomy during procurement decision-making in 
respect to select a medical device. This differs from other healthcare systems where 
users are self-employed and the procurement mechanism used by healthcare 
providers is independent of a central purchasing function [79]. Second, we explain 
procurement based on the supply link framework [66] and embed it along the three 
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administration (purchaser); and, internal customers (at the meso level) and users (at 
the micro level). The interaction between the main actors is shown by arrows and 
defined by (i) procurement (administrator or agent) and internal customer or user, 
and (ii) procurement and supplier. Third, we implemented the four knowledge 
management dimensions [80] as the underlying concept of this research approach 
and used them as orientation to analyse factors of managing knowledge (healthcare 
delivery levels), to assess the role of knowledge from clinical procedures and in 
relation to procurement, and to identify findings having the ability to improve 
managing knowledge. 
Research method 
The study was based on: (i) semi-structured interviews with healthcare system 
stakeholders that represented macro and meso levels (Group 1) to analyse how 
knowledge of clinical procedures is managed among the knowledge management 
dimensions; and (ii) semi-structured interviews with orthopaedic specialists who 
represent the micro level (Group 2) to assess the role of knowledge from clinical 
procedures and in relation to procurement of orthopaedic medical devices. 
Rationale and validity of selected research method 
We chose this approach because a quantitative approach would not have given us 
enough data and because there were so few prospective participants representing 
the macro level and low-to-moderate number of prospective participants representing 
the meso level. To ensure validity and reliability we used several strategies. First, 
during interviews we probed deeply to uncover attitudes and open up new 
dimensions of a problem, and to urge the stakeholder to describe their personal 
stake in the process. Secondly, we triangulated data by defining a heterogeneous 
sample of stakeholders per group, and finally, we used different interview guides 
(described in “data collection”) that we pre-tested with few stakeholders from Mexico. 
	 71	
Study population and participant selection 
We interviewed 48 people and their composition is presented in Table 5.1. 
Table 5.1. Composition of participants 
Expertise of participant 
Group 1 
n 
Group 2 
n 
Total 25 23 
Macro level   
   Regulation 4 0 
   Evidence synthesis 6 0 
   Orthopaedic association 3 0 
   Other expert 2 0 
Meso level   
   Institution 4 0 
   Care provider facility 6 0 
Micro level (orthopaedic specialist 
employed by different institutes)   
   Social Security – IMSS 0 8 
   Social Security – ISSSTE 0 4 
   Social Security – PEMEX, 
SEDENA 0 3 
   Ministry of Health 0 8 
 
IMSS, Instituto Mexicano de Seguro Social (Mexican Institute of Social Security); ISSSTE, Instituto de 
Seguridad y Servicios Sociales de los Trabajadores del Estado (Institute of Social Security and Services for 
State Workers); PEMEX, Petróleos Mexicanos (Mexican Petroleums); SEDENA, Secretaría de la Defensa 
Nacional (Secretariat of National Defense) 
 
We identified and recruited participants for interviews by (i) searching listings from 
the ministry of health and industry for orthopaedic HRMDs, national academic 
experts, orthopaedic specialists, organisations, hospitals, and institutions to identify 
potential interviewees and (ii), we asked interviewees to recommend other 
stakeholders. We based the sample on two criteria: (i) recruit a heterogeneous 
sample across different stakeholders; and (ii) stakeholder being involved in or familiar 
with regulations of medical devices, healthcare delivery of medical devices, 
procurement and provision of medical devices in Mexico. Sampling was rooted in a 
maximum variation strategy [90, 117]. 
Data collection 
The study was done in Mexico (Federal District and State of Mexico). In this area the 
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concentration of arthroplasty surgery across the country and the representation of 
important government officials or key stakeholders of healthcare providers is high. In 
Mexico, healthcare providers belong to an institution of the social security sector 
(IMSS, ISSSTE, PEMEX, SEDENA, MARINA) that operate on national level or to the 
ministry of health (Seguro Popular de Salud, SEDS, Programa IMSS-O) [70]. 
We approached prospective interviewees between February and March 2015 
them by email or phone. Before we invited them to an interview, the principal 
investigator talked or wrote to them. Interviews took place at the office of the 
interviewee or at a place the interviewee selected (e.g. conference room at work). 
Interviews averaged 23 minutes (min=18 min, max=35 min). Interviewees had a 
choice of being interviewed in Spanish or English. We used a file naming system and 
anonymised interviewees by generating a list of archival numbers. The principal 
investigator interviewed Group 1 participants and some Group 2 participants. A 
research assistant interviewed the rest of the participants from Group 2. Of the 48 
interviews we conducted, 96% were face-to-face, and 4% were phone interviews. We 
audio recorded all interviews and transcribed them with F5 software [89]. The 
principal investigator and two assistants transcribed the interviews, and the principal 
investigator reviewed them again. The interviewers used semi-structured interview 
guides including open-ended questions that encouraged interview participants to 
freely describe their opinions, thoughts and experiences (Table 5.2). Participants 
were not compensated monetary or otherwise.	
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Table 5.2. Extraction of interview guide questions 
Group 1 
Q1 On which organizational levels did Mexico achieve the required quality 
assurance of already established quality assurance programs? Please 
explain how. 
Q2 Which organizational level manifests the biggest barrier to translate 
efforts of quality assurance into results? 
Q3 Please describe your opinion on quality assurance and clinical efficacy 
as contributing elements for the provision of medical devices?. 
Q4 Please describe how clinical data from the clinical practice level is 
transferred back to the institutional level and how to the national level? 
Q5 Please describe the general consciousness of Mexican stakeholders 
for the contribution of clinical evidence to their practice. 
Q6 On which organizational levels or specific areas do you observe 
weaknesses with regards to the consciousness? 
Q7 Other countries say that it is a challenge to assure clinical 
effectiveness of a medical device without the support of clinical 
evidence? Only product safety is not sufficient for high-risk medical 
devices. Based on which attempts or programs Mexico tries to manage 
this situation. 
Q8 Please describe what this means for the clinical practice and outcome 
of the patient? 
Q9 What actions are needed to improve this situation? 
Group 2 
Q1 What should be the relation of the orthopaedic surgeon and the 
procurement of medical devices? 
Q2 Please describe your role and knowledge in terms of the procurement 
of medical devices? 
Q3 Please describe what this means for yourself as surgeon who takes 
over the responsibility for the clinical outcome of the patient?  
Q4 In Mexico it is common practice to procure the majority of medical 
devices through tenders and to award based on the best price 
(respecting its listing in cuadro basico). What is your experience on 
that?  
Q5 Please describe how you perceive the outcome of the procurement in 
terms of your clinical practice, the quality of supplier service, and the 
intrinsic quality of the product?  
Q6 How is clinical evidence and clinical data considered?  
Q7 Please describe how long you can stick to the same implant system in 
your public institution. Please distinct between trauma and 
reconstruction devices?  
Q8 Please describe what this means for the clinical practice and outcome 
of the patient?  
Q9 What actions are needed to improve this situation? 
Q10 How do you currently obtain sustainable information on clinical safety 
of a medical device? 
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Data analysis 
We used our research approach model as a working framework and opted to analyse 
the findings by the four knowledge management dimensions because in this way, we 
were able to describe the connectedness and interaction between the actors directly 
or indirectly involved in procurement based on knowledge-related factors. Other 
research approaches concerned with knowledge management have been used as 
well but for different research questions. We iteratively analysed the content of all 
interviews [90] in MAXQDA software version 11 [118] and to systematically inferred 
interdependencies between the experiences and opinions of stakeholders. First, we 
closely read each transcript (data orientation) during initial coding. Second, we 
clustered codes for similar themes and interrelated concepts (data reduction). Third, 
we revised our list of themes, improved codes and clustering if necessary, and 
clarified ambiguous statements (data display). Lastly, we drew on the themes we 
identified as deficiencies in the role and management of knowledge (conclusion 
drawing). The principal investigator analysed all data. Table 5.3 provides an 
extraction of relevant statements. 
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Table 5.3. E
xtraction of relevant statem
ents 
Them
es 
Illustrative quotations  
Interview
ee 
P
eople-related factors 
Leadership 
“A
t the strategic or functional level they define and develop and prom
ote an idea 
and there is a disposition but after that they are failing w
ith the im
plem
entation.” 
G
roup 1, M
acro – 
International E
xpert 
O
.2._201503101730_M
E
X
 
“There w
as once, in the past tw
o adm
inistrations, during president Fox and 
president C
alderon, very interesting quality assurance strategies for all public 
institutions. A
gain, m
ostly based on interpersonal quality and w
hat the different 
institutions and the different facilities…
 w
hat they achieved in term
s of quality…
 
depended a lot of the interest of particular clinical groups.“  
G
roup 1, M
acro - 
E
vidence synthesis 
O
.2._201502231200_M
E
X
 
“S
o in M
exico w
e have the problem
 that they don’t talk to each other, they don’t 
understand each other and there is no governance…
 so that the w
ay how
 they 
solve the problem
 is rather voluntary than an organizational or system
ic m
atter.”  
G
roup 1, M
acro - 
E
vidence synthesis 
O
.2._201502271200_M
E
X
 
K
now
ledge 
com
petence 
“The research culture here in M
exico is unfortunately very low
 in com
parison w
ith 
the culture of other north A
m
erican or E
uropean countries…
”  
G
roup 1, M
acro – S
ociety 
O
.2._201503191830_M
E
X
 
“W
e still don't have a clear consciousness of the im
portance of im
plem
enting 
quality assurance m
easures at the system
 level. Q
uality concerns are concerned 
m
ostly of few
 groups w
ithin institutions. S
o I think the big challenge, the first initial 
challenge w
ould be to develop a better consciousness of the im
portance of 
continuous im
provem
ent. This is I think the m
ain challenge.“  
G
roup 1, M
acro - 
E
vidence synthesis 
O
.2._201502231200_M
E
X
 
“…
 som
etim
es w
e receive drugs of very good quality. B
ut som
etim
es w
e receive 
very bad quality because procurem
ent doesn’t focus on this…
 A
s long as a drug 
passed the requirem
ents of the health regulation of C
O
FE
P
R
IS
 there is a m
arket…
”  
G
roup 1, M
acro - 
E
vidence synthesis 
O
.2._201502271200_M
E
X
 
K
now
ledge sharing 
 “The doctors don’t alw
ays accept to provide this inform
ation. Let’s think about 
health records. This is really a problem
 that the doctors use them
 correctly…
 the 
inform
ation that is collected is little reliable.” 
G
roup 1, M
acro – 
International E
xpert 
O
.2._201503101730_M
E
X
 
“The problem
 is that m
any don’t fill in the type of incident …
 they don’t provide the 
nam
e of the product. Therefore w
e cannot m
ake a m
atch and process the 
com
plaint adequately…
” 
G
roup 1, M
acro - 
E
vidence synthesis 
O
.2._201503120900_M
E
X
 
“…
 nobody notifies about adverse reactions in this country...” 
G
roup 1, M
acro -  
E
vidence synthesis 
O
.2._201503091215_M
E
X
 
M
utual learning &
 
“…
 they are still duplicating their efforts…
 but w
hat is difficult to change is the 
G
roup 1, M
acro – 
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skills 
burocratic territory of each institute and there is no incentive that could m
otivate 
them
 to focus on a com
m
on purpose…
 an therefore they m
ake w
hat they can but 
not alw
ays coordinated…
”  
International E
xpert 
O
.2._201503101730_M
E
X
 
“I believe that w
e have to im
prove the quality …
 conceiving a better interrelation 
betw
een C
O
FE
P
R
IS
 and other federal units of the secretariat of health.”  
G
roup 1, M
acro - 
E
vidence synthesis 
O
.2._201503091215_M
E
X
 
“B
ecause w
e don't have, neither the resources and very probably w
e don't have the 
expertise needed to follow
 up and to organize this kind of interventions.“ 
G
roup 1, M
acro – S
ociety 
O
.2._201503232000_M
E
X
 
O
rganization-related factors 
N
ational processes or 
structures 
“…
 apart of adverse events there is no interm
ediate inform
ation available. S
o there 
is a lot of inform
ation that w
e loose…
 as surgeon you are very lim
ited w
ith regards 
to access inform
ation…
”  
G
roup 1, M
acro - 
E
vidence synthesis 
O
.2._201503091215_M
E
X
 
“I believe the w
eakest area is the federal w
ith C
O
FE
P
R
IS
 and the strongest area is 
the C
onsejo de S
alubridad G
eneral by m
eans of C
E
N
E
TE
C
 w
hich is step by step 
better involved in the evaluation of m
edical technologies in a broad sense.” 
G
roup 1, M
eso - Institution 
O
.2._201503121800_M
E
X
 
“The problem
 is that no one m
akes a follow
-up of the output of results. R
ecently the 
secretariat of health has started to establish an evaluation system
 of the 
perform
ance of hospitals.” 
G
roup 1, M
acro – 
International E
xpert 
O
.2._201502240930_M
E
X
 
O
rganizational 
processes or 
structures 
 “They provide us w
ith som
e type of report, they inform
 us in general about num
ber 
of prosthesis and patients…
 but w
e don’t receive m
ore inform
ation.” 
G
roup 1, M
eso – 
Institution 
O
.2._201502241600_M
E
X
 
“Further m
any federal units have different organizational structures so that this 
m
akes the situation even w
orse…
 they are heterogeneous so that en som
e units 
they are w
ell organized…
 but in others there doesn’t even exist such an 
organization to adapt specific program
m
es…
” 
G
roup 1, M
eso – H
ospital 
O
.2._201503171700_M
E
X
 
“W
hen you ask w
hat is the num
ber of intra hospital infections that w
e have in 
M
exico nobody can provide you w
ith a general num
ber…
 this is som
ething that 
haven’t been established in M
exico.”  
G
roup 1, M
acro – 
International E
xpert 
O
.2._201502240930_M
E
X
 
M
anagem
ent-related factors 
S
trategy 
“…
 program
m
es are established, they are effused like docum
ents to be used but 
rarely there is a control if these program
m
es are realized…
  especially at the level 
of the secretariat of health…
 There is a deficiency beginning at the central legal 
level up to the state level w
here there are no adequate strategies to im
plem
ent a 
program
 to im
prove quality.” 
G
roup 1, M
eso – H
ospital 
O
.2._201503171700_M
E
X
 
 
“The healthcare system
s rem
ains in the 21st century or m
igrated back to the 20th 
G
roup 1, M
acro -  
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century. W
hat I w
ant to say is that this system
 is focusing to cover crises, episodes, 
but does not attend patients.” 
E
vidence synthesis  
O
.2._201502271200_M
E
X
 
 
“…
w
e are not using the inform
ation. W
e are collecting it and w
e are organizing it, 
w
e have the conditions to use it at very different levels, at the clinical level, at the 
top m
anagem
ent level, but w
e are not using it. “  
G
roup 1, M
acro -  
E
vidence synthesis 
O
.2._201502231200_M
E
X
 
G
oal 
“The problem
 is that w
e are affiliating people and little by little starting to guarantee 
regular access to com
prehensive service. U
nfortunately the overall quality of the 
services that are being provided is still very low
 especially at the am
bulatory level. 
S
o, it is good, that w
e are expanding coverage, but w
e need to expand coverage 
w
ith quality. If not, w
e are m
isspending the resources w
e have m
obilized.  “ 
G
roup 1, M
acro -  
E
vidence synthesis 
O
.2._201502231200_M
E
X
 
 
“R
ecently a new
 epoc has started w
here w
e can say w
hat are the palliative aspects 
that im
pacted …
 The fam
ous collateral dam
ages or additional expenses, or I had to 
keep the patient hospitalised longer because I could not operate him
 because the 
im
plant failed.”  
G
roup 1, M
eso – H
ospital  
O
.2._201503130830_M
E
X
 
 
“If you go to a hospital and you w
ant to certify it and you ask them
 “Is there 
technical support for cardiotocography in the urgency unit”, the answ
er m
ay be yes 
but no one w
ould ever ask if they also know
 how
 to interpret the data.” 
G
roup 1, M
acro -  
E
vidence synthesis 
O
.2._201502261200_M
E
X
 
M
easurem
ent 
“…
 the interesting thing is that there w
ere no indicators for the num
ber of 
prescriptions that are aligned w
ith the clinical guidelines.”  
G
roup 1, M
acro -  
E
vidence synthesis 
O
.2._201503091215_M
E
X
 
 
“A
nd so, here m
ost tim
e the evaluations stop evaluating the existence of a 
product…
” 
G
roup 1, M
acro -  
E
vidence synthesis 
O
.2._201502261200_M
E
X
 
 
“…
The infrastructure is lim
ited and this is a serious problem
 because there is 
interest …
 but also the m
oney is an im
portant lim
itation…
” 
G
roup 1, M
acro -  
E
vidence synthesis 
O
.2._201502261115_M
E
X
 
Inform
ation technology-related factors 
Infrastructure 
“…
 There are tw
o problem
s that I can identify: O
ne is the absence of basic 
inform
ation system
s …
 our inform
ation is in general not system
ised.“ 
G
roup 1, M
acro – 
International E
xpert  
O
.2._201503101730_M
E
X
 
“O
ur registries are not com
plete, they are not reliable because not everything is 
registered. Therefore it is an idea of num
bers…
 but a precise num
ber requires a 
good registry w
ith a very good system
atisation…
” 
G
roup 1, M
eso - H
ospital 
O
.2._201502251245_M
E
X
 
“…
There m
ight exist a lot of data in the different social security system
s or w
ithin 
the sam
e system
 but they are not in a single database” 
G
roup 1, M
acro -  
E
vidence synthesis 
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O
.2._201502250830_M
E
X
 
A
pplications 
“A
nd one of the m
ore serious problem
s is the inform
ation system
. They are not 
based in patients, they are based in m
edical consultations, in hospitalization…
” 
G
roup 1, M
acro -  
E
vidence synthesis 
O
.2._201502271200_M
E
X
 
“In som
e institutes …
 they do have an electronic health record, but it is another 
deficiency that our country w
as not able so far to consolidate the electronic health 
records on national level…
” 
G
roup 1, M
acro -  
E
vidence synthesis 
O
.2._201502261200_M
E
X
 
“…
 it is very difficult in the big hospitals and not all do have a health record, there 
are big hospitals that have health records but they don’t use it.” 
G
roup 1, M
acro - S
ociety 
O
.2._201503191830_M
E
X
 
Factors related to the role of know
ledge from
 clinical procedures 
R
elation of 
orthopaedic specialist 
and procurem
ent 
“…
 because the procurem
ent process here in …
 is rather confidential, not all 
doctors participate, and som
etim
es it is very superficial so that it is only about 
affirm
ative or negative, but …
 often som
eone like a doctor doesn’t participate.” 
G
roup 2, M
icro - S
ocial 
S
ecurity 
O
.2._201502241300_M
E
X
 
“They don’t take into consideration the surgeon to take decisions because often the 
adm
inistrators decides and they buy things that no one uses.” 
G
roup 2, M
icro – M
inistry 
of H
ealth  
O
.2._201503121730_M
E
X
 
“…
 this decides the head of the departm
ent together obviously w
ith the hospital 
director and …
 it is like a rather private situation…
” 
G
roup 2, M
icro - S
ocial 
S
ecurity 
O
.2._201503121830_M
E
X
 
K
now
ledge inform
ed 
decision-m
aking  
“…
no because it is expected that they (C
O
FE
P
R
IS
) have taken care of it, they have 
test it and everything is good and this is not true, m
any tim
e not.” 
G
roup 2, M
icro - S
ocial 
S
ecurity 
O
.2._201503241330_M
E
X
 
“…
 m
any tim
es the decision-m
aking is based on the m
aterial type and econom
ical 
aspects or the cost of these im
plants.” 
G
roup 2, M
icro - S
ocial 
S
ecurity 
O
.2._201503181300_M
E
X
 
“N
o, I think it is very bad (inform
ation flow
 betw
een m
icro and m
eso level) w
hat is 
exchanged betw
een us because w
e have requested a m
eeting betw
een the people 
of the S
eguro P
opular and us to explain w
hich m
aterial is good and adequate for 
the patients. B
ut this has never taken place…
” 
G
roup 2, M
icro – M
inistry 
of H
ealth 
O
.2._201503131230_M
E
X
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5.4. Results 
We found that knowledge is not necessarily generated and managed efficiently 
enough to support procurement of orthopaedic HRMDs. Generally, interviewees 
thought this is a problem at the meso level and related to the dimensions “people” 
and “organisation”. Table 5.4 shows the relevance of inadequately managed 
knowledge for all four dimensions, at the macro, meso, and micro level. 
 
Table 5.4. Relevance of inadequately managed knowledge for all four dimensions 
and healthcare delivery levels 
Dimension Macro level Meso level Micro level Total 
  People  ++ +++ ++ ++(+) 
  
Organisation ++ +++ ++ ++(+) 
  
Management + ++ + + 
  Information   
  technology + ++ ++ +(+) 
Total +(+) ++(+) ++ ++ 
 
+++ very relevant     ++ moderate relevant    + relevant 
 
The problems that were associated at the macro, meso and micro levels, for the 
various knowledge-related factors, influence the role of knowledge from clinical 
procedures and in relation to procurement of orthopaedic HRMD. The results of our 
study show that this leads to procurement decision-making that is insufficiently 
informed by this knowledge and thus negatively influences the provision and use of 
orthopaedic HRMDs. In Table 5.5 we summarize themes that describe these 
problems based on the knowledge management dimensions and the role of 
knowledge for procurement. 	 	
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Table 5.5. Summary of management and role of knowledge 
Topic Identified themes 
Dimension 
“people” 
• Absence of a mutual learning culture specifically for 
HRMDs. 
• Inadequate knowledge sharing culture to manage 
complaints. 
• No sustainable commitment to clinical knowledge-
informed quality assurance programmes. 
• Failure to engage people in generating knowledge. 
• Organisations unable to generate knowledge. 
• Uncertainty how to apply knowledge correctly. 
• Failure to identify the relevance of post-market 
surveillance data. 
Dimension 
“organization” 
• Absence of structures to improve handling and 
management of complaints and adverse events across 
departments. 
• Absence of structures to obtain adequate information of 
data from clinical procedures. 
Dimension 
“management” 
• Failure to develop strategies that merge the interests of 
the different sectors to achieve federal knowledge goals. 
• Weak exchange of information between federal units and 
insufficient to create synergies. 
• Failure to implement strategies that can adequately 
measure e.g. the clinical performance of MDs. 
Dimension 
“information 
technology” 
• Non-electronic patient data collection and records. 
• Lack of infrastructure for collecting national post-market 
surveillance data. 
• Need for an application that monitors performance of MDs 
in clinical use. 
Role of 
knowledge 
• Rigid evaluation criteria like demand calculation. 
• Lack of orthopaedic experts on decision-making 
committees. 
• Importance of lowest acquisition price. 
• Feedback loop on performance of HRMD between users 
and administrators. 
 
We divided our findings into three levels: (i) dimensions of managing knowledge, (ii) 
the role of knowledge from clinical procedures and in relation to procurement of 
HRMD, and (iii) opportunities to improve the situation. 
Dimensions of managing knowledge 
People-related factors as barriers 
	 81	
One of the management theory expectations that can be applied to this analysis is 
that if the culture of knowledge is well established among the actors in a healthcare 
system, knowledge can be adequately managed. However, the results of this study 
show that knowledge is not adequately managed at the meso level. To a lesser 
degree, this is also true at the macro and micro levels. Many stakeholders reported 
that there is not enough knowledge leadership (e.g., guidance and direction in using 
knowledge) or competence to ensure knowledge will be efficiently managed and 
used. The culture of knowledge sharing and mutual learning is underdeveloped. We 
found a number of themes in the transcripts that described the effect of people-
related factors on knowledge management, related to (i) leadership, (ii) knowledge 
competence, (iii) knowledge sharing, and (iv) mutual learning. 
Leaders direct the people who generate or manage knowledge. Some 
stakeholders emphasized the strong influence that key leaders have on directing and 
implementing knowledge sharing initiatives, or on continuing strategic quality 
assurance initiatives. Initiatives are often discontinued or disrupted when the initiator 
moves on to other tasks or passes the responsibility to others. 
“[T]here was once, in the past two administrations… very interesting quality 
assurance strategies for all public institutions… what they achieved in terms of 
quality… depended a lot of the interest of particular clinical groups.” (Group 1, 
O.2._201502231200_MEX) 
Knowledge competence and sharing allow people to integrate knowledge effectively 
into their work. Some participants mentioned this because in the area of clinical 
research and investigation of orthopaedic speciality little is published by Mexican 
orthopaedic specialists in scientific journals and they related this to lack of interest, a 
general weakness of the medical education system, or the work framework for 
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medical specialists in public hospitals. For orthopaedic specialists in other countries, 
the publication track record is important for their career paths. 
“[T]here is little culture to publish scientific work… few are really dedicated to 
this… because of a missing focus during the medicine study and because of 
high workload at the public institutes… and so it is difficult to focus on 
research.” (Group 1, O.2._201503191330_MEX) 
Some participants reported that care providers from the secretariat of health partially 
manage knowledge more efficiently than did social security systems. For instance, 
The National Institutes of Speciality (e.g., the National Institute for Rehabilitation) 
have a more developed system for managing and using knowledge than the regional 
hospitals of the secretariat of health. We found that this is a consequence of various 
people-related factors. 
“…[t]his is all a process and we are all at different levels and a lot of what can 
be achieved in each process can be related to the interest of research groups 
intra- or extra-institutional… but we are not all at the same level… some haven’t 
started yet.” (Group 1, O.2._201502251245_MEX) 
Organisation-related factors as barriers 
Efficient management and use of knowledge is facilitated if actors effectively use 
processes and structures in a healthcare system. But the results of this study show 
that knowledge is often inadequately managed at the meso level. This is less of an 
issue at macro and micro level. The formal processes and structures are insufficient 
to facilitate efficient management and use of knowledge because post-market 
surveillance data is inadequate. Thus, information flows insufficiently, knowledge 
spreads poorly, and there is little synergy created by processes that run in parallel. 
Interview participants described organisation-related factors that, in their view, 
contributed to the failure of national organisations to manage knowledge adequately, 
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especially on a process or structural level, such as the organisational processes or 
structures of social security systems or care providers of the secretariat of health. 
Many participants pointed out that current formal processes and structures 
make it difficult to collect adequate post-market surveillance data because they 
inadequately integrate knowledge about clinical procedures. 
“… [t]he principal weakness of the Mexican system is at the post-
commercialization…” 
(Group 1, O.2._201502261115_MEX) 
Clinical data collection starts with clinical procedures and needs to be established, 
e.g., a post-market surveillance system. Some interviewees said that current 
processes and structures do not connect the meso and micro levels well enough; 
data collection is inconsistent, so clinical procedures do not generate adequate 
knowledge. 
“…[a]part of adverse events there is no intermediate information available. So 
there is a lot of information that we lose… as a surgeon you are very limited 
with regards to access information…” (Group 1, O.2._201503091215_MEX) 
“[B]ut you don’t follow up (clinical cases). You know when you follow up, this is 
when there is any complication…” (Group 2, O.2._201503111600_MEX) 
Some participants claimed that medical specialists often have restricted access to 
information that coordinates meso level actors from departments like administration 
or research and quality. Medical specialists rely on a limited set of data to perform 
clinical procedures or research, and there are no monitoring processes for following 
up clinical cases over the long-term. 
 “[T]hey provide us with some type of report, they inform us in general about 
number of prosthesis and patients… but we don’t receive more information.” 
(Group 1, O.2._201502241600_MEX) 
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Further, participants noted that formal processes and structures that intended to 
improve quality did not allow actors in a health system to create synergy with other 
actors running in parallel. They also noted that these are poorly coordinated because 
the health system is fragmented and segmented. Creating synergies improve 
outcomes of single processes or strategies like national programmes and initiatives. 
“…[t]hey are still duplicating their efforts… but what is difficult to change is the 
bureaucratic territory of each institute and there is no incentive that could 
motivate them to focus on a common purpose… an therefore they make what 
they can but not always coordinated…” (Group 1, O.2._201503101730_MEX) 
For instance, formal processes and structures for the management of complaints 
related to the use of HRMD at the macro level: The National Commission for Medical 
Arbitration [119] receives complaints from patients about service attention of care 
providers, and the Department of Technovigilance of the Federal Department of 
Health and Human Services of Mexico (COFEPRIS) also documents HRMD 
complaints but on the level of e.g. adverse events (e.g. metal debris cause damage 
to bone reaction; bone cement insufficiently attaches to cemented implant surface; 
pelvis cap anchoring technology leads to early loosening of implant) and reported by 
the physician or medical device supplier. However, CONAMED and COFEPRIS have 
no processes in place to share and mutually learn from these complaints. 
Management-related factors as barriers 
Knowledge strategy, goals, and measurement (e.g., knowledge control, 
measurement criteria, performance indicators) provide direction to actors in a 
healthcare system. Actors can then manage and use knowledge efficiently and 
follow-up on strategies, thereby increasing the effectiveness of their strategies and 
goals. Some stakeholders felt they were not given adequate direction. This was 
moderately prevalent at the meso level, but rare at the macro and micro levels. Our 
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analysis revealed several themes where stakeholders related the failure to manage 
knowledge adequately to management-related factors, since these failures were 
observed in strategies, goals, and measurement of (i) federal units, (ii) care providers 
of the secretariat of health, (iii) social security systems, and (iv) healthcare 
professionals. 
The participants reported that it is difficult to fulfil the national goals in the health 
system since the coordinating role of the ministry of health is weak, particularly in the 
relations with the social security organizations and the health systems in the 
sovereign states in the country. Thus, care providers may thus not apply national 
strategies because they are not obliged to. 
“…[p]rogrammes are established, they are effused like documents to be used 
but rarely there is a control if these programmes are realized… There is a 
deficiency beginning at the central legal level up to the state level where there 
are no adequate strategies to implement a program to improve quality.” 
(Group 1, O.2._201503171700_MEX) 
Some participants explained that strategies are sometimes based on goals but are 
still disconnected from clinical procedures or rely on other data that may not fully 
represent clinical needs. For example, in recent years, many clinical guidelines have 
been written and introduced. Stakeholders who know clinical procedures complain 
that the goal of introducing so many clinical guidelines took precedence over 
developing strategies to benefit clinical procedures and processes. 
“[A]nd if we had focused to develop clinical guidelines for a limited number of 
diseases and have made the implementation strategy more carefully with 
measurements and incentives we would have another scenario… Now the 
problem is big because I don’t know how the clinical guidelines will be 
updated…” 
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(Group 1, O.2._201503101730_MEX) 
Federal units do not have well-established strategies to effectively collaborate with 
each other, as seen with CONAMED and COFEPRIS. 
“… [C]OFEPRIS… Consejo de Salubridad General… Cuadro Basico… 
CENETEC… and these four federal entities have been quite disconnected…” 
(Group 1, O.2._201503091215_MEX) 
There was a similar problem at the meso level. Departments for research and quality 
look at HRMD failures through the lens of material specification or technology. They 
focus strongly on the indications of the standard list for HRMDs “Cuadro Basico”, but 
do not seek to gain knowledge from the observations that orthopaedic specialists 
generate during clinical procedures. These observations might include other types of 
product failures like anatomical aspects of HRMDs, steps in inserting or removing a 
HRMD, or special components of the instrument that cost clinicians a lot of time. 
Information technology-related factors as barriers 
Infrastructure and applications create the technical environment where knowledge is 
managed within and between the different levels of healthcare delivery. Information 
technology is an important aspect to transfer and process knowledge [97]. Some 
interviewees pointed out inadequate knowledge management being moderately 
prevalent at the meso and micro levels, and less prevalent at the macro level. 
Technological support is less efficient at the meso and micro levels, where 
administrators and healthcare professionals operate. The problem consists of 
information being insufficiently collected and analysed. For several themes, 
interviewees associated the failure to manage knowledge adequately with the 
absence of technological solutions. 
Some stakeholders pointed out that current applications are not set up to run 
analyses of interest, like determining the performance of HRMDs in use. They said 
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that there is limited infrastructure for sharing clinical data with healthcare 
professionals or other care providers within the same public sector. Some explained 
that insufficient infrastructure and failure to systematise data makes it hard to merge 
data from different public sectors. 
“…[T]here are two problems that I can identify: One is the absence of basic 
information systems … our information is in general not systemised.“ (Group 1, 
O.2._201503101730_MEX) 
For instance, CONAMED uses a web-based system to collect information about 
clinical incidents, which are reported mainly by patients. Aligning this system with 
databases from the social security systems would increase the knowledge that could 
be drawn from these data. A few stakeholders reported that one of the social security 
sectors is working with CONAMED to do this. There are few adequately developed 
applications that collect and store patient data. Applications that monitor the 
performance of HRMD are incomplete or unavailable. 
“[I]n some institutes … they do have an electronic health record, but it is another 
deficiency that our country was not able so far to consolidate the electronic 
health records on national level…” (Group 1, O.2._201502261200_MEX) 
Role of knowledge from clinical procedures and in relation to procurement of 
orthopaedic HRMD 
Orthopaedic HRMDs are procured in Mexico through an administrative process that 
relies on standardized regulations to consolidate purchase power. These are mainly 
based on tender processes that regroup different purchases to increase purchasing 
power and negotiate better prices from suppliers. The results of this study show that 
knowledge from clinical procedures is insufficiently integrated into procurement 
decision-making. Many stakeholders thought this was caused by standardized 
procurement regulations and problems with knowledge exchange between 
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orthopaedic specialists and administrators or between management levels of care 
providers. We found a number of themes, which described the very small role played 
by knowledge of clinical procedures. 
A number of interviewees indicated that orthopaedic specialists are insufficiently 
involved and that procurement applies rigid evaluation criteria like demand 
calculation based on consumption history, and conformity controls based on 
technical or material specifications. However, stakeholders are very interested in 
procurement decision-making that integrates the orthopaedic specialist. 
“[T]hey don’t take into consideration the surgeon to take decisions because 
often the administrators decides and they buy things that no one uses.” (Group 
2, O.2._201503121730_MEX) 
Some interviewees claimed that when procurement did involve medical specialists, 
they were often not in orthopaedics or were unfamiliar with local clinical needs. Hiring 
of responsible staff that could contribute to improving the outcome of procurement 
decision-making was inconsistent. 
Other respondents stated that decision-making was strongly influenced by the 
lowest acquisition price. In our first study informants already noted this. Orthopaedic 
specialists attribute their inferior role in decision-making to the acquisition price 
factor. 
“…[i]t is a straight situation of money, this is the only thing that really matters…” 
(Group 2, CP_O.2._201503311600_MEX) 
Another theme that some participants emphasized was the formal complaint 
management processes. They noted that these did not influence procurement 
decision-making enough because complaints were not well-managed. For example, 
a group of orthopaedic specialists repeatedly received sub-standard quality of 
orthopaedic HRMDs, even after they had submitted formal complaints. They were 
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eventually able to change their local procurement practices to incorporate knowledge 
from clinical procedures and post-market surveillance data of HRMDs. This change 
was only possible because the specialists insisted on escalating their complaints to 
upper-level management in their social security system, over several years. This 
situation seems exceptional. According to stakeholders of other healthcare providers, 
the problem of receiving sub-standard quality of HRMDs and services has not been 
solved. 
“[L]et’s say that I think that these companies can’t afford to manage the volume 
of the hospital and for example the other day I wanted to implant a femoral cup 
size 52 but I only had available size 50 and 54 and so I had to implant the cup 
size 50.” (Group 2, O.2._201503181600_MEX) 
Opportunities to improve the situation 
Based on the first two objectives of this study we depicted which knowledge-related 
factors may lead to a situation of inconsistently generated knowledge of orthopaedic 
clinical procedures and in the context of procurement. The third objective of our study 
aimed to identify opportunities that may improve this situation by drawing on the 
findings of the previous two objectives and by asking interviewees what they believe 
is needed to improve the situation.  
Many factors that we identified during the thematic analysis are related directly or 
indirectly to technological aspects, which we found are insufficiently developed. 
“[W]ell, I believe it is a matter of stewardship… of the ministry of health where 
clinical evidence should be regulated, from the clinical guidelines, the eligibility 
of goods and their regulation, monitor the clinical practice and provide feedback; 
overall, feedback… regulated for the private and public sector” (Group 1, 
O.2._201503091215_MEX) 
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“[I]n some institutes, in some hospital centres of third level attention… there, 
electronical patient dossiers exist… however, and this is another deficiency, our 
country was unable to consolidate them at a national level, as it was proposed 
by the previous administration.” (Group 1, O.2._201502261200_MEX) 
For public procurement in Mexico we believe that there is an opportunity to develop 
an action plan how to improve the management of systems’ knowledge across all 
social security institutes and ministry of health. Options of information technology 
may provide a basis in order to improve the intersections that procurement has with 
the knowledge environment (areas and activities relating to evidence and knowledge 
synthesis). 
Procurement is an administrative area that is influenced by four principal 
aspects: Policy mechanisms and regulations; key procurement actors; degree of 
procurement centralization; and, criteria used to make procurement decisions [88]. In 
Mexico, public procurement varies from highly centralized to decentralized but 
procurement practices are highly standardized. Key procurement actors belong to the 
meso level but not to the micro level. The results of this study show that opportunities 
to improve the current situation were often associated with “key procurement actors” 
or “criteria used to make procurement decisions”.  
“[T]o improve we have to destroy the chains that limit the genuine commitment 
of doctors to look for a system, an implant of a quality; his decision nowadays is 
rather next to financial or administrative decisions. I believe we have to give 
greater emphasis to the doctor who is finally the user of implants…” (Group 2, 
O.2._201502251340_MEX) 
“[F]or me, at least in my institute that the technical advise is taken again into 
consideration…” (Group 2, O.2._201502271600_MEX) 
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“[T]here should be communication of the directive of the Sector towards the 
doctors… it should therefore integrate heads of departments and between them 
reach a consensus and a way to define the required materials to treat patients. 
(Group 2, O.2._201503131230_MEX) 
The mechanism of public procurement in Mexico may not allow to actively integrating 
users in decision-making but there are opportunities to better integrate user 
knowledge. For instance, monitoring relevant aspects of clinical procedures that are 
important to assure the healthcare worker and patient safety by modifying the needs 
assessment strategy in the course of upcoming tenders. 
5.5. Discussion 
In the Mexican Healthcare System and on behalf of the Ministry of Health many 
changes have taken place especially since 2006, such as comprehensive reforms to 
improve the health system [120-122], sectorial health programmes or research to 
improve quality across various dimensions [60, 76, 123-125]. This is an important 
strength of the system because it is frequently concerned with situations lacking the 
ability to make progress in their performance. 
Based on our findings it was evident that stakeholders in Mexico recognize that 
knowledge is an important resource but they are not able to manage it effectively and 
efficiently. The examples provided by the interview participants lead to important 
factors that trigger this situation and which we identify as information technology-
related factors. The knowledge-related problems reported by interviewees focused 
strongly on “People” and “Organisation” but are connected to information-technology. 
For instance, participants referred to problems of systematic databases, not using 
synergies and being unable connecting the variety of systems’ knowledge. Without 
adequate infrastructure and applications to manage big data across the different 
healthcare delivery levels knowledge-related problems summarized in Table 5.4 and 
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5.5 cannot be solved adequately. In Mexico, policy makers have already identified 
the added value of information technology supporting procurement. For instance, the 
introduction of Compranet as application that provides transparency in respect to 
expenditures and awards of public tenders, and which operates mainly on the meso 
and macro level. We did not identify applications established that are based on a 
systematic approach to manage knowledge from clinical practice and connecting to 
procurement. 
Overall we found that in Mexico the knowledge environment influences 
procurement regulations and practices of orthopaedic HRMDs in the following ways: 
1) deficiencies in the healthcare system’s ability to manage knowledge of clinical 
procedures efficiently; and 2) deficiencies in the management of knowledge from 
clinical procedures and post-market surveillance data as it directly relates to 
procurement. Analysing knowledge-related factors, guided by considering the four 
knowledge management dimensions, lead us understand which factors trigger 
ineffective and inefficient knowledge management. The findings of this study point 
out knowledge-related opportunities for procurement practices of orthopaedic 
HRMDs in Mexico. 
We found that the ability of procurement administrators or agents may improve 
when knowledge of orthopaedic clinical practices is adequately integrated in 
decision-making processes [88]. Procurement administrators or agents are 
concerned with providing the right quality of the purchased products (manage 
product complexity) and accompanying services (prevent commercial uncertainty) 
[67, 126]. Studies focus on knowledge gaps about buyer-supplier relationships [84] 
but not with knowledge-related factors influencing procurement and purchasing of 
HRMDs. 
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In our study we found that factors triggering the ineffective and inefficient use of 
knowledge can be associated with poorly developed technological solutions at the 
level of clinical procedures. We believe that there is an opportunity in managing 
knowledge in the field of orthopaedic HRMDs by adequately applied information 
technology solutions. Studies are concerned with health information management 
and technology and how it can be utilized to improve important outcomes and overall 
quality of care in different healthcare settings [127-130]. The interest in knowledge-
related topics in healthcare systems is often focused on clinical informatics to 
promote patient care and safety like, for example, clinical decision-making. In this 
context, many studies report about eHealth solutions (managing single and 
aggregated health information for healthcare professionals, patients, and healthcare 
consumers), and applying it in clinical decision-making [98, 100, 131, 132] like, for 
example, the use of electronic patient dossiers operating at both the clinician and 
patient level. 
Further, managing big data becomes more relevant [133] and we found that the 
use of options supporting knowledge management in the field of orthopaedic HRMDs 
by information technology applications are promising [130]. In the field of 
orthopaedics many policy makers use already approaches of information technology 
to guide decision-making. Examples for this are national arthroplasty registries [35], 
and approaches that build on such arthroplasty registries like, for instance the 
“Orthopaedic Data Evaluation Panel” [55] in the UK. ODEP is defined as a supporting 
decision-making instrument for procurement. ODEP rates implant survival data 
based on clinical information and clinical evidence. It represents a guideline for 
procuring orthopaedic HRMDs and is established by the National Institute for Health 
and Care Excellence of the UK. ODEP rates implant survival data based on clinical 
information and clinical evidence level, received from the “National Joint Registry” 
	 94	
(NJR) of the UK. The NJR collects information on orthopaedic joint replacement 
surgery from clinical procedures, and monitors the performance of orthopaedic 
implants. Other healthcare systems like, for example, Germany and Switzerland, 
integrate information from arthroplasty registries into their quality agenda [134, 94]. 
Without using information technology applications to manage big data it would not be 
possible to inform procurement decision-making adequately with information and 
knowledge of clinical practice. 
We found that knowledge-related factors influencing procurement practices are 
not a unique finding for Mexico and orthopaedic HRMDs. The results of this study are 
primarily relevant for Mexico but may also give impulsion to other health systems with 
an increase of centralized procurement, like for example: Collaborative procurement 
hubs (e.g. United Kingdom), and national or regional purchasing groups (e.g. France, 
Germany) [84, 88, 130]. 
Limitations and avenues for further research 
Our study has several limitations. First, even we have opted a sampling based on a 
maximum variation technique, we did not include (i) a larger number of stakeholders 
representing the meso level of different social security systems, and (ii) patients or 
representatives from rehabilitation centres to provide a broader range of attitudes of 
the micro level. Secondly, our ability to generalize the findings was limited as we only 
considered orthopaedic HRMDs. Third, attitudes of stakeholders from other states 
may differ from those of the State of Mexico and the Federal District. Fourth, we did 
not take a formal knowledge management approach to clearly differentiate, e.g., 
between knowledge management systems and information systems. More research 
is needed to clarify some issues raised in this study. What programmes could be 
established to improve the contribution of clinicians to knowledge management 
practices? What do our findings mean for the national health budget? Answering 
	 95	
these questions is imperative to improving the generation and management of 
knowledge about clinical procedures as it is related to the procurement of 
orthopaedic HRMDs in Mexico. 
5.6. Conclusions 
We believe this is a novel investigation of knowledge-related factors that influence 
procurement and clinical procedures for orthopaedic medical devices in Mexico. We 
identified specific aspects of knowledge and related them to procurement practices, 
using orthopaedic HRMDs as our example, and showed how they are related with 
clinical practice. We explored the perceptions of a range of healthcare actors around 
the topic of generating and managing knowledge for improved procurement 
processes of orthopaedic devices. We showed that knowledge is an important 
resource, identified factors along the dimensions of knowledge management and 
healthcare delivery levels that create barriers, and discussed them in the context of 
administrative processes. The deficiencies we identified should motivate researchers 
to further clarify the relationship between clinical procedures and administrative 
processes in the knowledge environment. 
Stakeholders in Mexico recognize that knowledge is an important resource, but 
they are not able to manage it effectively and efficiently. A favourable approach 
would be when procurement administrators exchange more knowledge with 
orthopaedic specialists who have performed surgical techniques, know the clinical 
properties of implants, and are familiar with the services provided by suppliers (e.g., 
the condition of instrument sets and availability of implant type or size), to improve 
procurement outcome. Without adequate solutions of managing knowledge for 
orthopaedic services, procurement processes for orthopaedic HRMDs will remain 
sub-optimal. Mexico needs versatile solutions for the meso level and the federal level 
of the Mexican healthcare system so as to better analyse information and data from 
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clinical procedures. Many of our findings can be attributed to poorly developed 
information technology aspects. Improving options of managing knowledge by 
information technology may positively influence the impact of procurement decision-
making on clinical practice and improve the healthcare worker and patient safety in 
the long-term. 
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6.1. Abstract 
Objective: 
To assess viewpoints of end-users concerning the purchasing process of high-risk 
medical devices and to discuss the relevance of technology assessments at the 
hospital level and other potential areas for improvement of purchasing processes. 
Methods: 
We used a cross-sectional study and assessed the attitudes and thoughts of 
orthopaedic specialists. The study took place between June and October 2015 in 
Mexico. 
Results: 
We collected data from 187 orthopaedic surgeons. Involvement of orthopaedic 
specialists in purchasing was reported by 86%. However, clinical practice was 
perceived as negatively influenced by purchasing outcomes by 92%. The problems 
were described as: material failure; effectiveness of medical devices; obsolete 
medical device technology; incomplete provision of implant / instrument sets; delayed 
provision of implants and instruments. 
Conclusions: 
To prevent sub-standard outcomes of purchasing decisions, this study and the 
current literature suggest that health technologies should be assessed during the 
purchasing process, end-users should be adequately involved, and decisions should 
be based on multiple criteria including clinical impact in the short-term (e.g. primary 
stability of implant) and long-term (e.g. survival of implant). The focus on Mexico is 
particularly novel and provides insights into a health system where Health 
Technology Assessment (HTA) is mainly present at the macro level and be used for 
the listing of medical device technologies in the standard list. This study concludes 
that Mexican stakeholders of the purchasing process underestimate the contribution 
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of HTAs at the level of purchasing decisions. HTA in Mexico has improved over the 
past years but still requires more advancement. 
Keywords:  
Medical devices, Purchasing, Orthopaedic, Healthcare delivery, Decision making, 
Mexico 
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6.2. Introduction 
The assessment of medical devices is an important function to support the 
appropriate introduction and use of health technology. Policy makers increasingly 
adapt health technology assessments [108, 135, 136] to evaluate high-risk medical 
devices (HRMDs). This serves to either assess different types of health technologies 
(e.g. anatomic cementless knee prosthesis of different bearing surfaces indicated for 
a knee joint replacement) or to assess different medical device brands grouped into 
the same class of health technology (e.g. different anatomic cementless knee 
prosthesis indicated for a knee joint replacement). HRMDs remain in the patients 
body and are grouped into the risk class III of medical device regulation, which 
includes knee joint implants [22]. Health Technology Assessments (HTA) contribute 
to decision making at the macro level (e.g. decisions about the listing of technologies 
in the National Formulary) as well as at the meso level (e.g. decisions about the 
purchasing of medical devices). The latter evaluation type is described in the 
literature as a hospital-based HTA or mini-HTA. Studies show that these can have a 
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major impact on decision making and decision outcomes [137-139], for example, 
preventing intra- and post-operative failures. High quality information is important for 
conducting HTAs [140]. 
Mexico lacks regional and national initiatives for the advancement of high 
quality of information on orthopaedic HRMDs and HTAs at the level of purchasing 
decisions [141, 142]. Between 2014 and 2015 we qualitatively analysed the 
regulation, assessment, and management of orthopaedic HRMDs to understand how 
they influenced clinical procedures. This analysis provided the starting point for the 
present article and the findings suggest that (i) decision making processes focus on 
mechanical and technical specifications and fail to integrate a broader spectrum of 
decision criteria such as clinical long-term outcomes of medical device brands; and 
(ii) orthopaedic specialists are not adequately integrated into decision making 
because their main role is to physically evaluate medical device brands that have 
been taken into consideration for decision making by the purchasing entity. 
In Mexico, HTAs are conducted by the Centre for Excellence in Health 
Technology (CENETEC), which is a specialized agency of the Ministry of Health to 
support policy decisions. Their reports are used by the Inter-institutional Commission 
of the National Formulary for Health Supplies to decide whether a new health 
technology will be listed or not in the National standard list. To date, the literature 
lacks studies about the relevance of HTA activities at the level of purchasing in 
Mexico. The Mexican health system is highly segmented and fragmented [70] and 
characterized by a public/private mix of hospital providers. The public sector 
represents the majority of treatments and encompasses various social security 
institutions and decentralized state healthcare systems (SESA). Studies about 
purchasing are of interest because tenders are frequently selected as a purchasing 
scheme and the organisation of purchasing decisions (e.g. at hospital level or 
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regional level) is based on the demand for a medical device of a single hospital, or a 
region covering several hospitals, or the entire social security institution. This 
determines how much decision autonomy is left to the hospital level. Reviewing the 
information provided by the governmental website Compranet [143], which was 
established to make public procurement activities in Mexico transparent, shows that 
the scope of tenders among the different social security institutions and SESA has 
varied considerably over the past years and that financial aspects dominated 
decision making. 
This cross-sectional study assessed the attitudes and thoughts of orthopaedic 
specialists regarding their role in purchasing decision making of HRMDs, their 
experience with purchasing processes and the relationship to clinical results, as well 
as potential areas for improvement. Based on the above criteria we discuss the 
relevance of adequate technology assessment and potential areas for improvement 
of purchasing processes. 
6.3. Materials and Methods 
The study is based on primary data collected through a survey, representing end-
users of orthopaedic HRMDs. Our research approach is based on a working 
framework and presented in Figure 6.1. 
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Figure 6.1. Working framework 	
The framework is guided by two considerations: (i) end-users have low purchasing 
decision autonomy, and (ii) purchasing fails to integrate a broader spectrum of 
decision criteria such as clinical long-term outcome of medical device brands. The 
framework influenced the data collection and analysis in three ways. Firstly, the 
framework helped to describe the role of orthopaedic specialists in purchasing 
decision making. Secondly, it was used to assess their experience with purchasing 
processes and the relationship to clinical results. Thirdly, ratings of them on areas for 
improvement of outcomes of purchasing processes were obtained. 
Study population 
The study population was defined as orthopaedic specialists in Mexico. Data or data 
sources listing orthopaedic specialists and orthopaedic procedures in Mexico are not 
publicly available, and the associations of orthopaedic specialists or national 
academies do not provide an accessible database on which this study would have 
been able to draw from. Based on information received from the associations of 
orthopaedic specialists, suppliers of the medical device industry, and pharmaceutical 
companies, we estimated a total of approximately 1,700 orthopaedic specialists in 
Mexico. Further, we estimated a total of 26,000 orthopaedic procedures (hip and 
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knee joint replacement), of which 45% are concentrated in the State of Mexico and 
the Federal District. We used the estimated data on orthopaedic specialists and 
procedures as orientation for the data collection. 
Sampling 
We used a non-probability (purposive) and maximum variation sampling technique 
[90] to reach a heterogeneous group of participants with a sufficient number of 
orthopaedic specialists per subgroup, defined by four participants’ characteristics: 
state; sector; care level; and work experience. The characteristic ’sector’ is important 
because the public sector is divided into services provided by social security 
institutions for the employees, and state healthcare systems, which cover the 
population that is self-employed or without an insurance cover. For the web-based 
survey, we searched listings of public hospitals, private hospitals, and associations of 
orthopaedic specialists to identify potential participants. For the paper-based survey 
we selected the sample from attendees of a national conference of orthopaedics in 
Mexico. 
Data collection 
We selected two routes of data collection (web- and paper-based questionnaire) and 
used a structured self-administered questionnaire (Supplementary File 6.1). 
	
Supplementary File 6.1. Questionnaire 
Survey among orthopedic surgeons 
This anonymous conducted survey serves to investigate the relation of procurement of 
orthopaedic high-risk medical devices and its effects on orthopaedic clinical procedures. 
 
Thank you contributing this research and answering the following questionnaire that will 
require approximately 8 minutes. We kindly ask you to indicate your answers in the 
highlighted areas.  
 
If you wish to contact us before or during you are answering questions of this questionnaire 
you may contact the following person: 
  
• Main researcher: Myriam Lingg (Email: myriam.lingg@unibas.ch)  
• Supervisor [82]: Dr. Luis Duran Arenas (Email: 
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lduran19@liceaga.facmed.unam.mx) 
• Supervisor (Switzerland): Dr. Kaspar Wyss (Email: kaspar.wyss@unibas.ch) 
 
>>> Thank you that you participate in this survey. We appreciate a lot your support 
and will be pleased to share with you our findings after finishing this investigation.  
 
Question 1 
 
In which public sector are you mainly practicing orthopaedic surgeries? Please indicate 
with an X your answer. 
 
 IMSS    PEMEX    SEMAR   
         
 ISSSTE    State services     Others   
         
 SEDENA    SSA    Only private   
 
Question 2 
 
Where do you realize your main professional work?  
 
State  
 
Zip code  
 
 
Question  3 
 
To which level of medical care attention does your institution belongs to? Please 
distinguish between “level 1 = family unit”, “level 2 = general hospital” and “level 3 = UMAE 
or specialized unit” 
 
 Level 1 
“Familiar”    
Level 2 
“General”   
 Level 3 
“Especializada”   
 Private   
 
 
Question 4 
 
Since how many years are you practicing in the field of orthopaedic surgeries? 
 
Number of years:  
 
Question 5 
 
Please describe the responsibilities of key persons for the procurement process of your 
public sector? Please indicate with an X your answer.  
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Director of hospital is involved with regards to …                
           
Head of orthopaedic unit is involved with regards 
to … 
               
           
Head of specialized sub-unit is involved with 
regards to … 
               
           
Specialized surgeon is involved with regards to 
… 
               
           
Resident is involved with regards to …                
 
 
 
Question 6 
 
Please describe your role in the procurement process of the public sector and the 
decision-making? Please indicate with an X your answer.  
 
  Fu
lly
 
ag
re
e 
 A
gr
ee
 
 P
ar
tia
lly
 
ag
re
e 
 Li
ttl
e 
ag
re
e 
 D
on
’t 
ag
re
e 
 N
o 
op
in
io
n 
   
I can influence the material planning                    
             
I can influence the clinical efficacy of a medical 
device 
                  
             
I can influence the medical device technology                    
             
My opinion on material planning (volumes, 
sizes, etc.) gets considered 
                  
             
My opinion on the clinical efficacy of medical 
device gets considered 
                  
             
My opinion on the medical device technology 
gets considered 
                  
             
The decision-making complies with my clinical 
needs concerning material planning  
                  
             
The decision-making complies with my clinical 
needs concerning clinical efficacy of medical 
device 
 
        
 
        
             
The decision-making complies with my clinical 
needs concerning medical device technology 
                  
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Question 7 
 
Please describe how much you perceive your clinical practice and patient outcome 
affected by the following aspects? Please indicate with an X your answer.  
 
 
  Fu
lly
 
ag
re
e 
 A
gr
ee
 
 P
ar
tia
lly
 
ag
re
e 
 Li
ttl
e 
ag
re
e 
 D
on
’t 
ag
re
e 
 N
o 
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io
n 
   
Quality of medical device - material failure                    
             
Quality of medical device - effectiveness of 
medical device 
                  
             
Product portfolio - medical device does not 
meet patients’ needs 
                  
             
Product portfolio - obsolete medical device 
technology  
                  
             
Accompanying services – incomplete 
provision of sets 
                  
             
Accompanying services – delayed provision of 
implants and instruments 
                  
 
Question 8 
 
Please describe how much you perceive an impact of the procurement process on your 
clinical practice and patient outcome? Please indicate with an X your answer.  
 
  Fu
lly
 a
gr
ee
 
 A
gr
ee
 
 P
ar
tia
lly
 
ag
re
e 
 Li
ttl
e 
ag
re
e 
 D
on
’t 
ag
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e 
 N
o 
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… wrong material planning                    
             
… low clinical effectiveness of medical device                   
             
… limited product portfolio                   
             
… inferior medical device technology                    
             
… low quality of instruments                   
             
… sub-standard services received from 
medical device supplier 
                  
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Question 9 
 
Please describe how much you can solve these problems without failing in your clinical 
practice? Please indicate with an X your answer.  
 
  So
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e 
w
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 S
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op
in
io
n 
 
   
Quality of medical device - material 
failure  
                  
             
Quality of medical device - effectiveness 
of medical device 
                  
             
Product portfolio - medical device does 
not meet patients’ needs 
                  
             
Product portfolio - obsolete medical 
device technology  
                  
             
Accompanying services – incomplete 
provision of sets 
                  
             
Accompanying services – delayed 
provision of implants and instruments 
                  
 
 
 
 
Question 10 
 
Do the following aspects contribute to an improvement of your clinical practice and the 
patient outcome? Please indicate with an X your answer.  
 
  Fu
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 A
gr
ee
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lly
 a
gr
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e 
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e 
 D
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’t 
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e 
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o 
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Tender culture: Sustainability and 
long-term clinical evidence of medical 
devices  
 
           
 
     
             
Digital access to clinical data from 
hospital to national level 
                  
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Reporting system on clinical efficacy of 
medical devices on hospital and 
national level  
 
           
 
     
             
Diffusion of scientific investigation on 
hospital and national level 
                  
             
Cooperation between orthopaedic 
societies, academic level and 
government units 
 
           
 
     
             
Integral strategy approach between 
government units to control and 
monitor quality on clinical practice level  
 
           
 
     
 
Question 11 (end of questions) 
 
Please describe how you perceive that the following aspects are considered in your 
public sector. Please indicate with an X your answer.  
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Tender culture: Sustainability and long-
term clinical evidence of medical devices  
                  
             
Digital access to clinical data from 
hospital to national level 
                  
             
Reporting system on clinical efficacy of 
medical devices on hospital and national 
level  
 
           
 
     
             
Diffusion of scientific investigation on 
hospital and national level 
                  
             
Cooperation between orthopaedic 
societies, academic level and 
government units 
 
           
 
     
             
Integral strategy approach between 
government units to control and monitor 
quality on clinical practice level  
 
           
 
   ☐ 
 
 
The questions were developed based on the results of two preceding studies [141, 
142]. The questionnaire was pre-tested on five orthopaedic specialists in Mexico. We 
captured responses for questions regarding purchasing using a 5-point Likert scale. 
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The questionnaire used to collect the data was administered on an online platform, 
SurveyMonkey®, and at a scientific conference. 
The web-based data collection took place between June and October 2015 
utilizing SurveyMonkey® to inform orthopaedic specialists about the survey and to 
collect their answers to the questionnaire. We made additional contact through email 
to identify orthopaedic specialists in order to increase participation rate. The paper-
based data collection took place on April 29 - 30 2015 and was conducted by two 
research assistants that were trained in the study procedures for administering 
questionnaires to study participants. We collected data from attendees of the “XXVIII 
National Mexican Conference of Orthopaedics and Traumatology 2015”. The two 
research assistants presented our study at this conference during registration and 
coffee break, informed attendees about the survey and asked them if they were 
interested to participate in the survey. 
Data analysis 
For the data analysis, we merged both sets of data and applied descriptive statistics. 
Ordinal scaled variables were transformed into a binary outcome by grouping the first 
two categories (e.g. “fully agree” and “agree”) into “1” and all other categories into 
“0”. Descriptive analyses were conducted using STATA software version 14 
(STATA/IC 14.1 StataCorp). The data was tabulated and proportions were compared 
between categories using the chi-squared test. We used Fisher’s exact test to 
examine the significance of the association between specific variables of interest, 
and assessed the level of agreement between responses to different items using the 
kappa statistic [144]. 
Ethics 
This project was approved by the ethical committees from Autonomous University of 
Mexico [82] (Date of approval: November 4th 2014, FMED/CI/SPLR/188/2014) and by 
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the Ethical committee from northwest and central Switzerland (Switzerland) 
exempted it from ethical review according to Swiss law (Date of exemption: June 24th 
2014). All interviewees gave written informed consent before the interview. 
6.4. Results 
Sample description 
We identified a total of 600 eligible orthopaedic specialists from the web-based 
search and 215 orthopaedic specialists during the conference (Figure 6.2). 
	
Figure 6.2. Survey process 	
Overall, 187 orthopaedic specialists agreed to participate in the survey, representing 
a 23% response rate based on the number of orthopaedic specialists contacted 
directly. Approximately half of the respondents had more than 15 years work 
experience, and a fifth had less than 5 years (Table 6.1). Most respondents were 
Questionnaires considered 
for analysis (n=187)
Questionnaires considered 
for analysis (n=84)
Questionnaires considered 
for analysis (n=103)
Orthopaedic specialists 
responded (n=84)
Orthopaedic specialists 
responded (n=103)
Web-survey successfully 
delivered (n=543)
Questionnaire successfully 
delivered (n=103)
Web-surveys sent out 
(n=600)
Contacted orthopaedic 
specialists (n=215)
Collection of Email adresses 
from websites of hospitals, 
orthopaedic associations, 
and providers
Recruitment of orthopaedic 
specialists during XXVIII 
National Annual Conference 
of Orthopaedic Association
Denied participa-
tion (n=12)
Web-surveys not 
delivered  (n=57) 
due to invalid 
email address
Orthopaedic 
specialists denied 
participation  
(n=112) 
	 112	
working in the public sector (68%, n=127), and located in the Federal District and 
State of Mexico (58%, n=108). 
 
Table 6.1. Characteristics of respondents by recruitment route 
Characteristics Total sample Web-based Paper-based 
 N (%) N (%) N (%) 
Total 187 (100) 103 (55) 84 (45) 
Care level    
Primary care 0 (0) 0 (0) 0 (0) 
Secondary care 43 (23) 10 (12) 33 (32) 
Specialist care 84 (45) 40 (48) 44 (43) 
Private 60 (32) 34 (40) 26 (25) 
Sector    
Public – Social 
Security Institutions 
IMSS 
79 [23] 32 (38) 47 (46) 
Public - State 
Healthcare System & 
others 
48 (26) 18 (21) 30 (29) 
Private 60 (32) 34 (41) 26 (25) 
State    
State of Mexico and 
Federal District 
108 (58) 54 (64) 54 (52) 
Other states* 79 [23] 30 (36) 49 (48) 
Work experience    
Up to 5 years 40 (21) 8 (10) 32 (31) 
6 to 15 years 61 (33) 27 (32) 34 (33) 
More than 15 years 86 (46) 49 (58) 37 (36) 
 
There were some differences in the characteristics between those recruited through 
the web-search and those recruited via the conference. Those attending the 
conference mostly worked in the public sector, had less seniority, and were located in 
other states. However, there were no indications that these differences affected the 
attitudes of the participants. 
Our study was concerned with purchasing processes in the public sector. 
Nevertheless, 60 participants reported working in the private sector and of these 58% 
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had more than 15 years work experience and only 10% had up to 5 years work 
experience. In Mexico, orthopaedic specialists often work in both the public and 
private sector and after their retirement from the public sector, continue working in 
the private sector. These participants reported on their experience when they 
previously worked in a public sector or opinions about purchasing in public sectors. 
We present the data as a whole and describe any relevant differences between 
orthopaedic specialists from the public and private sector. Table 6.2 summarizes the 
responses of the participants by key themes. 
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Table 6.2 Q
uestionnaire responses on role of involvem
ent, problem
s in clinical practice, effects of procurem
ent, and aspects im
proving 
clinical practice 
  
Total 
A
greed w
ith at 
least one 
statem
ent to be 
involved 
A
greed to 
have an 
affected 
clinical 
practice  
A
greed to see 
effects of 
procurem
ent on 
clinical practice 
A
greed on at least 
on aspect im
proving 
clinical practice 
A
greed that m
ost of 
these aspects are not 
considered in public 
sector 
 
N
 
N
 (%
) 
N
 (%
) 
N
 (%
) 
N
 (%
) 
N
 (%
) 
Total 
187 
161 (86) 
161 (86) 
172 (92) 
173 [23] 
121 (65) 
C
are level 
 
 
 
 
 
 
S
econdary 
care 
43 
35 (22) 
40 (25) 
42 (23) 
42 (24) 
29 (24) 
S
pecialist care 
84 
74 (46)  
74 (46) 
82 (45) 
82 (48) 
48 (40) 
P
rivate 
60 
52 (32)  
47 (29) 
57 (32) 
49 (28) 
44 (36) 
S
ector 
 
 
 
 
 
 
P
ublic 
127 
109 (68) 
114 (71) 
124 (68) 
124 (72) 
77 (64) 
P
rivate 
60 
52 (32)  
47 (29) 
57 (32) 
49 (28) 
44 (36) 
S
tate 
 
 
 
 
 
 
M
exico &
 D
F 
108 
94 (58)  
92 (57) 
104 (57) 
102 (59) 
66 (55) 
O
ther states* 
79 
67 [23] 
69 (43) 
77 (43) 
71 (41) 
55 (45) 
W
ork 
experience 
 
 
 
 
 
 
U
p to 5 years 
40 
35 (22) 
38 (24) 
40 (22) 
37 (21) 
25 (21) 
6 to 15 years 
61 
51 (32) 
53 (33) 
60 (33) 
55 (32) 
43 (35) 
M
ore than 15 
years 
86 
75 (46) 
70 (43) 
81 (45) 
81 (47) 
53 (44) 
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Orthopaedic specialists role in purchasing decision making 
Of the 187 surveyed orthopaedic specialists, 86% agreed with at least one statement 
that they had some form of involvement in decision making: “I can influence” (81%), 
“My opinion is considered” (72%), and “It contributes to my clinical needs” (69%). 
There was no evidence of a difference for the area of purchasing inputs: “Planning of 
material and quantity” (88%), “Effectiveness of medical device” (82%), and “Medical 
device technology” (74%). Fisher’s exact test for the three areas of purchasing inputs 
always resulted in 0.00. Interrater reliability provided a kappa between 0.63 
(substantial agreement) and 0.84 (almost perfect agreement) [144]. Those who 
thought they had some form of involvement in decision making had good agreement 
in the area of purchasing inputs. 
We observed a slightly lower proportion of participants indicating to have some 
form of involvement in decision making concerning orthopaedic specialists employed 
by the social security institution, Mexican Institute of Social Security (IMSS). The 
answers of participants in respect to other characteristics had little variation in terms 
of their care level (“Secondary care: 81%; “Specialist care”: 88%; “Private”: 87%), 
their location in the country (“Mexico & DF”: 87%; “Other states”: 85%) or their work 
experience (“Up to 5 years”: 88%; “6 to 15 years”: 84%; “More than 15 years”: 87%). 
Problems in clinical practice and associated with purchasing 
Of the 187 surveyed orthopaedic specialists, 161 (86%) reported that their clinical 
practice has been exposed to one of the following situations: “Material failure” (64%), 
“Low effectiveness of medical device” (63%), “Available medical device does not 
meet patients’ needs” (51%), “Obsolete medical device technology” (47%), 
“Incomplete provision of sets” (68%), and “Delayed provision of implants and 
instruments” (72%). However, 172 (92%) reported effects of purchasing on clinical 
practice (purchasing output attributes), including: “Wrong material planning” (89%), 
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“Low clinical effectiveness of product” (83%), “Inferior medical device technology” 
(79%), “Limited product portfolio” (83%), “Low quality of instruments” (85%), and 
“Sub-standard services received from medical device supplier” (87%). Participants 
agreed slightly more to have an affected clinical practice based on “Quality of 
services received” and “Material planning”. Fisher’s exact test for problems in clinical 
practice always resulted in 0.00. Inter-rater reliability resulted in a kappa between 
0.26 (fair agreement) and 0.62 (substantial agreement) [144]. Those who reported 
that they had an affected clinical practice or saw effects of purchasing on clinical 
practice had a moderate agreement in the area of purchasing output attributes. 
We observed a slightly lower proportion for experiencing problems in their clinical 
practice in terms of care level “Private” (78%), and work experience “More than 15 
years” (81%). The answers of participants in terms of other characteristics had little 
variation: care levels (“Secondary care”: 93%; “Specialist care”: 88%), sectors 
(“IMSS”: 94%; “ISSSTE”: 100%; “SSA”: 84%; “Other”: 83%), and work experiences 
(“Up to 5 years”: 95%; “6 to 15 years”: 87%). We did not observe a difference for 
participants looking at the characteristic states (“Mexico & DF”: 85%; “Other states”: 
87%). 
Relationship between orthopaedic specialists being involved in purchasing 
and orthopaedic specialists experiencing problems in clinical practice 
Among the respondents who had some type of involvement in decision making, 
many stated they had problems in their clinical practice in general (n=137), which 
was related to the availability of materials and effectiveness or technology of medical 
device, or reported seeing effects of purchasing on clinical practice (n=147), which 
was specified as low effectiveness of medical device, lack of meeting patients’ 
needs, obsolete medical device technology, lack of complete and adequate services 
provided through supplier. Fisher’s exact test to examine the significance of the 
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association between participants reporting that they have some form of involvement 
and problems in clinical practice resulted in 1.00. Fisher’s exact test between 
participants reporting that they have some form of involvement and their clinical 
practice has been exposed to problems associated to purchasing resulted in 0.722. 
The Kappa statistic was below 0.2 for affected clinical practice in general and for 
effects of purchasing on clinical practice. 
Aspects that may improve clinical practice 
Overall, 93% reported at least one aspect by which clinical practice could be 
improved: “Sustainable clinical long-term data of medical devices”, “Access to 
electronically stored clinical data”, “Report system on clinical effectiveness of a 
medical device”, “More clinical research”, “Cooperation between medical 
associations”, “Academic representations and federal agencies”, and “Better 
monitoring of quality in clinical practice”. 
We observed a slightly lower proportion of participants working in the private sector 
reporting that there are aspects that may improve clinical practice for two groups of 
characteristics: care level (“Private”: 82% against “Secondary care”: 98%; “Specialist 
care”: 98%) and sector (“Private”: 82% against “IMSS”: 100%; “ISSSTE”: 91%; 
“SSA”: 97%; “Other”: 97%). Overall, 65% responded that most of these aspects were 
not or almost not considered in their public sector. 
6.5. Discussion 
In this cross-sectional study among orthopaedic specialists we assessed viewpoints 
of end-users concerning the purchasing process of HRMDs. We identified two 
important findings: (i) the majority of participants agreed with at least one statement 
that they had some form of involvement in purchasing; (ii) many participants reported 
experiencing problems in their clinical practice and they associated several of them 
with purchasing. In Mexico, agents of the purchasing process are responsible for 
	 118	
preparing or realizing the needs assessment; this depends on whether the tender 
covers the demand for a single hospital or several hospitals. The heads of 
orthopaedic department and end-users provide information on the expected demand 
for new procedures and suggests the type of technologies needed for the expected 
surgeries. The orthopaedic specialist who is working within the team of the 
orthopaedic department is generally integrated in the purchasing process based on 
physical conformity checks of medical device specifications [141, 142]. This is 
reflected by the answers of participants concerning their influence on and the 
consideration of their opinion for a medical device technology. However, the answers 
on decision making suggest that the way in which decisions are made is not always 
well linked to end-users. In our previous studies we found that the decision autonomy 
of the end-user is relatively low, and that medical devices are not always evaluated 
based on post-market data once that they have been listed in the standard list [141, 
142]. 
Many of the identified areas of problems that participants reported may 
originate from the current practices of purchasing processes for orthopaedic HRMDs 
in Mexico. A previous study on purchasing identified similar findings for outcomes of 
purchasing practices exemplary for the social security institution IMSS [60]. In the 
function of healthcare delivery, the main process occurs at the clinical level between 
clinicians and patients [7]. For the production of direct services to the patient, the 
support of administrative processes such as purchasing is essential and it 
increasingly influences clinical practice and outcomes [145, 84, 60, 88]. 
Understanding the performance of these processes in healthcare systems is 
important because they support clinicians with products such as medical devices that 
are critical for the patient treatment [62, 66, 68, 79, 115]. Evaluating orthopaedic 
HRMDs at the meso level based on a systematic assessment scheme such as mini-
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HTA may bridge the gap between purchasing inputs and outputs, and thus improve 
purchasing decision outcomes. HTA in Mexico has improved over recent years [78] 
but requires still more advancement. 
Few of the identified areas of problems that participants reported may 
originate from post-market regulations for HRMDs in Mexico at the meso and macro 
level. This may be attributed to the experience of end-users that their complaint 
systems do not sufficiently contribute to solving their problems in clinical practice 
[141, 142]. However, in our previous studies, we also found that end-users often tend 
to neglect reporting these problems. When these problems are rarely discussed or 
addressed by the end-users, decentralized organs such as COFEPRIS that 
encompasses the Mexican Technovigilance department cannot exert their influence 
on post-market surveillance. 
This study provides insight into viewpoints of end-users for purchasing of 
orthopaedic HRMDs and into the potential contribution of HTAs at the level of 
purchasing decisions. Given the known needs for improvement of purchasing 
outcomes and aspects that may improve clinical practice, a critical analyses of 
purchasing processes will be necessary to determine real practice relevance and to 
define improvement plans. Those analyses should integrate how purchasing 
decisions influence the type of problem that end-users experience in their clinical 
procedures. 
Limitations 
For this study, we used non-random sampling, which does not necessarily guarantee 
the sample being representative for the population of orthopaedic specialists in 
Mexico. However, this study includes 187 end-users working as orthopaedic 
specialist, and is based on a purposive sampling. Thus it covers different groups of 
surgeons in terms of work experience, state within Mexico, and at the health service 
	 120	
attention level. The sample represents approximately more than 10% of orthopaedic 
specialists who practice orthopaedic surgery. Furthermore, in this study we collected 
data from end-users employed by different public institutions and self-employed 
orthopaedic specialists. Tender processes vary among institutions and over time and 
thus influence the response behaviour of participants. Therefore, this study does not 
provide insight into purchasing inputs related to a specific tender scheme. Instead 
this study provides insight into viewpoints of end-users on purchasing outcomes in 
general. These insights suggest that purchasing processes are in need of more 
detailed investigations. 
6.6. Conclusion 
The findings of this study suggest that purchasing processes need to be further 
investigated in more detail. The outcomes of purchasing decisions have been little 
investigated and a better understanding of these will contribute to the strengthening 
of the purchasing of HRMDs. Neglecting problems that end-users experience during 
their clinical practice leads to the continuation of sub-standard provision of 
purchasing outputs and increased burden of risk for both the orthopaedic specialist 
and the patient. To prevent sub-standard outcomes of purchasing decisions, this 
study and the current literature suggest that technologies should be assessed during 
the purchasing process, end-users should be adequately involved, and decisions 
should be based on multiple criteria including clinical impact in the short-term (tissue 
trauma, rehabilitation duration, primary stability of implant, etc.) and long-term 
(survival of implant, material performance, etc.). 
The focus on Mexico is particularly novel and provides insight into a health system 
where HTA activities are mainly realized at the macro level. However, this does not 
solve the need for adequate evidence-based evaluation of health technologies at the 
hospital level. This study concludes that Mexican stakeholders of the purchasing 
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process underestimate the contribution of HTAs at the level of purchasing decisions. 
HTA in Mexico has improved in recent years but needs more advancement. 
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7.1. Abstract 
Background: Policies for health technologies such as medical devices are essential 
and contribute to improved quality of healthcare. The regulation, assessment, and 
management represent important functions of medical devices. Insufficiently 
developed interactions between these functions impact the quality of delivered 
healthcare. To date studies lack to analyse these functions in a broad way. 
Objective: Analyse the regulation, assessment, and management of orthopaedic 
medical devices in Mexico and how they shape healthcare. 
Design and methods: This qualitative study included 42 stakeholders involved 
directly or indirectly in the regulation, assessment, or management for orthopaedic 
medical devices in Mexico. 
Results: The fragmentation of responsibilities for medical device functions may be a 
central aspect of our findings concerning challenges reported by interviewees. 
Strengthening technovigilance based on improved reporting across healthcare 
institutions emerged as pathway to improve medical device regulation. With regard to 
improving the medical device assessment, a comprehensive update of the standard 
list represents a relevant opportunity. Integrating advanced quality attributes into 
procurement processes regarding decision-making, purchasing strategy, and 
procurement agent is needed to fostering the management. 
Conclusions: This study provides a broad analysis of medical device functions 
within a health system and highlights in this specific context how improvements might 
be achieved. It addresses a broad range of interest groups represented by policy 
makers, health service providers, managers and administrators of healthcare 
facilities, and doctors with an interest in health technologies. In this paper we 
highlight important themes that influence outputs and outcomes of the regulation, 
assessment, and management and discuss strategies in fostering these areas. To 
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date, the regulation, assessment, and management of medical devices are rarely 
analysed in a broad way, even though these functions importantly contribute to the 
successful implementation of health technology policies. The quality of delivered 
healthcare is influenced by the performance between and within these functions. In 
Mexico, little discussion has been raised on challenges of the regulation, 
assessment, and management of medical devices. Changes to current processes 
and practices can improve outputs and outcomes of these functions and positively 
influence the quality of delivered healthcare. Stakeholder involvement and 
commitment is essential to this. 
 
Keywords: assessment; health technology; management; medical device; Mexico; 
regulation 
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7.2. Background 
Policies for health technologies such as medical devices are essential to assure 
equitable access to high quality and affordable devices and their appropriate use and 
thus contributing to improved quality of care [37]. The World Health Organization 
(WHO) emphasizes the importance of developing and implementing health 
technology policies within the context of a national health plan. WHO indicated that 
34% of 145 countries have a health technology national policy in place that is part of 
the national health programme [38]. Mexico is one of these countries and has 
established several government agencies (Table 7.1) and defined regulations that 
support policies for health technologies. This is key to organize and support, and 
strengthen important functions for medical devices. These functions are the 
regulation, assessment, and management of medical devices and compose 
important areas of the Medical Device Life-Cycle (MDLC) (Table 7.2) and support 
healthcare delivery at different organizational levels within the health system. 
 
Table 7.1. Principal actors involved in the regulation, assessment, and management 
of medical devices in Mexico 	
Stakeholders Main responsibility Relative importance 
for MDLC areas 
  
Te
hn
o-
vi
gi
la
nc
e 
A
ss
es
sm
en
t 
P
ur
ch
as
in
g 
• Sub-secretariat for 
Health System 
Integration and 
Development, SIDSS 
• Government agency whose 
mission is to propose to the MOH 
national policies that improve the 
quality of social health services; 
issues the Mexican Official Norms 
(NOM) 
++ +++ ++(+) 
• Departments of Sub-
secretariat for Health 
System Integration and 
Development 
• General directorate of health 
planning and development, DGPD: 
Governmental organization and 
unit under the authority of the 
SIDSS whose mission is to steer 
++ +++ ++(+) 
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the strengthening of health 
services among policy makers, 
and giving guidance to improve 
health services sustainable and 
cultural based on populations’ 
needs. 
• General directorate of quality and 
education, DGCE: Governmental 
organization and unit under the 
authority of the SIDSS whose 
mission is to ensure that the 
quality and safety of health 
services, including human 
resources of the health sector and 
the regulatory environment of 
social health supplies is aligned 
with national policies. 
• General Council of 
Health, CSG 
• Sanitary authority directly 
accountable to the President 
• Council whose mission it is to 
strengthen the governance and 
the articulation of the National 
System of Health. Founded: 1917 
• Publishes the standard list of 
Health Supplies 
• Holds the Inter-institutional 
Commission of the standard list for 
Health Supplies whose mission is 
to manage the approved 
technologies in the standard list for 
Health Supplies 
• Auditing of hospitals with regards 
to quality standards (certification 
process) 
++ ++(+) + 
• Federal Commission 
for the Protection 
against Sanitary Risks, 
COFEPRIS 
• Decentralized organ of the MOH 
whose mission is to protect the 
population against medical risks 
derived from the introduction of 
new medical drugs, medical 
devices and other health inputs. 
Founded: 2002 
• Sanitary Authorization 
Commission whose mission is the 
market approval of medical 
products and technologies. 
• Technovigilance department 
whose mission is to implement 
and realize post-market 
surveillance. 
• Support function of “Sanitary 
Authorization Commission” whose 
mission is to provide 
technovigilance reports for the 
renovation of market approval. 
+++ ++ + 
• National Centre for • Governmental organization and ++ ++(+) ++(+) 
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Health Technology 
Excellence, CENETEC 
unit under the scope of the SIDSS 
whose mission is to contribute to 
the development and governance 
of the National Health System in 
Mexico based on: Health 
Technology Assessments, 
Supervision of medical equipment, 
Telemedicine, Clinical guidelines. 
Founded: 2004 
• WHO collaborating centre. 
• Sub-systems: 
Centralized and 
decentralized health 
services 
• Functionary with national 
responsibilities within the sub-
system; director of healthcare 
facility; procurement agent 
+++ ++(+) +++ 
 • Functionary with local 
responsibility: Head of orthopaedic 
department 
   
 
+++  strong relation    ++  moderate relation    +  low relation     -  no relation 
 
 
Table 7.2. Important outputs and outcomes oft he MDLC areas (adapted from 
WHO [19, 46]) 
Areas Description Outputs Outcomes 
Regulation Safety and efficacy are 
in the focus of this 
phase to aim 
population safety. Key 
elements are 
performing testing, 
safety assessment & 
post-market reporting 
using criteria of safety 
and quality standards. 
 
Mandatory 
compliance 
Assuring 
minimal 
standards of 
quality 
Assessment Serving the population 
is in the focus of this 
phase to aim 
population health. Key 
elements are 
systematic analysis 
and critical review 
using epidemiology 
and evidence data. 
 
Recommendations 
on highly complex 
technologies 
Responsiveness 
and 
maximization of 
clinical 
outcomes and 
cost-
effectiveness 
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Management Health service 
providers are in the 
focus of this phase. 
Key element is the 
operational 
management of 
technology life-cycle 
using needs analysis 
and reliable device 
availability for clinical 
use. 
 
Operational rules 
and guidance for 
all medical 
devices 
Improved health 
delivery; 
sustainable 
availability of 
high-quality and 
safe devices 
 
Besides the development and implementation of health technology policies, WHO 
emphasizes the importance of the commitment for, and realization of a continuous 
improvement plan within and between the areas of the MDLC in order to strengthen 
the implementation of national health technology policies and to contribute to 
improved health [37]. This can be achieved when necessary interactions between 
these areas are established because of their interdependence. To date, there are 
indications of questions regarding different attributes of the MDLC for orthopaedic 
high-risk medical devices (HRMDs) in Mexico and their influence on clinical practice 
and thus on the delivered quality of healthcare [141, 142, 146-148]. HRMDs are 
implanted in the human body (such as a knee joint implant) and are therefore 
recommended subject to the highest level of pre-market and post-market regulation 
[22]. To date, little is known how these attributes affect outputs and outcomes of the 
MDLC and its meaning for quality of healthcare. The articles 83, 179 and 180 of the 
current Medical Device Regulation of Mexico indicate that there are no specific 
regulations for HRMDs differentiating them from lower risk medical devices. 
The Mexican health system is a complex system with multiple actors 
encompassing a public private mix of hospital providers [70]. The national healthcare 
system is decentralized with planning, management, and regulatory authority shared 
at the federal and state-level [72, 73]. In Mexico, the different sub-systems of 
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healthcare (social security and state-level healthcare systems (SESA)) are 
disconnected and the level of healthcare and outcomes between these sub-systems 
varies [32]. This leads to a fragmentation of responsibilities with regard to the MDLC 
areas, which might affect the ability of policymakers to comprehensively oversee the 
MDLC in Mexico. 
The aim of the present study is to analyse challenges of the regulation, 
assessment, and management of orthopaedic medical devices in Mexico and their 
impact on outputs and outcomes of the MDLC. Further, we discuss possible ways 
forward in fostering the regulation, assessment, and management and their influence 
on the quality of delivered healthcare. 
7.3. Methods 
Our research approach is based on a working framework (Figure 7.1), which is 
guided by two considerations: (i) MDLC represents key functions for medical devices 
and as a whole it is a functional system contributing to improved health, and (ii) 
important stakeholders related to the MDLC exert their influence at the macro level 
(regulation and policy mechanism), meso level (public healthcare institutions and 
care provider facilities), and micro level (healthcare professional and patient). 
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Figure 7.1. Working framework 
The framework guided the data collection and analysis. This research is part of a 
larger study to investigate the relation between the regulation, assessment and 
management of orthopaedic HRMDs in Mexico and their impact on clinical 
procedures. 
Study population and recruitment 
The study was done in Mexico. We identified and recruited participants for interviews 
by searching listings from the governmental offices, public sector, orthopaedic 
specialists (public and private sector), organisations, medical device supplier. We 
used a maximum variation sampling [90] to recruit key stakeholder based on three 
sample criteria: (i) stakeholders influencing MDLC areas; (ii) stakeholders influencing 
Systematic analysis and critical review using epidemiological 
data, statistics, analysis of efficacy, effectiveness, and appropriateness
Output: 
Recommendations, e.g. 
National Standard List
Outcome: 
Responsiveness and 
maximization of clinical 
outcomes
Macro level 
Normative & policy mechanism
Meso level
Public & private institutions
Micro level
Healthcare professional & patient
Regulation
Management 
Performing testing, safety assessment & post-market reporting
using safety and quality standards
Output: 
Mandatory compliance
Outcome: 
Risk mitigation and 
prevention of harm
Operational management of technology using needs analysis, 
specifications, reliable device availability for clinical use
Output: 
Operational rules and 
guidance
Outcome: 
Improved health care 
delivery
Supplier
Assessment 
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between MDLC areas; and (iii) stakeholders that have potential to influence MDLC 
areas in the future. 
Data collection 
In total 42 interviews were conducted between April and May 2016 by the principal 
investigator and a research assistant. The principal investigator and a research 
assistant conducted interviews in Spanish. We used a file-naming system and 
anonymized interviewees by generating a list of archival numbers. We used face-to-
face interviews (n=39) and phone interviews (n=3) (Table 7.3). 
 
Table 7.3. Respondent characteristics 
Stakeholder group Participant Male Higher 
management 
level 
N (%) N (%) N (%) 
Group 1 (macro level) 24 (57) 16 (63) 18 (58) 
(i) Having direct relation to MDLC 
areas 11 (46) 5 (45) 8 (73) 
CSG, MOH, General directorates 4 (36) 3 (75) 4 (100) 
COFEPRIS, CENETEC 6 (55) 2 (33) 3 (50) 
International organization or experts for 
Mexican health system 
1 [23] 0 (0) 1 (100) 
(ii) Indirect relation to MDLC areas 13 (54) 11 (85) 10 (77) 
MOH, General directorates 3 (23) 2 (67) 2 (67) 
National institutes, organizations, or 
experts concerned with public health, 
quality of health services, or patient 
safety 
8 (62) 8 (100) 6 (75) 
International organization or experts for 
Mexican health system 
2 (15) 1 (50) 2 (100) 
Group 2 (meso level)* 5 (12) 2 (40) 4 (80) 
Financing / provision of health 
services 3 (60) 1 (33) 3 (100) 
Quality of health services 2 (40) 1 (50) 1 (50) 
Group 3 (micro level)* 9 (21) 7 (78) 2 (22) 
Orthopaedic specialists 9 (21) 7 (78) 2 (22) 
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Group 4 (supplier) 4 (10) 3 (75) 4 (100) 
Medical device industry 
association 1 (25) 0 (0) 1 (100) 
Medical device supplier 3 (75) 3 (100) 3 (100) 
Total 42 (100) 28 (67) 28 (67) 
*Social security institutes and State-level healthcare systems 
 
All interviews were audio recorded, transcribed, and reviewed again by the principal 
investigator with the exception of one interview owing to employer requirements and 
we used an interview protocol. The interview guide (supplementary file 7.1) was 
previously validated among a small group of persons familiar with medical device 
regulation, assessment, and management. 
 
Supplementary File 7.1. Extraction of interview guide questions 
Question block 1 
 Introduction:  
The regulation, assessment, and management (procurement) of medical devices are 
confronted with the product complexity. Product complexity encompasses the limited 
knowledge regarding clinical safety of high-risk medical devices that are implanted in the 
human body, and the clinical long-term performance of them. The interrelation of multiple 
actor who are directly or indirectly involved with the regulation, assessment, and 
management of medical devices are crucial because they influence the mechanism 
behind product complexity such as knowledge and evidence synthesis, guidance, etc. 
 
Q1 What is your opinion about these aspects of the regulation, assessment, and 
management of medical devices? 
Q2 Is it important to manage product complexity and what aspects are important? 
Q3 Who or which area of the health system should be responsible to improve the 
management of product complexity? 
  
Question block 2 
 Introduction:  
Nowadays health technology policies consider to regulate medical devices based on 
market approval, health technology assessments, and procurement decision-making 
boards. Two dimensions are crucial to outreach a successful management 
(procurement) of medical devices: (i) involving relevant stakeholders in decision-making 
processes, and (ii) relying on high quality of data and information provided by the 
environment of procurement (represented by regulation and assessment). 
 
Q1 What is your opinion about these dimensions of the regulation, assessment, and 
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management of medical devices? 
Q2 Is it important to strengthen these two dimensions of the management of medical 
devices and what aspects should be strengthened? 
Q3 Who or which area of the health system should be responsible to strengthen these 
dimensions? 
  
Question block 3 
 Introduction:  
One important task of the management of medical devices (procurement) is to evaluate 
offers based on product specifications. For this multiple information is needed. Decision 
committees encompassing managers, administrators and clinicians realize this during a 
stepwise process to prevent sub-standard quality. However, results of a survey among 
187 orthopaedic clinicians showed that they perceive their clinical practice affected by 
the outputs and outcomes of procurement. 
 
Q1 What is your opinion about these aspects of the management of medical devices? 
Q2 Is it important to change aspects of procurement and in what aspects do you think? 
Q3 Who or which area of the health system should be responsible to change these aspects? 
 
Data analysis 
To assess views of stakeholders on challenges of and possible ways forward in 
fostering the MDLC areas, we thematically analysed the transcripts [149]. MAXQDA 
software (version 11, VERBI GmbH) was used to aid data management. To describe 
the views of stakeholders regarding challenges, first, we closely read each transcript. 
Second, we deductively coded one-third of the transcripts based on the themes of 
our conceptual framework and inductively coded for new themes. Third, we clustered 
codes into categories, revised the final list of codes and categories. Fourth, we 
systematically applied coding to all transcripts and drew on important themes. The 
principal investigator analysed all primary data alone, which implies a limitation of 
validity check. To integrate the views of stakeholders regarding possible ways 
forward in fostering MDLC areas into the discussion of the present study we 
analysed them in the context of the key findings, the findings of our previous studies 
and the results of our background research on current medical devices reforms and 
policies. 
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7.4. Results 
The results of this study are structured along the areas regulation, assessment, and 
management and summarized by their importance in Table 7.4. Illustrative quotations 
are presented in Table 7.5. 
 
Table 7.4. Frequency of discussed themes regarding challenges in organizational 
practice 
MDLC areas Total Group 1 Group 2 Group 3 Group 4 
Regulation ++(+) ++(+) ++(+) ++ +(+) 
Assessment ++(+) ++(+) + ++ +++ 
Management ++(+) ++ ++ +++ +++ 
 
+ low intensity; ++  some intensity; +++  high intensity 
 
Table 7.5. Quotations of interviewees 
Quotations Stakeholder 
group 
Area of regulation: Reporting culture of adverse events and complications during 
clinical practice 
„Often they don't know that there is a regulation for technovigilance.“ Macro level 
„... we explained to the health professionals that finally they are the 
ones who complain about a product that fails and that the product 
does not provide the required results. However, me as authority how 
can I take notice about that <complaints> if they <end-users> dont 
make notifications, if they don't report failures than I cannot find it out 
and if I don't find it out I cannot react, if I dont react the things stay as 
they are.“ 
Macro level 
„... not only the bad quality of the materials but also the bad service 
which they provide for technical assistance... This type of complaint 
converts into an internal report and stays there, I am sorry that I have 
to say that.“ 
Micro level 
„... do you believe that the authorities of the institutions don't know the 
needs that exist?“ 
 
Macro level 
Area of assessment: Decisions about the eligibility of HRMDs 
„... we noticed the extremely poor culture of science that was present 
in the area of technology assessment.“ 
Macro level 
„As a result of poor regulation every buys what he wants and we 
complain about lots of things...“ 
Meso level 
„A lot of people said as well that we should skip the institutional 
standard lists.“ 
 
Macro level 
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Area of assessment: Decisions about the eligibility of HRMDs 
„I believe that the first error of the pseudo transparency of implant 
procurement is that they buy at the lowest price.“ 
Macro level 
“It's incredible that a surgery has to be cancelled because the supplier 
did not arrive with the material ... Which economic penalty can 
compensate this damage to the patient...” 
Micro level 
“… a serious problem of the servicio integral is that they decide which 
brands they include in their service packages ... Cheaper products so 
that they make more profit.” 
Supplier 
„... there are constant changes, when a new person comes 
sometimes he dosent has sufficient preparation to realize a tenders.“ 
Micro level 
„... the procurement agent knows the standard list but little about the 
basics of a joint implant.“ 
Supplier 
 
Area of regulation: Reporting of adverse events and complications during 
clinical practice 
There was some degree of consensus among interviewees that technovigilance 
activities (post-market surveillance of approved medical devices) should be 
strengthened across all levels of health-care delivery, but mainly at the meso level 
(healthcare institutions). Further, these activities may contribute to a wider scope of 
decision-making such as purchasing decisions. In Mexico, monitoring activities for 
HRMD safety and performance take place under the supervision of the 
Technovigilance department of the Federal Commission for the Protection against 
Sanitary Risks, which relies on the reporting of healthcare institutions. Interviewees 
noted that the reporting of healthcare institutions is sub-optimal. The federal 
Technovigilance department encompasses decentralized departments of the SESA 
and the responsible technovigilance actors at the social security institutions. Few 
interviewees thought that they did not see significant advances in technovigilance 
activities since its introduction in 2013 and thought that it was not implemented 
sufficiently. They noted that technovigilance often only exists on paper rather than in 
daily practice. Interviewees provided different reasons for this. Many interviewees 
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thought that monitoring the safety and performance of HRMDs was insufficiently 
developed for a long time. Some interviewees from the macro level noted that a 
major difficulty to improve technovigilance was to coordinate the different sub-
systems of the Mexican health system. They stated that the commitment of users 
and suppliers to inform technovigilance officers about adverse events and incidents 
is irregular and activities at the meso level provide insufficient guidance to HRMD 
users. 
Intra-operative complications are negative outcomes of using HRMDs during 
surgery and accompanying services such as instruments, implant sets, surgical 
technique, or technical assistance of supplier during surgery. Some interviewees 
stated that users report intra-operative complications to procurement administrators 
so that they can be managed in the context of service and delivery contract duties. 
But some noted as well that managing information about these complications is 
essential as these failures may influence medical outcomes in the long-term, 
considering their nature and frequency. Further, few interviewees noted that the 
awareness of the involved stakeholders about how reporting can contribute to 
decision-making at the meso and macro levels is low. Some interviewees thought 
that establishing an effective reporting system and infrastructure may contribute to 
the strengthening of the evidence of intra-operative complications, which is 
contributing to technovigilance. 
Area of assessment: Decisions about the eligibility of HRMDs 
Many interviewees indicated that the eligibility of orthopaedic HRMDs was not 
regulated thoroughly enough. Some interviewees noted that the current version of 
the standard list for orthopaedic and osteosynthesis medical devices still included 
several obsolete technologies or misleading descriptions. They noted that a major 
difficulty is that, by law, these changes to the standard list require formal modification 
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requests from, e.g., a social security institution or a medical device supplier. Neither 
the inter-institutional committee nor the General Council of Health can implement 
such changes independently. Some interviewees thought that solving these problems 
of eligibility requires, among else, strong governance and improvement plans. They 
noted that updating the standard list is important, but only as a prerequisite rather 
than as a sustainable step in improving the post-market regulation of HRMD 
eligibility. Despite the national standard list (macro level), each public health 
institution manages its own standard list for health supplies (meso level). Few 
interviewees thought that it was necessary to unify these standard lists into one 
single standard list. 
Area of management: Procurement decision-making, purchasing strategy, 
procurement agent competencies 
In Mexico, decision-making is strongly guided by conformity checks of HRMD 
specifications (e.g. material, mechanical characteristics, dimensions) and lowest-
price offers [141, 142, 146]. Many interviewees thought that the applied procurement 
regulations and practices in use have not advanced over the past years. Some 
interviewees noted that decision makers had difficulties understanding differences 
between medical device brands in terms of their clinical performances (e.g. implant 
survival rate, primary stability of implant, implantation based on surgical technique). 
They thought that improved and systematic risk assessment of HRMDs might 
elucidate risks in a wider scope with the potential to lead to a more thorough use of 
public budgets, such as Health Technology Assessments (HTA) at hospital level. 
They noted that medical devices are currently not assessed sufficiently such as 
implant survival rate. Some interviewees thought that integrating aspects of quality 
more thoroughly could contribute to the changing of decision-making criteria. 
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Some interviewees thought that solving deficiencies of specific purchasing 
strategies could positively influence procurement outcomes and the quality of 
services provided, respectively. They noted that nowadays outcomes are affected by 
sub-optimal supplier performance; suppliers are often unable to respond timely with 
material and technical support to contract assignments because they are often 
contracted shortly before the contract period started. Many interviewees noted that 
the increasing use of the bundling of services through Servicios integrales requires 
more quality control. A Servicio integral encompasses a range of disposable and 
non-disposable medical products used for surgery and merges them into one 
supplier service. Some interviewees noted that this facilitates the public sectors’ 
administrative processes, but it also removes the procurement administrators’ control 
of the final selection of the orthopaedic HRMD brand. 
Some interviewees explained that decision makers underestimated the role 
played by the procurement agent who is concerned with administrative tasks and 
processes to support needs assessment or analysing supplier offers. They thought 
that procurement agents should have minimal professional skills underlined by 
specific certificates so that they were able to understand clinical needs better and to 
not affect negatively procurement results. Many noted that administrators often have 
difficulty understanding the clinical needs of users and underestimate the 
consequences of their decisions about clinical procedures. Some of the interviewees 
mentioned the importance of continuous training; it could contribute to changing a 
purely administrative passive support into a more integrated service function. Until 
now, little attention has been paid to the continuous education of procurement 
agents. 
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7.5. Discussion 
Interview participants identified important challenges in relation with the MDLC areas 
in Mexico (affecting policy outputs and outcomes), which might influence the quality 
of care. With regard to regulation, reporting of adverse events was perceived as the 
most important challenge; assessment is challenged by several obsolete or wrongly 
described technologies in the standard list for orthopaedic and osteosynthesis 
products; while integrating advanced quality attributes into procurement processes 
was a mayor issue raised regarding the area of management. According to 
interviewees, subjacent to these challenges is the fragmentation of responsibilities 
with regard to the MDLC areas and the disconnection of the several sub-systems of 
healthcare. Overall we found that this causes a lack to support well-integrated MDLC 
areas and translates into sub-standard outputs and outcomes. In consequence the 
multiple actors have difficulties to improve the quality of delivered healthcare. 
Possible ways forward in fostering the regulation, assessment, and management of 
medical devices in Mexico are: 
• Regulation: Strengthening technovigilance 
• Assessment: Updating the Standard list for orthopaedic and ostheosynthesis 
medical devices 
• Management: Introducing a decision-making guidance with focus on quality 
attributes for decision-making, purchasing strategy, and procurement agent 
competencies 
We found that strengthening technovigilance can potentially improve outputs 
and outcomes of the regulation in the following ways: It can influence the compliance 
of involved stakeholders (e.g. for post-market reporting) and contribute to improved 
quality. To strengthen technovigilance three aspects may be considered: (i) including 
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technovigilance tasks in the requirement catalogue of hospital certifications, (ii) 
fostering inter-institutional technovigilance guidelines, and (iii) implementing a 
technovigilance code of conduct (for hospital providers, health-care workers and 
suppliers). Further, in the literature we found that countries having a well-functioning 
post-market surveillance system complement their regulatory tasks by integrating 
specific approaches into the regulators’ work to evaluate health technologies or 
define benchmarks for quality standards [58, 59]. 
We found that introducing a guidance focusing on quality attributes can 
improve outputs and outcomes of the assessment and management in the following 
ways: It can enrich decision-making by knowledge about clinical longterm 
performance of medical devices, and improve clinical outcomes and cost-
effectiveness. Further, it can influence operational rules and guidance for orthopaedic 
HRMDs and contribute to improved quality of delivered of healthcare. To introduce 
stronger quality attributes the following aspects may be considered: (i) introducing 
quality benchmarks for orthopaedic procedures (e.g. survival rate requirements) and 
establishing survival rate expectations for new listed technologies; and (ii) Introducing 
HTA at the level of hospitals or purchasing groups that allow to integrate a risk 
assessment of orthopaedic HRMDs into decision-making. Further, we found that in 
the United Kingdom the National Institute for Health and Care Excellence defines 
recommendations including benchmarks, e.g., for the quality of hip prostheses, as 
“the new joint should work well in at least 95% of hip replacements over 10 years, 
instead of the current 90%” [57]. These recommendations contribute to the 
maximization of clinical outcomes and cost-effectiveness and can be reflected in risk 
assessments for orthopaedic HRMDs [55, 56]. Understanding the role played by 
decision makers concerning the absence of high-quality data is an important insight 
into procurement activities such as purchase and supply [150, 151]. 
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We found that enhancing competencies of procurement agents can improve 
outputs and outcomes of the management phase in the following ways: It can 
influence operational rules and guidance for orthopaedic HRMDs and contribute to 
improved healthcare delivery. To enhance competencies of procurement agents the 
following aspects may be considered: (i) Updating requirements for core 
competencies needed for procurement agents, and (ii) integrating procurement 
agents into evaluation tasks of outcomes of applied purchasing strategies such as 
Integral Services. Further, in other countries the orthopaedic specialist still has high 
decision-making autonomy, which alleviates some responsibility from the 
procurement agent. Thus we had difficulties to find examples emphasizing the aspect 
of enhancing competencies of procurement agents. 
This study highlights important findings in a national context. However, some 
of the problems that we have discussed in this study might emerge in a similar way in 
other health systems as well. For instance, the Swiss healthcare system is 
characterized by a decentralized structure and the autonomy of the cantons is 
relatively high. However, the healthcare legislative allows for initiatives and 
programmes that benefit the whole sector; the fragmentation of responsibilities 
regarding the MDLC areas is relatively low. For instance, Switzerland did face similar 
challenges relating to post-market surveillance and the level of clinical long-term data 
available for orthopaedic medical devices. They have introduced a national 
arthroplasty registry, which is overseen by the National Association for Quality in 
healthcare facilities. This was only possible by substantial commitment of the 
different parties concerned by the registry such as policy makers at national and 
decentralized level, insurances, associations of orthopaedic surgeons, and the 
medical device industry associations. The Mexican healthcare system is 
characterized by various sub-systems of health service provision. The healthcare 
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legislative limits the authority of central MOH offices to establish initiatives or 
programmes regarding medical devices that could benefit the whole sector. For 
instance, the social security institutes apply their own regulations for the assessment 
and management of medical devices. We found that this fragmentation of 
responsibilities influences the ability of policy makers to carry forward promising ways 
to improve outputs and outcomes of the MDLC areas. However, the relation between 
the MOH and sub-systems is in a transition and some recent advances demonstrate 
that [32, 82, 152]. As next steps for the policy making process in Mexico we 
recommend to take into account that the integration of stakeholders such as the 
National Academy for Medicine, the associations of orthopaedic specialists, and the 
associations of the medical device industry might benefit the establishment of 
initiatives and programmes to improve the MDLC areas, and help to partially 
overcome the fragmentation of responsibilities. 
Limitations of the study 
For this study, we used non-random sampling, which does not necessarily guarantee 
the sample being representative for the population of person involved in the 
regulation, assessment, and management of medical devices in Mexico. However, 
this study includes 42 stakeholders working in the field of regulation, assessment, 
management or clinical practice. Thus it covers different groups of stakeholders in 
terms of expertise. We were not granted permission to include employees of the 
Mexican Institute of Social Security, which is the largest social security institution in 
Mexico, because of its research study approval policies. Further, the sampling is 
based on a maximum variation strategy and may constitute a selection bias. The 
interpretation of the findings that served to define possible ways forward to fostering 
the regulation, assessment, and management of orthopaedic medical devices is a 
subjective process. 
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7.6. Conclusion 
This study provides a broad analysis of medical device functions within a health 
system and highlights in this specific context how improvements might be achieved. 
It addresses a broad range of interest groups represented by policy makers, health 
service providers, managers and administrators of healthcare facilities, and doctors 
with an interest in health technologies. In this paper we highlight important themes 
that influence outputs and outcomes of the regulation, assessment, and management 
and discuss strategies in fostering these areas. To date, the regulation, assessment, 
and management of medical devices are rarely analysed in a broad way, even 
though these functions importantly contribute to the successful implementation of 
health technology policies. The quality of delivered healthcare is influenced by the 
performance between and within these functions. In Mexico, little discussion has 
been raised on challenges of the regulation, assessment, and management of 
medical devices. Changes to current processes and practices can improve outputs 
and outcomes of these functions and positively influence the quality of delivered 
healthcare. Stakeholder involvement and commitment is essential to this. 
To overcome the impact of the fragmentation in the Mexican health system, 
policy makers could orientate on what other countries with a similar complex health 
sector are doing to improve outputs and outcomes of the MDLC such as the United 
States, Germany, or Switzerland. An important advance is that the Ministry of Health 
is developing a new policy that targets to strengthen technovigilance across all sub-
systems. This is a promising way forward in fostering the regulation and to fully 
engage all stakeholders. This study may contribute to show to policy makers 
additional ways forward in fostering the regulation, assessment, and management 
towards improved quality of delivered healthcare. 
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8.1. Introduction 
Studies concerned with the epidemiology of hip and knee joint replacements show 
that the demand for primary joint replacements and revision surgery is growing [24, 
25]. To control the financial impact of joint replacement, it is important to achieve 
good implant duration rates because the health expenditures of revision surgery are 
significantly higher than primary joint replacement [153]. Arthroplasty register data 
shows that the clinical performance of hip and knee implants in the long-term 
demonstrate a strong variation [26]. Using poorly performing implants increases the 
revision risk. Yet, little is known about health policies encompassing strategies to 
decrease the use of poorly performing hip and knee implants. The objective of this 
study is to analyse the contribution of duration rate benchmarks as recommendations 
for decision-making and to discuss the health economic contribution of introducing 
duration rate benchmarks in Mexico. 
8.2. Issues related to orthopaedic high-risk medical devices 
Medical device regulation is challenged with the mismatch of the information validity 
needed for market approval and evidence from actual use of high-risk medical 
devices (HRMD) [49-51, 18]. One reason for this is that pre-market regulation is 
mainly based on conformity assessments and does not include findings from clinical 
long-term outcome studies [51, 52]. HRMDs are implanted in the human body and 
are therefore recommended, subject to the highest level of pre-market and post-
market regulation [22]. 
Policymakers from other countries are frequently concerned by effectively 
ensuring standards of clinical safety, performance and efficacy of HRMD [47, 48]. 
Countries use different strategies to ensure or monitor safety and performance of 
medical devices such as strengthening post-market regulation [54, 40]; monitoring 
clinical treatment outcomes by introducing arthroplasty registers [34]; assessing 
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HRMD risk  through post-market due diligence programmes [55]; classifying implant 
quality [56] and establishing revision rate benchmarks to prevent the use of poorly 
performing implants [57]. These strategies are frequently integrated into regulators’ 
work and help bridge the gap of evidence and uncertainty [58, 59]. 
Epidemiology of Joint Replacements and in the Context of Age 
Joint replacements in Mexico will increase and life expectancy may be an important 
indicator for the development of joint replacement demand. In Mexico, life 
expectancy has improved over the past 15 years [29], the incidence of osteoarthritis 
increases rapidly in patients over 50 [30] and in obese population [31], which is a 
serious health burden in Mexico [32]. Patients who have already received a joint 
replacement are exposed to revision surgery by the increase in years since primary 
surgery took place. 
Revision Surgeries in the Scope of Quality Concerns 
The clinical long-term performance of HRMD is an important input parameter for 
decision-making, because it determines the future need of revision surgery. Many 
countries have access to high-quality data on joint replacements, which they use to 
evaluate medical outcomes [34, 26, 35]. Using poorly performing medical devices is 
one of the reasons for high revision rates. For instance, increased incidence of post-
operative problems resulting from the use of metal-on-metal hips led to higher hip 
revision rates [36]. However, in Mexico medical device regulation does not include 
clinical long-term performance of HRMD in their quality agenda with exception of the 
federal techno-vigilance department and health technology assessments, the findings 
of which are used to include technologies on the standard list for eligible health 
technologies. Between 2014 and 2015, we conducted studies in Mexico on the 
regulation, assessment and management of orthopaedic HRMD [141, 142, 146]. 
These studies showed quality concerns related to post-market regulation and 
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procurement of orthopaedic HRMD. In Mexico, several governmental offices as well 
as a number of non-governmental stakeholders are involved in the regulation, 
assessment and management of medical devices. Nevertheless, reviewing articles 
83, 179 and 180 of the Medical Device Regulation of Mexico shows that there are no 
specific regulations for HRMD differentiating them from lower risk medical devices. 
Further, before 2016, HRMDs were included together with other medical devices in a 
general standard list (Standard List for Medical Care Products). 
8.3. Policy implications 
Health Economic Analysis 
In health systems, decision-making takes place at different levels of healthcare 
delivery to allocate limited resources optimally [154]. Health economic analysis 
significantly contributes to this and encompasses important perspectives to attribute 
cost and benefit to specific healthcare provisions. Economic costs for joint 
replacements are high [155] and are differentiated into direct costs (hospital 
admissions, medical examinations, drug therapy), indirect costs (losses in 
productivity resulting from absence from work) and intangible costs [154]. The direct 
costs associated with joint replacements are high and driven by the cost of surgery, 
hospitalization and rehabilitation. Different methods are available to conduct health 
economic evaluations based on specific health economic principles that inform policy 
decisions, encompassing the efficiency and effectiveness of medical treatments 
[156]. 
At the policy level, health economic analysis is increasingly taken into 
consideration. For instance, HTA are a form of policy research that seeks to inform 
policy makers about the clinical and economic value of health technologies such as 
medical devices and includes findings derived from results of health economic 
analysis [157, 37]. Further, in orthopaedics health economic analysis increasingly 
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receives more attention due to its financial impact [158]. It is an essential element in 
decision-making and HTAs at purchasing decision-level are increasingly discussed 
[139, 140, 138, 137]. 
Duration Rate Benchmarks 
A promising strategy to ensure quality is to implement guidance for duration rate 
benchmarks [153]. For instance, these are used in the UK and they are important in 
the regulation of HRMD, used to improve outcomes. The National Institute for Health 
and Care Excellence [57] defines recommendations including benchmarks  for the 
quality of hip prostheses for example, as “the new joint should work well in at least 95 
percent of hip replacements over 10 years, instead of the current 90 percent” [57]. 
This is an important contribution to decision-making processes because it suggests 
that decision makers should thoroughly review all available evidence. 
In Mexico, no data is available on national implant duration rates. However, 
policymakers in Mexico could introduce such benchmarks and request decision-
makers consult duration rate data from countries with an arthroplasty register or 
consult the findings of risk assessment programmes as they are used in the 
Netherlands or the UK [56, 55]. 
8.4. Conclusion 
The use of survival rate benchmarks may have a positive impact on revision rates 
and their financial burden. Introducing these duration rate benchmarks may improve 
the eligibility of medical devices, strengthen quality assurance and enhance 
organisational governance. The Mexican health system lacks high-quality data for 
orthopaedic surgeries. However, average duration rates from different arthroplasty 
registries could be used as reference. Economic analysis in orthopaedics provides a 
powerful tool for the evaluation of health-care technologies and treatment strategies 
[159]. 
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More research analysing the potential financial impact of using duration rate 
benchmarks may provide important findings. In the case of Mexico, even though no 
high-quality data is available, sufficient information of implants purchased in the past 
is publically available. It is stored at the electronic contracting system Compranet  of 
Mexico. To apply economic analysis, the data from Compranet and average duration 
rates from different arthroplasty registries could be used. 
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9.1. Abstract 
Objective: To analyze interests, positions, and power of stakeholders to three 
alternative strategies to improve processes and practices regarding the regulation, 
assessment, and management of orthopaedic medical devices in Mexico. 
Method: The study was based on document analysis and 17 structured interviews 
with multiple actors within the Mexican health system to inform a stakeholder 
analysis aiming at assessing the political feasibility of these strategies. 
Results: The majority of respondents had a positive position towards the discussed 
strategies. Major barriers are: required increase in financial and human resources, 
and organisational culture towards reform. Governmental bodies concerned with 
quality and cost-effectiveness of health services were the actors with highest 
potential to influence the adoption and implementation of the strategies. 
Conclusion: Discussed strategies are political feasible; these entail changes 
directed to improve outputs and outcomes of medical device life-cycle and positively 
influence the quality of health care and the health system’s performance. 
9.2. Background 
Medical devices, together with drugs and other health technologies, comprise one of 
the six components considered as essential for good health system performance 
[16]. Accordingly, the regulation, assessment, and management of medical devices 
receive increasing attention by policy makers and health system experts involved in 
efforts to attain universal coverage of safe, equitable and high-quality health services 
[54, 41, 18, 160]. At the centre of the discussion is the improvement of outputs and 
outcomes of the Medical Device Life-Cycle (MDLC) [37]. A cohesive medical devices 
policy, well planned, supported and coordinated among all areas represented by the 
MDLC stakeholders is necessary [37] to meet the population needs and to ensure 
the quality of health care. 
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In a series of previous studies we analysed critical aspects between and within key 
MDLC functions and discussed ideas about desired changes to overcome identified 
challenges [141, 142, 146, 161] (Table 9.1). 
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Table 9.1. C
hallenges betw
een and w
ithin M
D
LC
 areas and possible strategies 
M
D
LC
 A
reas 
D
escription 
O
utputs 
O
utcom
es 
C
hallenges identified in 
M
exico 
Strategies 
R
egulation 
S
afety and efficacy are 
in the focus of this 
phase aim
ing 
population safety. K
ey 
elem
ents are perform
ing 
testing and safety 
assessm
ent prior to 
m
arket approval and 
post-m
arket reporting 
using criteria of safety 
and quality standards as 
part of technovigilance. 
M
andatory 
com
pliance 
A
ssuring 
m
inim
al 
standards of 
quality 
Technovigilance is not 
sufficiently applied by the 
m
ultiple actors; lack of data 
availability; data quality across 
sub-system
s not balanced 
’Strengthening 
Technovigilance’:(i) including 
technovigilance tasks in the 
requirem
ent catalogue of hospital 
certifications, (ii) fostering inter-
institutional technovigilance 
guidelines, and (iii) im
plem
enting a 
technovigilance code of conduct 
(for hospital providers, health-care 
w
orkers and suppliers). 
A
ssessm
ent 
M
eeting the population 
health needs. K
ey 
elem
ents are system
atic 
analysis and critical 
review
 using 
epidem
iology and 
evidence data. 
R
ecom
m
endati
ons on highly 
com
plex 
technologies 
R
esponsivene
ss and 
m
axim
ization 
of clinical 
outcom
es and 
cost-
effectiveness 
S
tandard list includes obsolete 
descriptions and technologies; 
system
 lacks to consider 
dynam
ic clinical long-term
 data 
such as survival rates; no 
initiatives aim
 at advancing 
quality of inform
ation regarding 
orthopaedic m
edical devices; 
H
ealth Technology 
A
ssessm
ents at purchasing 
level m
issing or characterised 
by sub-standard m
ethodology 
’A
m
plifying quality attributes for 
assessm
ents by clinical long-
term
 aspects’: (i) introducing 
quality benchm
arks for orthopaedic 
procedures (e.g. survival rate 
requirem
ents), and (ii) introducing 
technology guidance 
M
anagem
ent 
H
ealth service providers 
are in the focus of this 
phase. K
ey elem
ent is 
the operational 
m
anagem
ent of 
technology life-cycle 
using needs analysis 
O
perational 
rules and 
guidance for 
all m
edical 
devices 
Im
proved 
health delivery; 
sustainable 
availability of 
high-quality 
and safe 
devices 
Lacking quality guidelines 
regarding im
plant survival; 
problem
s that end-users 
experience during clinical 
practice are not w
ell responded 
by the system
 and not reflected 
by changes in organizational 
‘Introducing orthopaedic 
specific purchasing strategy’: (i) 
introducing H
TA
 at the level of 
hospitals or purchasing groups that 
allow
 to integrate a risk 
assessm
ent of O
M
D
s into decision-
m
aking, (ii) enhancing core 
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and reliable device 
availability for clinical 
use. 
practice; fluctuation of w
orkforce 
and insufficient skills of 
procurem
ent agents regarding 
com
plex clinical needs 
com
petencies of procurem
ent 
agents, and (iii) evaluating 
outcom
es of applied purchasing 
strategies such as Integral 
S
ervices. 
 S
ource: M
D
LC
 adapted from
 W
H
O
 [19, 46] C
hallenges and strategies adapted from
 [previous studies] 
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The findings highlighted that the overall MDLC system in Mexico is not 
coherently outlined and set-up across the regulatory, the assessment, and the 
management domains of orthopaedic medical devices (OMDs), and that this results 
in a situation that the quality of services delivered to patients is sub-optimal. This 
finding resonates with concerns raised by other authors regarding the regulation, 
assessment, and management of health services in Mexico at different levels of 
health care delivery [78, 72, 38, 32, 11]. 
In this study, we use a stakeholder analysis [81, 162-164] to analyse interests, 
positions, and power of stakeholders involved in the MDLC to three alternative 
strategies (see table 1) to improve processes and practices of the MDLC in Mexico. 
The Mexican health system is composed by a complex structure that includes 
various sub-systems in charge of health service regulation, financing and provision. 
Most important providers are the public social security institutes and the state-level 
health care services (SESA), which function along a large number of private health 
care providers [32, 70]. The Ministry of Health (MOH) and its departments enact 
regulations and recommendations at the federal level for the public and private 
sector, but the sub-systems (such as social security institutes) comply with these in 
different ways due to their specific legal regulations and embedment [72, 73]. The 
health system is characterized by a distribution of roles and responsibilities across a 
substantial number of actors resulting in a fragmentation of responsibilities. 
This fragmentation of roles and responsibilities is well illustrated with regard to 
medical devices: the General Health Council (CSG) (responsible for overseeing the 
Inter-institutional Commission of the Standard List for Health Supplies), the Federal 
Commission for the Protection against Sanitary Risks (COFEPRIS), and the National 
Centre for Health Technology Excellence (CENETEC) [165]. Notwithstanding their 
important achievements, it has been stressed that the functioning of these agencies 
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has room for improvement; specially, with regard with their linkage with guidelines for 
the quality of care and with assuring value for money across all sub-systems [32]. 
The Mexican Congress is discussing the creation of the Federal Commission for the 
Regulation and Surveillance of Health Care Services and Facilities [166], which could 
generate momentum for the uptake of a broad spectrum of aspects concerning 
quality in health care and this may support outcomes of the MDLC areas; therefore, 
the stakeholder analysis presented here comes in a timely manner. 
9.3. Methods 
Demarcating the analysis 
This study encompasses three strategies regarding the regulation, assessment, and 
management of orthopaedic medical devices as displayed in table 9.1. We used a 
national level of analysis collecting data from the multiple stakeholders directly or 
indirectly related to these strategies. 
Identifying stakeholders 
For this study, we developed a list of most relevant stakeholders regarding medical 
device regulation, assessment, and management (Table 9.2). 
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Table 9.2. G
eneral list of stakeholders 
Level 
Stakeholders 
M
ain responsibility 
R
elative im
portance 
 
 
 
Regultion 
Assessment 
Management 
(Purchasing) 
M
acro 
• S
ub-secretariat for H
ealth S
ystem
 
Integration and D
evelopm
ent, SID
SS
 
• G
overnm
ent agency w
hose m
ission is to propose to the M
oH
 
national policies that im
prove the quality of social health 
services; issues the M
exican O
fficial N
orm
s (N
O
M
) 
++
 
+++
 
++(+) 
 
• D
epartm
ents of S
ub-secretariat for 
H
ealth S
ystem
 Integration and 
D
evelopm
ent 
• G
eneral directorate of health planning and developm
ent, D
G
PD
: 
G
overnm
ental organization and unit under the authority of the 
S
ID
S
S
 w
hose m
ission is to steer the strengthening of health 
services am
ong policy m
akers, and giving guidance to im
prove 
health services sustainable and cultural based on populations’ 
needs. 
• G
eneral directorate of quality and education, D
G
C
E
: 
G
overnm
ental organization and unit under the authority of the 
S
ID
S
S
 w
hose m
ission is to ensure that the quality and safety of 
health services, including hum
an resources of the health sector 
and the regulatory environm
ent of social health supplies is 
aligned w
ith national policies. 
++
 
+++
 
++(+) 
 
• G
eneral C
ouncil of H
ealth, C
SG
 
• C
ouncil w
hose m
ission it is to strengthen the governance and 
the articulation of the N
ational S
ystem
 of H
ealth. Founded: 1917 
• P
ublishes the standard list of H
ealth S
upplies 
• H
olds the Inter-institutional C
om
m
ission of the standard list for 
H
ealth S
upplies w
hose m
ission is to m
anage the approved 
technologies in the standard list for H
ealth S
upplies 
• A
uditing of hospitals w
ith regards to quality standards 
(certification process) 
++
 
++(+) 
+
 
 
• Federal C
om
m
ission for the 
P
rotection against S
anitary R
isks, 
C
O
FEPR
IS
 
• D
ecentralized regulatory organ of the M
oH
 w
hose m
ission is to 
protect the population against health risks, including those 
derived from
 the introduction of new
 m
edical drugs, m
edical 
devices and other health inputs. Founded: 2002 
• S
anitary A
uthorization C
om
m
ission w
hose m
ission is the m
arket 
+++
 
++
 
+
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approval of m
edical products and technologies. 
• Technovigilance departm
ent w
hose m
ission is to im
plem
ent and 
realize post-m
arket surveillance. 
• S
upport function of “S
anitary A
uthorization C
om
m
ission” w
hose 
m
ission is to provide technovigilance reports for the renovation 
of m
arket approval. 
 
• N
ational C
entre for H
ealth 
Technology E
xcellence, C
EN
ETEC
 
• G
overnm
ental organization and unit under the scope of the 
S
ID
S
S
 w
hose m
ission is to contribute to the developm
ent and 
governance of the N
ational H
ealth S
ystem
 in M
exico based on: 
H
ealth Technology A
ssessm
ents, S
upervision of m
edical 
equipm
ent, Telem
edicine, C
linical guidelines. Founded: 2004 
• W
H
O
 collaborating centre. 
++
 
++(+) 
++(+) 
 
• N
ational A
cadem
y of M
edicine, A
N
M
 
• P
rofessional association of doctors that prom
otes scientific 
corporation, organises congresses and continuous professional 
education; consultant organization of the Federal G
overnm
ent of 
M
exico that proposes and discuss am
ong its affiliates solutions 
to the m
ain health problem
s of the M
exican society. 
+
 
+(+) 
+
 
 
• International organization / health 
system
 expert 
• e.g. P
an A
m
erican H
ealth O
rganization, PA
H
O
 
+(+) 
+(+) 
+
 
 
• N
ational Institute of P
ublic H
ealth, 
IN
SP
 
• G
overnm
ental academ
ic institute that conducts research and 
teaching on public health. 
+
 
+
 
- 
 
• N
ational C
om
m
ission for M
edical 
A
rbitration, C
O
N
A
M
ED
 
• C
ontribute to guarantee the right of health protection and to 
im
prove the quality of health providers in term
s of intervening in 
case of patient/health provider conflicts. 
+
 
- 
- 
M
eso 
• S
ub-system
s: C
entralized and 
decentralized health services 
• Functionary w
ith national responsibilities w
ithin the sub-system
; 
director of healthcare facility; procurem
ent agent 
+++
 
++(+) 
+++
 
 
 
• Functionary w
ith local responsibility: H
ead of orthopaedic 
departm
ent 
 
 
 
M
icro 
• O
rthopaedic com
m
unity 
• A
ssociation of orthopaedic specialists such as S
M
O
, A
M
E
C
R
A
, 
A
M
O
T, S
M
C
C
, S
M
O
P
 
• orthopaedic specialists 
+(+) 
- 
++(+) 
S
upplier 
• M
edical device com
m
unity 
• M
edical device industry association such as A
S
E
M
E
D
 or A
M
ID
 
• M
edical device supplier 
+ 
+ 
+ 
 +++  strong relation    ++  m
oderate relation    +  low
 relation     -  no relation 
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We classified stakeholders into those belonging to the (i) macro level (normative and 
policy mechanism), meso level (service provision), micro level (specialists and 
orthopaedic associations), and supplier level (medical device suppliers and medical 
device industry associations). Many of the stakeholders relevant to this study belong 
to the macro level in charge of overall regulation and steering of the Mexican health 
system. We identified potential participants ‘list of stakeholders’ by using four data 
sources: (i) the government website Portal de Obligaciones de Transparencia, which 
lists all government units or institutes and their departments and facilitates the 
access to government information; (ii) listings of orthopaedic specialists; and (iii) 
stakeholder information of our previous study as additional data source. 
Data collection 
We contacted prospective participants between November 2016 and January 2017 
by email and presented our study rationale and research. We used a maximum 
variation sampling to recruit stakeholders to achieve a balanced variety of 
stakeholders and diversity of data (supplementary file 9.1). 
.
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Supplementary File 9.1. Questionnaire 
Questionnaire 
During this interview we will ask you to share with us your opinion about possible ways forward in 
fostering the regulation, assessment, and management of high-risk medical devices. You may not feel 
comfortable to discuss each of the possible ways forward and we kindly ask you to choose those that 
you feel most comfortable with. If you do not feel comfortable to answer any of the following questions 
please do not hesitate to tell the interviewer. 
 
Questionnaire for possible way forward # ____ 
 
 
When you choose to answer not on you or your organization bur on other organizations, 
departments, or persons please move directly to question Q9 and don’t answer Q1 to Q8 
 
 
 
 
Q1. What are the potential benefits to you and your organization of this possible opportunity for 
improvement? Please provide short examples or key words 
 
Potential benefit #1 Potential benefit #2 Potential benefit #3 
   
 
Q2. What are the potential disadvantages to you and your organization concerning this possible 
opportunity for improvement? Please provide short examples or key words 
 
Potential disadvantage #1 Potential disadvantage #2 Potential disadvantage #3 
   
 
Q3. Which of these categories describe best your opinion on this possible opportunity for improvement? 
 
Support Moderate support Neutral Moderate oppose Oppose 
☐ ☐ ☐ ☐ ☐ 
 
 
 
When you answered “support” or “moderate support” or “neutral” proceed with question Q4 to 
Q6 and skip Q7 to Q9 
 
When you answered “oppose” or “moderate oppose” proceed with question Q7 and skip Q4 to 
Q6 
 
 
 
 
Q4. Which aspect(s) of the described opportunity for improvement do you support? 
 
Aspect #1 Aspect #2 Aspect #3 
   
 
Q5. For those aspects of the opportunity for improvement that you support: 
 
In what manner would you demonstrate this support? 
 
 
Would you take the initiative in supporting this 
opportunity for improvement or would you wait for 
others to do so? 
 
 
Do you have financial or human resources available 
to support this opportunity for improvement? 
 
 
 
Q6. Under what conditions would you choose NOT to support this opportunity for improvement? 
 
 
 
 
 
 
Q7. Which aspect(s) of the described opportunity for improvement do you oppose? 
 
Aspect #1 Aspect #2 Aspect #3 
   
 
 
 
 
Q8. For those aspects that you oppose: 
 
In what manner would you demonstrate this opposition? 
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Would you take the initiative in opposing this opportunity 
for improvement or would you wait for others to do so? 
 
 
Do you have financial or human resources available to 
support this opportunity for improvement? 
 
 
 
Q9. Under what conditions would you choose NOT to oppose this opportunity for improvement? 
 
 
 
 
 
 
Q10. What other organizations, department or persons do you think would support or oppose this 
opportunity for improvement? Please fill in the name and mark if they rather support or oppose 
 
Organization #1:  
 
Support Moderate support Neutral Moderate oppose Oppose 
☐ ☐ ☐ ☐ ☐ 
 
 
Organization #2:  
 
Support Moderate support Neutral Moderate oppose Oppose 
☐ ☐ ☐ ☐ ☐ 
 
 
Organization #3:  
 
Support Moderate support Neutral Moderate oppose Oppose 
☐ ☐ ☐ ☐ ☐ 
 
Q11. Do these organizations have financial or human resources available to support this opportunity for 
improvement? Please fill in with YES or NO 
 
Organization #1 Organization #2 Organization #3 
Yes ☐ No ☐ Yes ☐ No ☐ Yes ☐ No ☐ 
 
Q12. With which of these organizations do you or does your organization has an alliance? Please fill in 
with YES or NO 
 
Organization #1 Organization #2 Organization #3 
Yes ☐ No ☐ Yes ☐ No ☐ Yes ☐ No ☐ 
 
 
 
If you have answere in Q10 “support” or “moderate support” or “neutral” answer Q13 and Q14. 
Otherwise this questionnaire stops here 
 
 
 
 
Q13. If an organization was classified as “support” “moderate support” or “neutral” what are the potential 
benefits to these organizations of this possible opportunity for improvement? Please provide key words 
 
Organization #1 Organization #2 Organization #3 
   
 
Q14. If an organization was classified as “support” “moderate support” or “neutral” would this organization 
take the initiative to actively support this opportunity for improvement? Please fill in with YES or NO 
 
Organization #1 Organization #2 Organization #3 
Yes ☐ No ☐ Yes ☐ No ☐ Yes ☐ No ☐ 
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Opportunity 1: Strengthening technovigilance
Potentially can improve the overall reporting 
competencies and data generation on inci-
dents and other complications.
• Including technovigilance tasks in the 
requirement catalogue of hospital certifi-
cations.
• Introducing inter-institutional technovigi-
lance guidelines.
• Implementing a technovigilance code of 
conduct (for hospital providers, health-ca-
re workers and suppliers).
Opportunity 2: Introducing quality 
benchmarks
Potentially can prevent the purchasing of 
sub-standard medical device brands
• Evaluating orthopedic medical devices 
among else on their survival rate.
• Defining and introducing benchmarks as 
„do-not-do-recommendations“ and thus 
as additional decision-making guidance to 
ensure quality.
Opportunity 3: Introducing technology guidan-
ce for decision-makers
Potentially can improve the outcome of deci-
sion-making processes at the level of purcha-
sing.
• Applying a risk-assessment of orthopae-
dic medical devices based on a syste-
matic technology guidance including 
long-term clinical performance data.
• Introducing Health Technology Assess-
ments at the level of purchasing decisions 
for tenders or local purchase to evaluate 
differences in clinical performance among 
different medical device brands.
Opportunity 4: Strengthening the delivery and 
service modality
Potentially can improve and ensure the provi-
sion of standard quality
• Evaluating the cost-benefit of INTEGRAL 
SERVICES.
• Monitor quality of delivered services (of 
supplier) and its influence on clinical 
practice.
Opportunity 5: Enhancing competencies for 
procurement agent
Potentially can ensure that procurement 
agents acquire advanced competencies to 
improve their overall performance and their 
understanding of high-risk medical devices 
and doctors needs.
• Re-defining core competencies for procu-
rement agents.
• Developing a capacity development plan 
for procurement agents.
Opportunities for improvement chart
Related to regulation / safe use Related to assessment / quality Related to management / safe use
		 165	
Data collection was based on (i) 17 structured interviews to collect data from the 
interviewees on themselves but also their opinions on other stakeholders, and (ii) 
complemented by findings from our previous studies and detailed review of grey 
literature on the identified stakeholders. For the interviews we used a questionnaire 
(supplementary file 9.2) with mainly closed-ended using a 5-point Likert scale. The 
questionnaire was previously tested among three Mexican stakeholders. We used a 
file-naming system and anonymised interviewees by generating a list of archival 
numbers.		
Supplementary File 9.2. Participants 
Stakeholder group Participant 
N (%) 
Male 
N (%) 
Group 1 (macro level) 10 (59) 9 (90) 
MOH 2 (20) 1 (50) 
COFEPRIS 1 (10) 1 (100) 
CSG and CENETEC 2 (20) 2 (100) 
Others 5 (50) 5 (100) 
Group 2 (meso level)* 2 (12) 1 (50) 
Group 3 (micro level)* 2 (12) 2 (100) 
Group 4 (supplier) 3 (17) 2 (67) 
Total 17 (100) 14 (82) 
 
*representing public and private sector 	
Analysing stakeholder’s interest, position, and power (Data analysis) 
A structured data analysis approach [81] was followed and applied triangulation 
based on peer debriefing. First, we classified the stakeholders regarding their 
‘potential stake’ to distinguish between stakeholders potentially important to carrying 
the discussed strategy forward, considered being moderately valuing with the 
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strategy, or not important to carrying the discussed strategy forward. Second, we 
characterized the stakeholders by using three characteristics: (i) ‘Interest’ to display 
the stakeholder’s opinion in the strategies based on advantages or disadvantages 
that these may bring to the stakeholder; (ii) ‘Position’ to present whether the 
stakeholder supports, opposes, or is neutral about the strategy; and (iii) ‘Power’ to 
differentiate between high to low influence regarding the realization of the strategy. 
9.4. Results 
Table 9.3 provides indications of the different stakeholders positions toward the three 
strategies: (i) Strengthening technovigilance, (ii) Amplifying quality attributes for 
assessments by clinical long-term aspects, and (iii) Introducing orthopaedic specific 
purchasing strategy. We identified the Department of Quality and Education of the 
Ministry of Health (DGCE), CSG, COFEPRIS, CENETEC as the main stakeholders 
to influence the adoption and implementation of the discussed strategies in terms of 
‘power’. Stakeholders that were identified to have some potential to influence the 
strategies (but not being main stakeholders) were identified as social security 
institutions at the meso-level, healthcare providers at the micro-level, and medical 
devices suppliers. 
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Table 9.3. S
takeholder table 
Stakeholders 
Potential 
stake in 
strategy 
Interest based on perceived advantages*** 
Position 
Pow
er 
 
Tehno-
vigilance 
Assessment 
Purchasing 
Tehno-
vigilance 
Assessment 
Purchasing 
Tehno- 
vigilance 
Assessment 
Purchasing 
Tehno-
vigilance 
Assessment 
Purchasing 
M
O
H
, nam
ely 
D
G
C
E
 
M
S 
H
S
1 
M
S
2 
M
S
3 
H
S
4 
V
igilance of quality; 
patient safety; data 
availability; quality 
of health services 
1 relate decision-
m
aking to quality 
attributes; guide 
decisions; quality of 
health services
 
2 transparency on 
decisions; 
technology 
assessm
ent at 
hospital level; 
expenditures; 
evidenced-based 
decisions 
3 B
alanced quality of 
health services 
across sub-system
s; 
expenditures; real 
cost-benefit 
4 quality of health 
services; quality of 
procurem
ent 
outcom
es; 
governance of 
hum
an resource 
skills 
S 
S
1 
SM
2 
S
3,4 
+++ ++(+) 
1,2 
++
3 
C
S
G
 
M
S 
M
S
1 
H
S
2 
N
S
4 
Q
uality culture and 
of health services; 
broader safety 
spectrum
 
1 in line w
ith current 
quality efforts 
2 E
videnced-based 
decisions; quality of 
health services 
4 quality of health 
services, efficiency 
and efficacy of 
healthcare facility 
SM
 
N
1 
SM
2 
S
4 
+++ ++
1,2 
+ 
C
O
FE
P
R
IS
 
H
S 
M
S
1 
N
S
4 
R
eport quality; 
stakeholder 
com
m
itm
ent; 
quality of health 
services; 
prevention of sub-
1 requirem
ents for 
m
arket-approval; 
engage device 
supplier to provide 
high quality; 
technology 
4 saftey of 
healthw
orker and 
patient 
S 
S
1 
S
4 
+++ ++(+)
1 
+(+) 
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standard products 
evaluation 
C
E
N
E
TE
C
 
M
S H
S
1,2 M
S
4 
D
ata quality and 
availability; 
stakeholder 
com
m
itm
ent; 
enhancing 
know
ledge 
1 D
ata bases; 
regulations for 
quality; safe use of 
products; quality 
culture 
2 stew
ardship; 
technology 
assessm
ent at 
hospital level 
4 cross-sharing of 
C
enetec expertise 
S 
S
1,2 
S
4 
++ 
++(+) 
1,2 
+(+) 
A
N
M
 
N
S 
M
S 
N
S
3,4 
Q
uality of health 
services; patient 
safety; broader 
reasoning of 
incidents 
1 data availability; 
quality of decisions 
2 technology 
assessm
ent at 
hospital level; 
evidence-based 
decisions 
3 R
eal outcom
es; 
recognition 
4 recognition and 
representation of 
surgeon’s clinical 
needs 
S 
S
1,2 
S
3 
SM
4 
+(+) +(+) 1,
2 
+
3 
P
A
H
O
 
N
S 
N
S
2 
N
S
4 
B
est practice 
sharing tow
ards 
other countries; 
balanced quality of 
health services 
across sub-
system
s 
2 B
est practice 
sharing tow
ards 
other countries 
4 B
est practice 
sharing tow
ards 
other countries; 
quality of 
procurem
ent 
outcom
es 
S 
S
2 
S
4 
+(+) +(+) 2 
+ 
IN
S
P
 
N
S 
N
S
1 
- 
R
esearch quality; 
quality culture; data 
availability 
1 research culture; 
decision-m
aking; 
know
ledge 
- 
N
 
S
1 
- 
+(+) 
+
1 
- 
C
O
N
A
M
E
D
 
N
S 
- 
- 
Q
uality of health 
services; broader 
reasoning of 
incidents and 
patient-doctor 
conflicts 
- 
- 
SM
 
(N
) 
- 
- 
+ 
- 
- 
S
ub-system
s: 
C
entralized and 
M
S 
M
S
1 H
S
3,4 
B
alanced quality of 
health services 
1 Q
uality of health 
services, patient 
3 R
eal cost-benefit; 
quality of health 
SM
 
SM
 
SM
3 
+++ 
+++ +++
3 
		
169	
decentralized 
health services 
across sub-
system
s; data 
availability; 
reporting culture; 
prevention of sub-
standard products 
safety; expenditures 
services; prevention 
of problem
s during 
clinical practice 
4 D
evelop specialist 
procurem
ent group; 
satisfying outcom
es; 
updating profile 
requirem
ents 
O
rthopaedic 
com
m
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Strengthening Technovigilance 
The analysis identifies COFEPRIS as an important stakeholder (potential stake) for 
carrying technovigilance strengthening forward. Its ‘interest’ is relatively focused on 
the following advantages that this strategy would imply for their own organisation: 
improving report quality of e.g. incidents; achieving stakeholder support; improving 
quality of health services; preventing sub-standard products. Its ‘position’ was 
categorized as supporter of this strategy. The ‘power’ of COFEPRIS is being 
considered by different stakeholders as high, because technovigilance is one of its 
responsibilities. 
“… improving the quality of reports and the culture of reporting. Reports are 
essential and often the commitment of the stakeholders is missing…” 
(employee of COFEPRIS) 
Other relevant stakeholders considered being moderately supporting the strategy but 
to be involved in one way are MOH, DGCE, CENETEC, sub-systems (different actors 
in charge of health service regulation, financing and provision), orthopaedic 
community and medical device community. Their ‘interest’ is relatively focused on 
‘access to data’ such as data quality and availability; stakeholder support; enhancing 
knowledge. Their ‘position’ was categorized between supporter and moderate 
supporter, and the level of their potential influence ranged from moderate to low. 
COFEPRIS is a critical organization within the Mexican health system and 
holds the overall responsibility for technovigilance. Its financial and human resources 
should be increased to pursue the objective to strengthen technovigilance based on 
improved reporting of healthcare facilities and professionals and based on 
processing and analysing the increased amount of received reports. The strategy 
‘strengthening technovigilance’ is overall feasible and a broad group of stakeholders 
indicated high interest toward this strategy. Few stakeholders mentioned that the 
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requirement catalogue for hospital certification, which is not compulsory, should 
include as well technovigilance as a component. In Mexico, hospital certification is 
aligned to the Joint Commission requirements [109] and overseen by CSG. 
Amplifying quality attributes for assessments by clinical long-term aspects 
The analysis identifies DGCE, CSG, and CENETEC as important stakeholders for 
carrying forward quality attributes of medical device assessments. Their ‘interest’ is 
focused on the following advantages that this strategy would imply for their own 
organizations: relating decision-making to quality attributes of medical devices; 
guiding decisions on eligibility of medical devices; improving quality of health 
services; generating transparency on decisions; introducing technology assessment 
at hospital level; controlling expenditures; being in line with current quality efforts; 
improving data bases; creating regulations for determining quality of medical devices; 
assuring safe use of products; strengthening decisions about medical device 
eligibility. Their ‘position’ was categorized as supporter of this strategy. The ‘power’ of 
these three stakeholders was being considered as moderate, because clinical long-
term aspects of medical devices as dynamic quality attribute haven’t been in the 
focus of any of these stakeholders so far. 
“It is essential because it represents measuring results… it will help to know 
prior to purchasing a medical device its quality…” (Director of a MOH 
department) 
Other relevant stakeholders considered being moderately supporting the strategy but 
to be involved in one way are COFEPRIS, National Academy of Health (ANM), sub-
systems, and orthopaedic community (e.g. orthopaedic specialists and orthopaedic 
associations). Their ‘interest’ is focused on the following advantages that this strategy 
would imply for their own organisations: promoting transparency and evidence-based 
decisions. Their ‘position’ was categorized between supporter and moderate 
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supporter of stronger quality attributes of assessments, and the level of their potential 
influence low to high. 
“This would help to fight less for the lowest price and more for the quality…” 
(Director of medical device supplier) 
To date, not one MOH department alone is responsible for this type of quality 
strategy. The power and leadership of CENETEC’s power and leadership should be 
increased to integrate stronger attributes such as implant survival rate into the 
assessment and decision-making for OMDs. Few stakeholders mentioned that such 
strategy requires an increase in human resources but that recent budget cuts may 
currently not allow allocation of required financial resources to pursue such strategy. 
Introducing orthopaedic specific purchasing strategy 
The analysis identifies MOH and sub-systems of healthcare as important 
stakeholders for carrying forward an orthopaedic specific purchasing strategy. The 
‘interest’ of these two actors is focused on the following advantages that this strategy 
would imply for their own organisations: achieving similar level of quality of health 
services across sub-systems; improving the management of financial resources; 
achieving cost-benefit; improving quality of health services; improving quality of 
procurement outcomes; enhancing human resource skills; preventing problems 
during clinical practice; developing procurement specialists based on medical 
speciality for high-risk class medical devices; satisfying outcomes; updating profile 
requirements of procurement agents. Their ‘position’ was categorized as supporter of 
this strategy. The ‘power’ of MoH is being considered as moderate and that of social 
security institutes (sub-systems of healthcare) as high. 
“… the current situation leads to costs to solve failures caused by inferior 
quality…” (Ex-director of orthopaedic services at social security institute) 
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Other relevant stakeholders considered being moderately supporting the strategy, 
but to be involved in one way are CENETEC and the orthopaedic community. Their 
‘interest’ was focused on the following advantages that this strategy would imply: 
cross sharing expertise between involved stakeholders, and prevention of sub-
standard outcomes. Their ‘position’ was categorized as supporter, and the level of 
their potential influence low to high. 
“… the procurement agent mentality is still focused on prices” (Director of 
medical device supplier) 
Few stakeholders mentioned that the role played by DGCE should be strengthened 
to enhance the competencies of procurement agents and to realize subsequent 
effects of improved outcomes of purchasing strategies such as Servicio Integral. 
9.5. Discussion 
The discussed strategies to improve the MDLC were largely perceived to be within 
the competence of central government agencies, namely COFEPRIS, CSG, DGCE, 
and CENETEC. These are the different interest groups that have started looking 
deeper into needs that this study focuses on; however, in Mexico as in other 
countries the discussion about challenges or weaknesses regarding the MDLC areas 
develops slowly [32, 166, 167]. For instance, at the government level the MOH is 
developing a new policy that aims to strengthen technovigilance across all sub-
systems of the health-system. One aspect of this policy is to integrate 
technovigilance into the requirement catalogue for hospital accreditation. Further, the 
participation of the private sector (industrial-commercial sector) in the policy-making 
increases and will contribute to enrich policy discussion by their interests. At the 
same time the participation of the public and professional associations in decision-
making remains limited [141, 142, 146]. We found that ANM can act as visionary for 
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at least orthopaedic associations and therefore play an important role to change this 
situation in the future. 
During this study we only identified significant differences regarding the power 
of the multiple actors to potentially influence policy (in favour). Central level 
government agencies were perceived as those with greater power to influence 
policies. In this sense, we found that the policy environment is in favour of developing 
such strategies and no one strategy seems to be preferred over the other. This leads 
to the impression that they are all politically feasible. However, organisational culture 
towards reform and leadership is a barrier. This came up in some of the interviews 
and was referred to the relation of national government offices (macro level) and 
social security institutions (meso level). For instance, the sub-systems tend to adapt 
the national standard list to their needs. Further, any strategy that intends to change 
processes or practices of the MDLC functions requires to be included into the political 
agenda at federal level. 
For all three discussed strategies, only few interviewees identified 
disadvantages thereby however the costs of introducing and operating each strategy 
were mentioned. The discussed strategies were a matter of multiple actors and 
emphasized the role played by the social security institutions regarding the 
successful realization of any changes to processes and practices in order to improve 
outputs and outcomes of the MDLC areas. Overall, we found that improving the 
MDLC may positively influence the health system performance regarding two central 
aspects. First, it may increase quality of care e.g. at the level of health care 
professionals because their clinical practice will be less affected by sub-standard 
medical devices and patients will benefit from orthopaedic medical devices that 
create less burden of revision. Second, it may support the health system’s efficiency 
by post-market surveillance activities that effectively identify medical devices of sub-
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standard clinical long-term performance, and improve decision-making through 
improved technology assessments. 
OECD recommended specifically in its report from 2016 to improve technology 
assessment and regulation of medical devices, and strengthening the role of 
CENETEC [32]. We found that good progress has been made in the authorisation 
and safety of new technologies through COFEPRIS. Still, however, not enough is 
known about the quality and outcomes achieved by the multiple social security 
institutes. A national and comprehensive approach to collect data of the quality of 
care remains lacking. At the level of medical device assessment, CENETEC has the 
potential to be strengthened in its role and take on a more extensive responsibilities 
in e.g. producing Health Technology Assessments (HTAs). Analyses should not just 
be applied to new treatments but to existing ones as well, to encourage value for 
money across the system. Rather than just focussing on services for the uninsured 
provided by the MOH health services, CENETEC’s remit should expand to cover the 
social security institutes as well. The expansion of CENETEC’s role will require 
increased investment, and modification of its legal status may also be necessary. 
Currently, it operates as a subsidiary unit within the MOH and is limited in its ability to 
contract with external bodies. Re-establishing CENETEC as an independent and 
decentralized office would solve this issue [32]. 
Limitations 
This study has several limitations. We used the stakeholder analysis as foresight, 
which deals with uncertainty but helps as well to probe system boundaries. 
Additionally, the way in which we conducted and interpreted the analysis is not value 
free and potentially may have resulted in some bias. The stakeholder analysis did not 
reveal any group that presented itself as opposed to any of the three strategies. In-
depth analysis of each strategy is necessary to assess direct or indirect 
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improvements of cost-benefit aspects of health technologies, patient safety, 
workforce, quality of health care and performance of organisational processes that 
aim at discussing them in greater detail in the context of financial and human 
resources of the identified ‘main stakeholders’ for each strategy. 
9.6. Conclusion 
In Mexico, discussion and proposals by interest groups are slowly gaining 
momentum on how to improve the regulation, assessment, and management of 
medical devices. Changes to current processes and practices can improve outputs 
and outcomes of these functions and positively influence the quality of health care 
and the health system’s effectiveness. Stakeholder involvement and commitment of 
different interest groups are essential to this in order to establish consensus and to 
move forward. However, needs for improvement are rarely analysed in a broad way, 
even though these functions contribute importantly to the successful implementation 
of health technology policies. The coordination of changes among stakeholders is 
complex in Mexico due to the longstanding distribution of roles and responsibilities 
across multiple organisations. To build on the three areas that were subject to this 
stakeholder analysis, we propose to initiate working groups at national level that aim 
at refining the discussed strategies. This study may help enhance the policy 
environment and the communication between different interest groups as identified in 
this analysis. At the level of OMDs advances in policies and organisational practice 
are necessary. 
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10. Discussion 
This Ph.D. extends on the current knowledge on critical aspects between and within 
key MDLC functions. The research further discusses the potential way forward in 
Mexico so to overcome identified challenges. The starting point of this research was 
the MDLC function ‘management’ of orthopaedic medical devices. We identified a 
broad range of themes regarding problems within or between the MDLC areas, 
discussed their meaning in relation to the goal of the MDLC, and explained its 
relevance with reference to the quality of health care. We generated findings that 
help to enrich the knowledge about critical aspects, which result in barriers of reforms 
within the Mexican health system. In the literature these barriers are often described 
as (i) limited financial resources, (ii) efficiency and quality of the health system, and 
(iii) fragmentation of the health system [71, 165]. These barriers and the 
fragmentation of the health system are not unique for Mexico; other countries such 
as Argentina, Ecuador, El Salvador, or Nicaragua are confronted with a similar 
situation [168, 169]. 
10.1. Methodology with reference to the validity of findings 
The methodology adopted to frame this study was based on a multi-methodological 
approach mainly using qualitative research methods. We chose this approach 
because a purely quantitative approach would not have given us enough data and 
there were so few prospective participants representing the macro level and low-to-
moderate number of prospective participants representing the meso level. We found 
that this contributed importantly to the validity of the applied research methods. For 
this research we collected data from a variety of stakeholders (166 interview 
participants and 187 survey participants) during five sub-studies between June 2014 
and January 2017. 
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To ensure internal validity of the findings we used several strategies. First, 
during interviews we probed to uncover attitudes and open up new dimensions of a 
problem and urge the stakeholder to describe their personal stake in the process. 
Secondly, we used a maximum variation sampling technique to recruit stakeholders 
and to achieve a balanced variety of stakeholders and diversity of data. Third, for in-
depth and semi-structured interviews, we used different interview guides to meet the 
different profiles of stakeholders that we pre-tested with few stakeholders from 
Mexico. Finally, we used inductive and deductive methods to generate findings and 
to support validity. Taking these strategies into consideration, we found that the 
internal validity of the findings is relatively high. 
With regards to external validity, this Ph.D. research may have few limitations 
even though the conclusions we were able to draw from the findings did not change 
during the different sub-studies but became more precise. We chose an overall 
qualitative research approach because a quantitative approach would not have given 
us enough data to explain current problems and opportunities of the MDLC in 
Mexico. Even though we intended on ensuring saturation by a maximum variation 
sampling strategy external validity may be compromised because we mainly 
collected data from stakeholders representing the micro and meso levels that were 
located in Mexico City. Attitudes of stakeholders from other states may differ from 
those of the State of Mexico and the Federal District. Therefore, the interpretation of 
the findings of the sub-studies using a qualitative method is a subjective process. 
Finally, we did not compare the findings from the single sub-studies with other 
countries similar as Mexico. A comparison may support the validity of the findings 
and proposed strategies for other countries with similar problems. 
10.2. Main findings 
Main findings with reference to ‘regulation’ 
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Our research showed that in Mexico technovigilance receives relatively high attention 
by policy makers but that stakeholders of the MDLC underestimate its contribution 
regarding improving MDLC outcomes. With reference to normative and 
organisational aspects technovigilance is well established. This is an important 
aspect of strengthening systems for medical device regulation and not all Latin 
American countries have equally advanced with reference to their pre- and post-
market regulation [170, 171]. Our findings show that there is a need to strengthen 
technovigilance regarding its implementation across the various sub-systems (at the 
meso and micro levels) with reference to post-market surveillance such as quality 
and quantity of reports received from the meso and micro levels. This need may be 
similar to other countries with a fragmented health system such as Argentina, 
Ecuador, El Salvador, or Nicaragua even though literature lacks data on this [168, 
169]. Currently, the number of reports from health care providers regarding adverse 
events or incidents or any other form of observations at the clinical practice level is 
relatively low in Mexico. But also high-income countries are concerned with 
regulatory processes and clinical evidence produced [172]. 
The understanding of potential health risks associated with the use of sub-
standard HRMDs is still insufficiently anchored in the mind-set of the multiple 
stakeholders. In Mexico stakeholders believe that the market approval process 
contributes sufficiently to the prevention of sub-standard quality of HRMDs. In 
comparison to high-income countries with an arthroplasty registry for example, we 
found that government agencies concerned with technovigilance have identified the 
need to strengthen post-market surveillance activities to better monitor clinical long-
term performance of HRMDs aiming to take necessary actions [35, 34, 26, 153, 43, 
24, 58, 173]. Further, in Mexico, post-market surveillance is not providing significant 
value to decision-making and this may be similar in other LMIC. But post-market 
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surveillance activities in high-income countries are providing significant value to 
decision-making. Technovigilance outputs are already linked to programmes 
monitoring the performance of HRMDs such as in the United Kingdom or the 
Netherlands [55, 56]. 
 
Main findings with reference to ‘assessment’ 
Our research showed that in Mexico, HTA still adds too little value to the 
effectiveness of decisions. However, HTA-based evidence can help to optimize 
decision-making processes [174]. To date, HTA at the level of hospitals has not 
received a lot of attention yet even though it may provide important benefits to the 
quality of health care and to the health system’s effectiveness. Further, the adoption 
of medical devices is less stringent than for drugs and assessments for medical 
device technologies don’t specify the brand or model. The introduction of a specific 
standard list for orthopaedic and osteosynthesis medical devices in 2016 is an 
important advance regarding risk class differentiation. But there is a growing need for 
rational priority setting using HTA and other policy tools to improve medical device 
assessment. Current applied HTA methodology at the national level and the absence 
of HTA at the hospital level are critical barriers for improving outcomes of the MDLC. 
As there was some controversy about the contribution provided by current HTA 
methodology to decision-making during the first sub-study, we decided to also 
support the above described finding with a study focusing on the management of 
data, information, and knowledge within the MDLC at the macro, meso and micro 
level of health care delivery. We found that data, information, and knowledge are not 
managed appropriately across the sub-systems and on the national level, thus 
impacting all MDLC functions. This study helped us to specify the finding with 
reference to the knowledge culture of stakeholders related to the MDLC functions 
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and to describe the role played by HTA at the national and hospital level for the 
Mexican health system. 
For other LMIC that commit to universal health coverage, a study showed that 
there is a growing need for rational priority setting using HTA and other policy tools 
[175-179]. Countries increasingly identify the need to institutionalize and strengthen 
health technology assessment. For example, Colombia „has been advancing with 
firm steps, articulating legal support, with the infrastructure required in responding to 
challenges that arise from efficient use of health technology“, Brazil is focussing on 
strengthening the link between HTA and evidence-based policy, and Argentina, Chile 
and Ecuador are still in the early phase of HTA implementation [180-185]. In high-
income countries, HTA at hospital level is already advanced and recommended or 
applied to add value to decision-making [186-189]. Policy makers and stakeholders 
of ‘assessment’ are paying more attention to improving HTA [190, 91, 191]. 
 
Main findings with reference to ‘management’ 
Our research showed that stakeholders of the MDLC in Mexico underestimate the 
role played by procurement regarding purchasing of orthopaedic HRMDs. 
‘Procurement’ receives little attention even though the actors involved in procurement 
or impacted by procurement decisions observe relevant challenges and problems. 
Decisions are either based on simple decision criteria or impacted by lowest-price 
offers. Further, stakeholder involvement is low and decision-making is insufficiently 
guided by HRMD relevant aspects such as the consideration of clinical long-term 
performance of an implant. As there was some controversy about the involvement of 
orthopaedic specialists during the first two sub-studies, we decided as to support this 
finding with a survey among orthopaedic specialists. We found that orthopaedic 
specialists are often involved in a simple decision-making setup. This set-up means 
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orthopaedic specialists are not able to add significant value to purchasing decisions 
such as knowledge from clinical practice (intra-operative observations, post-operative 
observations, handling, etc.). In relation to ‘procurement’, we took notice of reports 
that came to similar conclusions: PricewaterhouseCoopers report from 2015 [152] 
and OECD report from 2016 [32]. 
For LMIC we did not identify literature, which describes the involvement of 
stakeholders in decision-making. However, aspects of purchasing and the role 
played by cost-related decisions have been discussed previously [192]. In high-
income countries the input of orthopaedic specialists is providing significant value to 
decision-making but depending on the procurement scheme and policies, this value 
is impacted by final cost-related or cost-containment decisions of procurement [88, 
193, 194]. The management of medical devices is still not sufficiently studied and 
only few research provide important insights [195, 196]. 
10.3. Policy relevance of findings 
Since we started interviewing stakeholders about the MDLC of orthopaedic medical 
devices, we have noticed increased interest by different stakeholders regarding the 
themes that our research covered. We expect that this Ph.D. will encourage the 
policy discussion about the MDLC of orthopaedic medical devices and other HRMDs 
in Mexico but also encourage health system experts from other middle-income 
countries to draw more attention to their MDLC. To date, there is a dearth of literature 
about concerns regarding the MDLC and only few studies provide similar insights into 
the MDLC [197]: “Health care systems have considered the introduction of health 
technologies a linear process in which different stakeholders (innovators, 
manufacturers, regulators, health technology assessors, reimbursement bodies, 
health care providers, health care professionals, patients, and citizens) did interact in 
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each of the steps of the process, but were not involved in a continuous dialogue and 
knowledge exchange.“ 
This research may contribute to advancements because it represents a broad 
overview of important aspects of the MDLC of medical devices in Mexico and 
discusses ways of fostering the MDLC. First, this Ph.D. provides important insights 
into a selection of themes at the level of policy environment, which could encourage 
policy makers to move forward with the improvement of outputs and outcomes of the 
MDLC areas. Second, it indicates how the little integration between the sub-systems 
and the MOH can lead to inefficiencies at the level of service provision and it shows 
possible ways towards improvement. Third, it provides important insights into 
improvement needs for the MDLC functions such as ‘regulation’, ‘assessment’, and 
‘management’. Fourth, it shows that the integration of multiple stakeholder positions 
about outputs and outcomes of the MDLC for HRMDs is necessary to identify and 
analyse current needs and problems. Finally, it shows that stakeholders involved in 
the MDLC have a positive attitude towards changes to current processes and 
practices, but that aspects such as an increase in financial and human resources 
may be critical barriers. 
Some of the findings of this research may be relevant for middle-income 
countries that do have a national policy on health technologies and have established 
a regulatory agency, a national health technology assessment unit, and a national 
health technology management unit. According to WHO, Argentina, Brazil, and 
Ecuador, for example, comply with a national policy on health technologies besides 
other middle-income countries [38]. Thus, the identification of possible steps forward 
in fostering the MDLC areas in Mexico provides a helpful and sustainable orientation 
for similar countries in terms of: (i) reflecting on their own health system performance 
from a new point of view, and (ii) critically analysing the proposed strategies of this 
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Ph.D. thesis for the Mexican health system regarding its possible application in the 
context of the health system of other countries. It may contribute to enhancing the 
policy environment and deliberation between different interest groups that are 
potentially affected by similar problems as discussed in this research. 
The MOH, its departments and affiliated institutions at the macro level govern 
and regulate important parts of the MDLC. In Mexico, the fragmentation of 
responsibilities of the MDLC areas, which has been conditioned by the health system 
structure, has recently received more attention from different stakeholders and is 
subject to the current policy discussion. The suggested changes of current processes 
and practices of the regulation, assessment, and management can improve outputs 
and outcomes of these functions and positively influence the quality of health care 
and health system’s effectiveness. Much of the generated evidence that this research 
produced is based on interviews with stakeholders representing important areas of 
the Mexican health system. Many of these stakeholders have the power to influence 
processes and practices of the MDLC. They have also been contributing to the 
definition or specifying ideas of strategies with reference to improve MDLC functions. 
We found that due to this and based on continuous feedback that we received after 
publishing our findings that this research may have high policy relevance regarding 
influencing current and future policy discussion in Mexico. However, policy relevance 
for other countries may be limited in terms of benchmarking and not contribute 
directly to accelerate any policy discussion. 
During the various sub-studies we found that the management of data and 
information is a critical aspect of the performance of the MDLC and forms already 
part of the policy discussion in Mexico. Our research provided insights into problems 
related to data and information, and how this might have an influence on outputs and 
outcomes of the MDLC. Managing data and information adequately is not a problem 
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unique for Mexico or other LMIC. Overall, information technology in health systems is 
in a transition [198, 199]. The focus on knowledge-related factors (second sub-study) 
allowed us to better explain the relation of MDLC functions such as ‘management’ 
and clinical procedures for orthopaedic medical devices in Mexico. We showed that 
knowledge is an important resource, identified factors along the dimensions of 
knowledge management and healthcare delivery levels that create barriers, and 
discussed them in the context of administrative processes. Stakeholders in Mexico 
recognise the value of knowledge as important resource, but they are not able to 
manage it effectively and efficiently. This study demonstrated that many themes 
describing problems of the MDLC functions may be attributed to poorly developed 
information technology aspects. Our findings are policy relevant in general because 
information technology in health systems increasingly receives more attention and in 
specific for Mexico. One outcome of the policy discussion regarding information 
technology in Mexico is the development and implementation of SINBA, the National 
System of Basic Information in Healthcare, which is expected to solve some of the 
identified problems. Managing the huge amount of data and information, and to add 
value to decisions influencing the quality of health care and the health system’s 
effectiveness, is essential. We expect that by sharing our findings we can encourage 
the different interest groups in Mexico to further invest time in strategies to solve this 
problem and to contribute to the development of SINBA. 
 
Policy relevance of findings with reference to ‘regulation’ 
Technovigilance is an important element of post-market surveillance (after market 
approval). Our study provided insights into problems related to an insufficient 
implemented technovigilance across the multiple sub-systems of health care. Our 
findings may be policy relevant at the level of ‘regulation’ because they address 
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several aspects that are currently inconsistently covered by the Mexican health 
system: (i) medical devices continuously conform to the requirements for safety and 
performance, (ii) problems or changes in safety and performance of medical devices 
are well detected and acted on in an effective and timely manner, (iii) medical device 
post-market surveillance are effective to cover national responsibilities, (iv) market 
surveillance based data is used to be aligned with standards of safety and 
performance. Further, our findings may reinforce the already on-going policy 
discussion of how to strengthen technovigilance. In the centre of this discussion lies 
the quality and quantity of reports from the meso and micro level. Our findings 
regarding ‘regulation’ may be policy relevant for other Latin America countries such 
as Colombia where difficulties regarding the implementation of technovigilance is 
explained and is a matter of culture [200]. Further, in 2012 a working group on 
medical devices for the region of Latin America has been established. Its goal is to 
strengthen the regulatory capacity for medical devices in the region of the Americas 
[171, 201]. The policy relevance of our findings for high-income countries may be low 
because their policy discussion regarding technovigilance is already advanced [202]. 
 
Policy relevance of findings with reference to ‘assessment’ 
Government offices and other stakeholders concerned with the eligibility of medical 
devices in Mexico are in a transition; they have started to better distinguish between 
the different medical device risk classes and the different requirements that HTA 
should have. Our findings may contribute to improving the development of HTA and 
increasingly using HTA-based evidence for decision-making processes. In that way, 
HTA may support purchasing decisions of medical devices that have a short life-
cycle in terms of technological advancements. To date, HTA in Mexico is little 
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discussed in literature and we expect that our findings will encourage researcher to 
draw more attention to this topic [78]. 
Our findings may contribute to improving the development of HTA in other 
LMIC countries, which may have similar problems [178]. In 2011, a Regional Network 
of HTA for the Americas was established aiming “to promote and strengthen HTA 
through regional exchanges of information to support decision-making on regulation, 
use and replacement of technologies, improvements in the quality of care and 
rational use of technologies, and contribute to the sustainability and equity in access 
to health systems“ [203]. The frequent exchange of experiences and best practice 
between the member countries may contribute to the overall development of HTA in 
the Americas. However, the findings of this research are less relevant for high-
income countries which are rather focusing on optimizing their current HTA 
processes and use of HTA-based evidence [204]. However, disinvestment strategies 
may have policy relevance for these countries as well. Going beyond ad hoc positive 
or negative inclusion lists and using disinvestment strategies for orthopaedic medical 
devices (“do not do recommendation”) may be an important step forward in the work 
of HTA agencies in general as shown by the example of the United Kingdom, and 
strengthens evidence-based decision-making. This is not only relevant for Mexico but 
also for other countries in general. 
 
Policy relevance of findings with reference to ‘management’ 
Stakeholder involvement and technology guidance for decision-making currently do 
not form part of the policy discussion in Mexico. Looking at different health systems 
we found that there was always tension between cost and quality, and concern about 
the interaction between the area ‘management’ and the user (orthopaedic specialist). 
In the function of healthcare delivery, the main process occurs at the clinical level 
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between clinicians and patients [7]. For the production of direct services to the 
patient, the support of administrative processes such as purchasing is essential and 
it increasingly influences clinical practice and outcomes [60, 84, 88, 145]. Our 
findings may be policy relevant because they show that (i) a better technology 
guidance of decision-making may be beneficial to preventing sub-standard quality of 
implants, and (ii) an improved relationship between ‘procurement’ and ‘clinical 
practice’ where orthopaedic specialists have certain decision autonomy to represent 
their clinical needs sufficiently may be beneficial to bridging the gap between 
purchasing inputs and outputs. 
Our findings may be policy relevant for other LMIC where procurement is 
based on public tendering and where HTA don’t specify the brand or model of a 
medical device [205]. In high-income countries, stakeholder involvement and 
technology guidance for decision-making form part of the policy discussion [84] and 
our findings may be less relevant to these countries. Research on procurement in 
comparison to LMIC is not only focused on cost-containment but also on aspects that 
may optimize decision-making [206-208]. 
10.4. Perspectives for future research work 
In this research we presented possible strategies of improvement in the context of a 
stakeholder analyses. In a group process, we assessed not only the stakeholders’ 
position on different changes of processes and practices of the MDLC but also their 
opinions on stakeholders who might be directly involved in the proposed changes, 
and opinions regarding the possible positions that these stakeholders might have. 
However, such strategies that address changes in current processes and practices of 
the MDLC areas must be co-created with involvement of the relevant stakeholders, 
which was not subject to this Ph.D. study. Our future study suggestion for the MDLC 
in Mexico is to co-create specific activities with the identified relevant stakeholders 
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per proposed changes of current processes and practices and to assess their 
technical and political feasibility. 
Many health systems are undergoing a critical analysis of their regulation and 
technology assessments. A general trend in European countries is linked to 
knowledge management in terms of learning from clinical outcomes and identifying 
sub-standard qualities that incorporate a health burden to the patient more quickly. 
To date only few studies represent a critical analysis of these aspects for middle-
income countries. Our second study suggestion is to describe recent advancements 
regarding the MDLC of medical devices in other middle-income countries (e.g. 
Argentina, Brazil, or Ecuador) and to identify possible changes of current processes 
and practices of the MDLC areas. Overall, this will contribute to a better 
understanding of challenges that middle-income countries do have in comparison to 
high-income countries regarding the improvement of the MDLC areas in their 
countries. 
In Mexico, there is still little integration between the orthopaedic associations 
and government units but there is a need to change this. A first move forward might 
be strengthening the relation between the National Academy of Medicine and the 
orthopaedic associations. This may contribute to continuous communication, defining 
overall needs of the interest group ‘orthopaedic specialists’ and initiating programmes 
aiming to improve clinical practice. 
11. Conclusions 
The MDLC represents an on-going cycle of inputs, outputs, and outcomes aimed at 
improving the quality of health care. The relevance and importance of a well-
functioning MDLC is growing in both high- and middle-income countries. A broad 
analysis of the MDLC and the relation of important functions for medical devices are 
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rarely the subject of literature. Studies specifically either focus on aspects of the 
‘regulation’, ‘assessment’, or ‘management’ of medical devices. While ‘regulation’ 
and ‘assessment’ are often analysed in a broader health system context, 
‘management’ is often analysed in a relatively close context of operative aspects. 
Through this thesis, new evidence on the MDLC was generated and the holistic 
perspective supported the integrative understanding of problems that result from 
single MDLC functions. 
Only some of the findings that our research has produced have been 
discussed in the literature before such as the complexity of the Mexican health 
system or sub-standard outputs of procurement processes. The complexity of the 
Mexican health system is a barrier for initiatives and programmes that address all 
sub-systems, and policy makers are unable to assure a similar level of health care 
between these sub-systems [32]. The country made important progress in ensuring 
and improving the quality of health care. However, researchers suggest Mexico 
continue searching for ways to strengthen its healthcare system by improving the 
delivery of healthcare in terms of coverage [125, 147, 209-213], and translating 
financial resources into more effective, equitable and responsive health services to 
achieve better quality [165, 32]. 
This research is novel in terms of its specific focus on key MDLC functions and 
on orthopaedic medical devices. Further, it was timely because some of the 
presented themes are currently undergoing policy discussion in Mexico. To be 
precise, the Mexican Congress is discussing the creation of the Federal Commission 
for the Regulation and Surveillance of Health Care Services and Facilities [166], 
which could generate momentum for the uptake of a broad spectrum of aspects 
concerning quality in health care and this may support outcomes of the MDLC areas. 
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The MDLC system in Mexico is not coherently outlined and set-up across the 
regulatory, the assessment, and the management domains of orthopaedic medical 
devices. This results in a sub-optimal quality of services delivered to patients. This 
finding resonates with concerns raised by other authors regarding the regulation, 
assessment, and management of health services in Mexico at different levels of 
health care delivery [11, 32, 38, 72, 78]. Further, policy makers from Mexico 
insufficiently integrate the relevance and importance of a well-functioning MDLC into 
their policy discussion. LMIC compared to high-income countries may still be in a 
process of defining and establishing government agencies or processes that are 
necessary to adequately support their MDLC. In high-income countries, MDLC 
functions are well defined and established and policy discussion is geared towards 
aspects of optimizing the outcome of the MDLC. Policy makers and other 
stakeholders related to the MDLC in Mexico may benefit from consulting the 
outcomes of policy discussion in high-income countries. 
The new evidence produced by our research shows that neglecting the 
problems related to the MDLC functions leads to the continuation of the sub-standard 
provision of quality of health care and low health system’s effectiveness. Based on 
the findings of this research we have the following recommendations to the Mexican 
policy makers and other stakeholders related to the MDLC: 
• A government agency is needed to broadly oversee, monitor and report on 
quality-related issues within the health system. To date, no government agency 
is responsible for the uptake of a broad spectrum of aspects concerning quality in 
healthcare. 
• Decision-makers should apply an integrative approach of selecting medical 
devices to better prevent an economic and health burden due to disconnected 
processes and practices of the MDLC functions. 
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• Specific policies and organizational practice targeting orthopaedic medical 
devices are necessary. To date, Mexico lacks initiatives or programmes, and 
research studies focussing on this. Further, there is a need to improve the 
understanding of the quality of the delivered health care in a broad way such as 
analysing it in the context of the MDLC areas. 
• Technovigilance needs to be strengthened to improve the understanding of 
potential health risks associated with sub-standard HRMDs. Particularly, post-
market surveillance should providing significant value to decision-making. 
• Data, information, and knowledge need to be managed appropriately across the 
sub-systems of health care provision. The National System of Basic Information 
in Healthcare [74] is an important step forward but needs to uptake orthopaedic 
specific variables as well to increase transparency on treatment performance, 
burden of revision, etc. 
• Technologies should be assessed during the purchasing process by applying 
strategies such as risk assessment, the adequate involvement of end-users, and 
basing decisions on multiple criteria including clinical impact in the short-term 
(tissue trauma, rehabilitation duration, primary stability of implant, etc.) and long-
term (survival of implant, material performance, etc.). 
• The methodology applied to technology assessments for evaluating HRMDs 
needs to be adapted to the gold standard and HTAs at the level of hospitals 
should be introduced. 
• Decision-making needs to distinguish between different risk classes of medical 
devices because decisions on complex medical devices are based on simple 
decision criteria. Particularly, the understanding of potential health risks 
associated with the use of sub-standard HRMDs is still insufficiently anchored in 
the mind-set of the multiple stakeholders. 
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• ‘Procurement’ needs more attention so that actors involved in procurement or 
impacted by procurement decisions are less confronted by problems. 
Particularly, procurement agents need more guidance and support to improve 
purchasing decision-making, and knowledge of orthopaedic specialists should be 
better integrated into the decision-making process. 
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